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1 SUMMARY  
Introduction: To be absorbed from the gastrointestinal tract, a drug has to be sufficiently soluble, 
because, with some exceptions, passive diffusion of dissolved drug molecules from high to low drug 
concentration is the driving force of drug absorption. Different physicochemical and physiological 
properties determine the reasons for poor drug absorption, which are poor water solubility, low 
membrane permeability, carrier mediated drug efflux, drug metabolism, and pharmacological 
interactions. A successful strategy to improve the oral bioavailability of poorly water soluble drugs in 
vivo is the use of lipid containing dosage forms. Lipid formulation can reduce the inherent limitation of 
slow and incomplete dissolution of poorly water soluble drugs by facilitating the formation of 
solubilized phases containing the drug, from which absorption may occur. Only few commercially 
available products on this basis have been approved so far. Reasons for this small number of 
approved products may be the limited knowledge about formulation parameters that are responsible 
for good in vivo performance because of limited understanding of the underlying mechanisms. 
Compared to an aqueous suspension of lipophilic drug, it is generally agreed so far that improved drug 
absorption takes place because the drug is solubilized already in a lipid containing dosage form. There 
is little information in literature dealing with the effect of lipid containing dosage forms on the passive 
permeation. The objective of this thesis was to elucidate mechanisms by which a lipophilic drug that is 
contained in a lipid formulation is absorbed by the intestine. For this purpose, a theoretical model and 
experimental procedures were developed, using Caco-2 cell monolayer. 
 
Methods: Different formulations were tested as model formulations. Since it is known that several 
formulation components may work as permeation enhancers by tight junction modulation, 
trans-epithelial electrical resistance (TEER) was used as criteria to test monolayer integrity. As model 
formulations phosphatidylcholine liposomes, an emulsion with a lipid phase consisting of 67% (m/m) 
triglyceride (Captex 8000), 5% (m/m) mixture of mono- and diglycerides (Capmul MCM), 18% (m/m) 
surfactant (Cremophor EL), and 10% (m/m) ethanol, and a microemulsion with a lipid phase consisting 
of 35.05% (m/m) Captex 8000, 17.58% (m/m) Capmul MCM, 36.84% (m/m) Cremophor EL, and 10% (m/m) 
ethanol were chosen. To determine the influence of these model formulations on the permeation of 
lipophilic drugs, different drugs were evaluated as suitable model compounds. Propranolol, 
progesterone, saquinavir, and triclabendazole were finally selected. An equilibrium dialysis method to 
determine the free fraction of the drugs in the different formulations was developed. The influence of 
liposomes, microemulsion, and emulsion on transport processes of the model drugs through Caco-2 
monolayer was determined with a bi-directional Caco-2 assay, using purely aqueous drug solutions as 
reference. At least three different lipid concentrations for each formulation in the range of 0.1-50 mg/ml 
were tested. Within each lipid concentration at least three different drug concentrations were tested 
per drug. Apparent passive permeability coefficient of the apical (Pa) and of the basal membrane (Pb), 
formulation-to-cell partition coefficient, and carrier mediated apical efflux rate were deduced by fitting a 
mathematical model to the experimental concentration data of the bi-directional assay using Easy Fit® 
fitting software. Further, a biophysical model was developed to delineate the contribution of drug 
transport in the diffusion boundary layer and drug permeation through cell membrane to the 
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determined apparent permeability coefficient. Additionally, a differentiation was introduced between 
permeation of free drug through the cell membrane and permeation following direct drug transfer from 
the lipid particles to the membrane upon collision. Drug uptake and passive drug efflux for selected 
drugs and formulations were further studied in the Caco-2 cell monolayer. 
 
Results and Discussion: Both, the model for the determination of absorption parameters in Caco-2 
cells and the biophysical model for delineating the components of apparent permeability coefficient 
explained the experimental data satisfactorily. Generally Pa, Pb, and free fraction decreased with 
increasing lipid concentration. Within the same lipid concentration, no influence of drug concentration 
on Pa, Pb, and free fraction was determined. Triclabendazole showed lower Pb than Pa whereas 
permeability coefficients of all other drugs were equal for both membranes. Carrier mediated apical 
drug efflux was found for saquinavir only and its rate, when expressed as zero order, decreased with 
increasing lipid concentration and increased with increasing drug concentration. Formulation-to-cell 
partition coefficient increased with increasing lipid concentration for all drugs and formulations. 
Deduced permeability coefficients of diffusion boundary layer, reflecting drug transport in the apical 
and basal solution, was smaller than overall permeability coefficient of cell membrane for all drugs 
except saquinavir for which values were comparable. This indicates that the compounds are good 
permeable for cell membrane. Permeability coefficient of the drug corresponding to direct mass 
transfer from lipid particle to cell membrane (Pm,L) was for progesterone greater than the permeability 
coefficient corresponding to permeation of free drug through cell membrane (Pm,d). For triclabendazole 
Pm,L was smaller than Pm,d. For saquinavir Pm,L was comparable or smaller than Pm,d. Finally for 
propranolol Pm,L was smaller than Pm,d for liposome formulation. For propranolol emulsion and 
microemulsion, no interaction of formulation and drug was observed, therefore no meaningful values 
were obtained for Pm,L. The rate limiting step of transport and the dominating mechanism of membrane 
permeation depend on the corresponding permeability coefficients and the free and lipid bound drug 
concentration. These observations apply to all three structurally different lipid formulations used in this 
study. Permeability coefficients of drug uptake of progesterone formulations and passive drug efflux of 
progesterone and triclabendazole formulations in the Caco-2 monolayer decreased with increasing 
lipid concentration, which was consistent with the permeation experiments. 
Drug fluxes increased with increasing drug concentration within the same lipid concentration and 
decreased with increasing lipid concentration within the same drug concentration. Fluxes of 
progesterone in experiments with equal free drug concentration increased with simultaneously 
increasing drug and lipid concentration. This was demonstrated with progesterone liposomes and can 
be related to the larger Pm,L compared to Pm,d found for this drug.  
 
Conclusions: Lipid formulations containing the drug in a molecular form provide the possibility to 
increase the concentration of poorly water soluble drugs in a macroscopically aqueous system. 
Apparent drug permeability coefficient for the cell membrane is decreased by these formulations. 
Apparent drug permeability coefficient depends on free fraction, whereas drug flux depends on 
absolute amount of free drug in water phase. Therefore simultaneous increase of drug and lipid 
concentration can provide an undiminished drug flux, which may improve bioavailability by prolonged 
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intestinal absorption at a sustained rate. These findings are independent of the composition and the 
structure of the lipid formulation lending support to the universal nature of this conclusion. In addition 
flux can be further increased by direct drug transfer from lipid particle to cellular membrane. This was 
observed for only one drug in the present work. The necessary drug properties for this direct transfer 
to take place should be investigated in the future. The results of this work shed light into the 
mechanism of drug absorption from lipid formulations and demonstrate potential beneficial effects of 
these formulations on absorption of lipophilic drugs in vivo. They may be used for the development of 
efficient oral dosage forms to improve bioavailability for these drugs. 
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2 INTRODUCTION AND OBJECTIVES  
2.1 Introduction 
After oral drug administration, which is the most accepted route for drug administration, a drug has to 
overcome several obstacles to reach the site of its pharmacological action. The drug has to be 
absorbed from the gut lumen to the blood stream which is the most important prerequisite for a 
compound to act as drug. The unchanged amount of absorbed drug determines the bioavailability and 
the systemic exposure of the body to the drug. Many in vitro highly active compounds, generated by 
modern drug discovery strategies, possess unfavorable biopharmaceutical properties including poor 
oral absorption, caused by poor solubility or low intestinal wall permeability. A general drug 
classification of the impact of drug solubility and membrane permeability on drug absorption has been 
done by the framework of the biopharmaceutics classification system (BCS) (1, 2). Different 
physiological properties determine the reasons for poor drug absorption such as carrier mediated drug 
efflux, drug metabolism, and pharmacological interactions. The most important cause for low 
permeability is the inability of the molecule itself to cross a biological barrier by passive diffusion. 
Several physicochemical properties are influencing the ability to cross biological barriers which are 
lipophilicity, molecular weight, hydrogen bonding capacity, and charge (3-6). Lipinski’s “rule of five” 
assesses on the basis of these properties the ability of a drug to be absorbed after oral administration 
(7).  
An increasing number of drugs have been identified to be subject of carrier mediated efflux which is 
limiting the trans-membrane permeability and finally oral bioavailability. Carrier mediated efflux is 
caused by proteins located in the apical cell membrane by pumping back drug molecules from the 
cellular lumen to the intestinal lumen. These efflux pumps have a broad substrate specifity which is a 
powerful mechanism to prevent the body from the uptake of toxic alimentary ingredients and, 
unfortunately, from the oral absorption of many drugs (8). Most important efflux transporters for drugs 
belong to the ATP-binding cassette (ABC) family, e.g. P-glycoprotein (Pgp), breast cancer resistance 
protein (BCRP) and MRP2 (9-13).  
Drug metabolism may affect oral bioavailability by an extensive first pass metabolism of both, the 
intestinal epithelium and the liver. Drug metabolism is divided into phase I metabolism that includes 
degradation of the drug molecule by oxidative reactions catalyzed by enzymes, e.g. Cytochrome 
P450, and phase II metabolism that includes conjugation of the drug or its phase I metabolite with 
hydrophilic moieties such as glucuronic acid or sulfate (14-19). Because of a large pH-range from 1.5 
to 7.4 in the intestinal tract, orally administered drugs may further undergo chemical degradation, 
which is limiting oral bioavailability too.  
The water solubility of poorly water soluble drugs strongly influences absorption and oral 
bioavailability. It is generally agreed that one of the preconditions for diffusion through a biological 
membrane is dissolution of the compound in the occurring media. Consequently, water solubility of a 
compound is one of the most important parameters affecting drug absorption. If the solubility of poorly 
water soluble drugs is increased, an increase in absorption is observed (2, 20, 21). Several strategies 
have been developed to increase solubility of poorly water soluble compounds such as chemical 
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modification, use of salts of ionizable compounds, use of cosolvents, use of surfactants and the use of 
complexing agents like cyclodextrins. Another strategy is the formulation of poorly water soluble drugs 
with lipid containing formulations such as self emulsifying drug delivery systems (SEDDS). This 
strategy has been used successfully to improve the oral bioavailability of some drugs deemed to be 
hardly deliverable, like cyclosporine A, saquinavir or indinavir (22-28). Only a small number of 
approved oral lipid formulations are commercially available. Reasons for this small number may be the 
limited knowledge about formulation parameters that are responsible for good in vivo performance 
because of limited understanding of the underlying mechanisms. It is generally agreed so far that lipid 
formulation can reduce the inherent limitation of slow and incomplete dissolution of poorly water 
soluble drugs by facilitating the formation of solubilized phases containing the drug from which 
absorption may occur. The underlying molecular mechanisms besides the solubility enhancement and 
the possibility of direct lymphatic uptake of these lipid containing systems in vivo are rarely known (29, 
30).  
Many in situ and in vitro models of different levels of complexity and sophistication have been 
developed to assess and predict the absorption and permeation properties of compounds at different 
administration sites of the body (31). One of the best characterized and most used model to study 
drug absorption in the gastrointestinal tract is the Caco-2 cell model. The cells of human colon 
adenocarcinoma cell line Caco-2 spontaneously differentiate into enterocyte like cells. Seeded on 
semipermeable filter supports, a cell monolayer expressing a number of active transport proteins 
results, which permits to investigate simultaneously different absorption mechanisms e.g. passive 
diffusion and active carrier mediated efflux (32, 33). The Caco-2 model is a useful tool for a 
mechanistically understanding of drug absorption, which results in an increasing knowledge of the 
different mechanisms that are part of drug absorption (34). 
Like all in vitro models the Caco-2 model has some disadvantages. Caco-2 cells require under 
standard culture conditions usually three weeks culture on filters before they can be used for drug 
permeation experiments. Because of their nature as tumor cells, Caco-2 cells may possess different 
expression levels of transporters and metabolic enzymes and may undergo spontaneous 
mutagenesis. Inter-laboratory variability and variation of morphological and biochemical properties 
depending on used passage numbers and culturing conditions are often encountered problems. 
Standardized cell culture conditions (media, seeding density), the use of established marker 
compounds, and the use of a predefined small number of passages may help to lower often reported 
differences of permeability measurements of selected compound for different labs (35-39). 
The commonly used approach to assess cell permeability of drugs by the calculation of apparent 
permeability coefficient Papp possesses some limitations: The cell monolayer is modeled as a single 
rate limiting barrier, without taking into account the influence of a diffusion boundary layer on 
permeability of highly permeable compounds. This method is not sensitive to mass balance problems 
such as metabolism, cellular accumulation or nonspecific binding to the device surfaces, and drug 
stability, because it depends on the total mass transported to the receiver relative to initial mass. The 
use of this approach still requires the establishment of the linear phase of absorption because the 
method describes just the initial drug transport under sink conditions. Active apical efflux substrates 
are identified by comparison of the drug permeability coefficient from apical to basal compartment with 
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the drug permeability coefficient from basal to apical compartment, forming the efflux ratio (ER) and by 
performing transport experiments with inhibition of the carrier (40). To overcome unspecific adsorption 
of highly lipophilic drug molecules to the plastic made surface and to maintain sink conditions additives 
like albumin were commonly used, sometimes without taking into account a possible influence of 
these additives to drug permeation (41-43).  
Few attempts have been undertaken to investigate complex drug formulations with the Caco-2 
models, most of them by searching more physiologically relevant media. Most of these experiments 
were focusing on cell viability and qualitative effects of the tested formulation on various model drugs 
(44-53). Little systematical work on the quantitative interactions of lipid containing drug formulations on 
cellular drug permeation has been published so far. 
2.2 Objectives 
Because the mechanism of lipid formulations on drug absorption is not clear, in particular the pathway 
by which the drug that is contained in lipid particles is taken up by epithelial cells has been debated in 
literature.  
The objective of this thesis was to elucidate mechanisms by which a lipophilic drug that is contained in 
a lipid formulation is absorbed by the intestine. For this purpose, a methodology for determining 
unbiased parameters in in-vitro cell culture models describing the absorption of lipid containing 
formulations of poorly soluble drugs in the Caco-2 system was developed. A mathematical model had 
to be developed and evaluated, describing the processes involved in this system. The aim was to 
provide a tool to investigate the influence of lipid containing drug formulations on drug permeation 
through the Caco-2 cell monolayers grown on permeable filter supports in Transwell plates. This 
methodology consisting of a mathematical model and an appropriate experimental design was 
developed to provide parameters that delineate passive, carrier mediated, and formulation induced 
effects on drug permeation and allows the study of different lipid containing drug formulations. It 
should be able to quantify the contribution of different transport parameters to the epithelial 
permeation. The model included additionally a partition coefficient describing drug partition of the 
formulation to the cell and should be used for the quantitative analysis of model compound bi-
directional permeation through Caco-2 cell monolayer. Suitable lipophilic model drugs had to be found 
exhibiting different properties with respect to solubility and permeability. Model compounds with the 
following properties were identified: High permeability and high solubility (propranolol), high 
permeability and low solubility (progesterone), low solubility and low permeability (triclabendazole), 
low permeability, low solubility, and subject to carrier mediated efflux (saquinavir). 
Different lipid containing drug formulations were investigated which had different properties concerning 
the nature of particles. It was of high importance to use formulations of simple composition out of 
components that are known to be compatible with the Caco-2 cell model. The used model 
formulations were liposomes, a microemulsion and an emulsion. The formulations were characterized 
for optical aspect, particle size and free fraction. Concerning free fraction, a reliable method had to be 
developed for the quantification of the free fraction of structurally different lipid containing dosage 
forms, which was equilibrium dialysis.  
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The final benefit of this work is to gain fundamental knowledge about the influence of lipid containing 
formulations on drug absorption by understanding the mechanism. The result of this work may be 
used for the development of efficient oral dosage forms to improve bioavailability of poorly water 
soluble drugs. 
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3 THEORETICAL SECTION  
3.1 Drug Absorption after Oral Application  
The oral delivery of drugs is the most accepted administration of drugs for patients. Orally 
administered drug formulations are preferred to their non-invasive alternatives like dermal or 
pulmonary delivery for different reasons. A tablet or capsule is very suitable for self medication and 
compliance; it can easily be swallowed and transported. For the industry, the low production costs, 
established formulation strategies and long shelf life are important issues. 
To ensure an efficient oral delivery, a drug has to be suitable for oral administration. Several criteria 
have to be met. Due to the enormous pH-range of the gastrointestinal tract from 1.5 in the stomach up 
to 7-8 in the intestine, a drug has to resist to these conditions. Furthermore, a drug has to resist to 
high enzymatic activity, specially degradation and metabolism. To be absorbed from the 
gastrointestinal tract, a drug has to be sufficient soluble, because, with some exceptions, passive 
diffusion from high to low drug concentration of dissolved drug molecules is the driving force of drug 
absorption. Drug absorption is generally defined as the process by which unchanged drug proceeds 
from site of administration to site of measurement within the body (54). Consequently, this means that 
an orally administered drug has to be able to permeate sufficiently through the gastrointestinal 
epithelium to reach its active site. 
 
A huge number of potentially new chemical entities have been generated since the introduction of 
modern drug discovery strategies like combinatorial chemistry and high throughput screening. 
Resulting compounds of these strategies are often more lipophilic, less soluble, and have a higher 
molecular weight than traditionally synthesized compounds. A lot of these in vitro highly active 
compounds possess unfavorable biopharmaceutical properties, which can lead to termination of the 
clinical development. If the drug development is stopped in an early clinical phase, because the 
candidate has a low oral bioavailability, an enormous financial effort was spent. One effort to improve 
properties of potential drug candidates was the introduction of the “Rule of 5” which defines a range of 
certain properties that a compound has to possess to be absorbed in gastrointestinal tract to achieve 
good oral bioavailability (7). Oral bioavailability is defined as the fraction of an oral dose reaching the 
systemic circulation (55). 
A growing effort to predict the oral bioavailability at an early development stage is spent. Ideally, the 
bioavailability may be predicted out of the chemical structure of the compound. The most important 
predictive properties of a drug for the determination of the absorption are considered to be solubility 
and permeability. While a lot of strategies are available to increase the solubility of a drug, limited 
options to increase the membrane permeability are available. It is of enormous importance to assess 
the solubility and permeability of a new potential compound as early as possible during the 
development, to secure that the new compound achieves good solubility and good membrane 
permeability. 
In recent years, the biopharmaceutics classification system (BCS) was proposed, established, and 
many commercial available drugs have been classified according to this system (1, 2). It classifies 
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drugs into four different classes according to their solubility and permeability. This theoretical 
classification enables an estimation of oral absorption if conclusive data are available. The BCS 
classifies compounds into 4 classes: Class I contains compounds with good solubility and high 
permeability, class II contains compounds with low solubility and high permeability, class III contains 
compounds with high solubility and low permeability, and class IV contains compounds with low 
solubility and low permeability (2). According to the BCS classification, a drug is highly soluble if the 
highest oral dose strength is soluble in 250 ml or less of aqueous media over a pH range of 1-7.5. A 
drug is highly permeable if the extent of absorption is determined 90% or more of the administered 
dose in vivo (2, 56). 
Aqueous solubility of a drug is an important physicochemical parameter that has a significant role in 
various physical and biological processes. According to the simplest definition, the solubility of a drug 
is the maximum amount of the most stable crystalline form, which is molecularly dispersed in a solvent 
in equilibrium, in a given volume at a given temperature and pressure. Inadequate solubility of a drug 
results in incomplete and slow oral absorption in vivo. Through the various phases of discovery and 
development of a drug, solubility information serves a wide range of needs: At an early stage of 
development, solubility is an important parameter to decide that a compound is soluble enough to be 
used in activity screenings. Later, solubility data is extensively used to assess absorption of the drug 
and in formulation development for early and late clinical phases (20). Strategies to improve the 
solubility and the permeability of a drug will be discussed later in this section. 
3.2 The Gastro-Intestinal Tract and the Intestinal Epithelium  
After swallowing, an oral dosage form enters the stomach. The acidic environment of pH 1-2 in fasted 
state and 3-4 in fed state degrades bacteria as well as some drugs (57). A drug solution, drug 
suspension, or an intact dosage form enters then the duodenum and the small intestine, which are the 
main intestinal segments for absorption. The gastrointestinal tract is geometrically idealized a tube, 
covered with epithelia. In the duodenum and the small intestine, a macroscopic mucosal surface area 
magnification including circular folds, villi, and a microscopic surface area with brush border on the 
apical membrane, ensures a huge surface (around 200 m2) for absorption (see Figure 1). The mucosal 
membrane of the intestinal epithelial cells is regarded as the primary permeability barrier to drug 
absorption from oral administration. Epithelial tissues generally demarcate body entry points like skin, 
respiratory and gastrointestinal epithelia, predisposing a general barrier function. The gastrointestinal 
epithelia serve special function promoting efficient nutrient digestion and absorption. This dual 
absorption-protection function of the epithelia requires an efficient strategy to attenuate the entry of 
noxious solutes.  
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The gastrointestinal epithelia is composed of different cell types, namely paneth, goblet, endocrine, 
and absorptive cells. Enterocytes, the absorptive cells, dominate the cellular population of the 
epithelium and serve the major role in gastrointestinal solute transport. The enterocytes are highly 
polarized cells. The apical side, which is directed to the intestinal lumen, exhibits a microvillus brush 
border membrane. The paracellular space is sealed with tight junctions. Close to the basal membrane 
there are blood capillaries and lymphatic vessels to assure efficient absorption of nutritients. The 
mucosa is covered with a layer of intestinal mucus with a thickness between 50 and 450 µm and 
consists of water (>95%), glycoproteins (mainly mucine), and lipids (58). 
The Intestinal mucus layer, the apical membrane of the enterocyte in parallel with the tight junction 
barrier, cytosol, basolateral membrane in parallel with the lateral intercellular space basement 
membrane, and parallel lamina propria endothelial membranes of blood vessels and lymphatic vessels 
contribute to the barrier function of the epithelia (59). 
3.3 Mechanisms of Membrane Permeation  
Different parameters are influencing pharmacokinetics and pharmacodynamics of drugs to reach their 
target in sufficient, therapeutic relevant concentration. The site of application is usually apart from the 
site of action, thus most drugs have to cross biological membranes after application. If the drug does 
not reach its molecular target, no therapeutic effect will take place. The ability of a drug to cross 
membranes is one of the most important properties for a successful systemical therapy because it 
influences the pharmacokinetic profile in absorption, distribution and elimination. 
The main process to cross biological membranes is passive diffusion, which is influenced by both, the 
physicochemical properties of the drug and the biological barrier. For permeates, the main 
 
Figure 1 Increasingly magnified views of intestinal epithelia from cylindrical tube to enterocyte 
(Figure originally published in Friedmann, MH Principles and Models of Biological Transport, 
Springer-Verlag, Berlin 1986) 
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physicochemical properties influencing the permeation through membranes are lipophilicity, molecular 
weight, size, hydrogen-bonding capacity, and charge. The presence of water pores, the lipophilic 
manner of the bilayer, and the membrane surface area are considered to be important factors 
influencing membrane transport. The transport through a biological barrier, e.g. the gastrointestinal 
epithelium, can be divided into passive transport through the cellular membrane (passive transcellular 
permeation), passive transport through tight junctions (paracellular transport) and active transport 
processes (carrier or vesicle mediated) (3, 60). These different mechanisms will be discussed in the 
next chapters. 
3.3.1 Passive Transcellular Permeation  
Our current understanding of the structure of biological membranes, consisting of a lipid-double-layer, 
is the fluid-mosaic model (61). The double layer structure is a result of the orientation of amphoteric 
lipids in aqueous medium. The double layer consists of phospholipids, glycolipids, and cholesterol. 
Major membrane constituents are different amphiphilic phospholipids. Phospholipids consist of a 
glycerol backbone, two fatty acids and a phosphorylated alcohol. Typical chain length of the fatty acids 
are 14-18 carbon atoms. Most important phospholipids are phosphatidylcholine, phosphatidylserine, 
and phosphatidylethanolamine. The double layer structure with a lipophilic core and a polar surface is 
highly flexible and allows its constituents lateral and transversal movements (3). Inner and outer leaflet 
of cellular membranes are differently composed. Additionally, there are many different proteins 
embedded in the membrane performing different functions. A cellular membrane is 7-8 nm thick and is 
permeable for neutral and lipophilic compounds and water. Ions are not able to pass the phospholipid 
barrier. Special trans-membranal proteins form selective ion channels. Membrane composition varies 
depending on tissue type and location. 
The fluid mosaic model was further developed by the lipid raft hypothesis. Lipid rafts are membrane 
microdomains enriched in cholesterol and sphingolipids. These extremely small rafts are formed by 
highly dynamic clustering of sphingolipids and cholesterol and involve interactions of both proteins and 
lipids (62). The rafts have been implicated in processes as diverse as signal transduction, 
endocytosis, cholesterol trafficking, and altering of function of trans-membranal proteins. A lot of 
papers dealing with rafts were published but there is still skepticism about the real nature of existence 
and their functions. More work is still needed to confirm or neglect the raft hypothesis (63). 
The passive transcellular transport can be divided into several steps. The partitioning of the permeant 
into the apical monolayer is considered to be the first step, followed by either partitioning and diffusion 
through the cytoplasm following partition into the basolateral membrane or translateral diffusion inside 
of the lipophilic core of the cell membrane. The resulting pathway is depending on the 
physicochemical properties of the permeate, as translateral diffusion is expected mainly for highly 
lipophilic molecules. After reaching basolateral membrane, the permeate partitions out of the 
membrane to the basolateral space. Diffusion to the membrane surface and through the cytoplasm are 
fast processes, whereas the rate of passive transcellular permeability is mainly determined by the 
transport across the cell membrane. Passive permeation depends to a large extent on three 
interdependent physicochemical properties, which were lipophilicity (independent of pKa: log P, 
dependent of pKa: log D), polarity (charge, hydrogen bonding), and molecular size of the permeant (3, 
Marcel Schneider Page 22 of 172 University of Basel, 2008 
60). Gastrointestinal epithelial cells are polarized. The apical surface borders to the intestinal lumen 
and is covered with microvilli and the brush border, while basolateral plasma membrane faces the 
basal lamina and underlying tissue. To maintain an optimal physiological function, the two membranes 
are different in their protein and lipid compositions. The basolateral membrane is enriched e.g. in 
sphingomyelin and phosphatidylcholine (64, 65). Consequently, the membrane permeability coefficient 
of a compound may be different through apical and basolateral membrane. 
3.3.2 Paracellular Transport  
The passive paracellular pathway is an aqueous, extracellular route across the epithelium. The driving 
forces are the electrochemical potential gradients derived from differences in concentration, electrical 
potential, and hydrostatic pressure between the two sides of the epithelium. The main barrier to 
passive paracellular diffusion is the tight junction (66). The tight junction is an intracellular junctional 
structure that mediates adhesion between epithelial cells and is required for epithelial cell function. 
Tight junctions control paracellular permeability across epithelial cell sheets (67). The dimension of the 
paracellular space in tissues is between 10 and 30-50 Å suggesting that molecules with a molecular 
radius exceeding 15 Å (ca. 3.5 kD) will be excluded from this uptake route (68). The available pores of 
epithelial tissues, where cells are connected to each other by tight junctions are smaller. The 
calculated pore radii of the human intestinal tract tight junctions are 6-8 Å in jejunum, 2.9-3.8 Å in 
ileum, and less than 2.3 Å in colon (69). The pore radius of Caco-2 monolayer was determined to be 
12 Å (59). The paracellular pathway is the preferred pathway of larger hydrophilic compounds and 
ions. The total contribution of the paracellular pathway to general drug transport is very low because of 
the low surface fraction of the pores to the total surface. The cell membrane surface is more than 1000 
times larger than the paracellular surface area (70). 
3.3.3 Drug Transporters: Carrier Mediated Influx and Efflux  
The small intestinal mucosa expresses large numbers of absorption transporters responsible for 
absorption of nutritients and vitamins. In addition to their physiological function, these transporters 
have shown to mediate the absorption of some drugs, e.g. transporters for di- and tripeptides, amino 
acids, bile acids, nucleosides, and monocarboxylic acids. These influx transporters can increase the 
drug absorption by binding dissolved compounds from intestinal fluid and transport them through the 
epithelial membrane. Compounds that are substrates of these transporters exhibit intestinal absorption 
higher than expected from their diffusion across cell membranes. 
In contrast to absorption transporters, efflux transporters can have the opposite effect by transporting 
compounds from the cell lumen or the inner membrane leaflet to the intestinal lumen. This process is 
called apical efflux and is mediated by transporters that belong to the ATP binding cassette (ABC) 
superfamily. P-glycoprotein (Pgp) is the most studied member of the apical efflux transporters and is 
the product of the MDR1 gene. Pgp has 2 subunits with 6 trans-membrane domains and two ATP 
binding sites. It is located on the apical cell membrane of enterocytes and also expressed in other 
tissues (66). Pgp was one of the first transporters that have been identified to be involved in the efflux 
of drugs. It has broad substrate specificity and transports a lot of structurally diverse drugs (12). 
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All of these described mechanisms and examples of transporters have in common, that carrier 
mediated transport can be directed against a concentration gradient, is energy dependent, and 
undergoes saturable transport kinetics. A saturable transport undergoes an increased passive 
transported fraction with increased dose. If the drug has a low permeability, a decreased fraction 
absorbed results (70). 
3.3.4 Vesicular Transport 
The vesicular transport process starts when the plasma membrane forms invaginations that pinch off 
and form small vesicles that migrate from the cell membrane inwards to the cellular lumen. These 
vesicles fuse with endosomes and if they undergo fusion with the basolateral side of the cell 
membrane followed by release of the vesicle lumen to the basolateral space the process is called 
transcytosis (66). This route is less attractive for drug transport, because of its low capacity, but it is an 
interesting transport pathway for large and highly potent molecules. In gastrointestinal tract 
transcytosis of macromolecules is mainly performed by M-cells that are overlying the lymphoid tissue 
in gastrointestinal tract (70). 
3.4 In Vitro Assessment of Drug Permeability: Models  
In vivo drug absorption in animals is generally a good predictor for human absorption, but with the 
increasing number of potential drug candidates resulting out of modern lead finding strategies, in vivo 
models are too complex and too inefficient to screen a large number of compounds. Due to the 
hazardous potential of unknown compounds, ethical concerns, complexity of the analytical methods, 
and the time and work intensive nature of the experiments are disadvantages of in vivo experiments. 
For an efficient strategy to test compounds of ADME properties, fast and easy in vitro models are of 
growing importance to the pharmaceutical research. The following section gives a brief overview over 
in vitro methods used in drug discovery. 
3.4.1 Excised Tissue Models  
Excised tissue models have been extensively used to study drug absorption. They have the big 
advantage that the architecture of the tissue is obtained. One of the common tissue models is the use 
of perfused intestinal segments. The isolated segment comprises the absorptive cells and the 
underlying muscle layers. Sampling is done only on the mucosal side which implies that drug 
disappearance is assumed to be equal to the drug absorption. Efflux, metabolism and accumulation in 
the tissue could lead to a wrong estimation of absorption. Because of physiological differences of 
intestinal segments, the number of intestinal segments obtained from one animal are limited. 
Additionally, the viability of a segment is limited. This technique is not suitable for a screening tool but 
may be useful in the evaluation of complex drug formulations (71, 72). 
Another common tissue model is the everted sac model. A piece of intestine is inverted and the ends 
are tied. After filling the segment with buffer, the sac is placed in a solution of the test compound and 
samples are taken inside and outside of the sac. It suffers from similar problems as the perfused 
intestinal segments model (73, 74). 
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Diffusion cells with intestinal mucosa without muscle layer as barrier between the two compartments is 
used too. It allows the determination of transport polarity and the study of drug absorption within 
different intestinal segments. The complexity of this technique, specially the preparation of mucosa, is 
a big disadvantage compared with modern cell models (66, 72). 
3.4.2 Cell Models to Study Drug Absorption 
Numerous different cultured cells have been used to study intestinal absorption. Today, mainly Colon 
Adenocarcinoma Cells (Caco-2), HT-29, and Madin-Darby Canine Kidney Cells (MDCK) are used. 
Since drug transport studies in cell monolayers are easy to perform and require only small drug 
quantities, they are extensively used screening tools at an early stage of drug development (70). 
 
Madin-Darby Canine Kidney cells form polarized monolayers and develop tight junctions under 
adequate culture conditions. They need short culture times and the Trans Epithelial Electrical 
Resistance (TEER) is similar to the in vivo situation. The cells are well characterized but the origin of 
this cell line is generally considered as disadvantage compared to intestinal cell lines (36, 66). 
 
HT 29, a cell line derived from a human colonic adenocarcinoma, form under adequate culture 
conditions monolayers of polarized cells and differentiate into enterocytic or mucus secreting goblet 
cells. Different clones have been used to study intestinal absorption (66). One clone, the HT29-H 
clone, secrets mucus and may be an interesting model to study drug absorption but these cells grow 
very slowly. Culture times up to 43 days are needed (75). 
 
Most drug transport studies in cell monolayers have been performed using Caco-2 cell monolayer. 
The Caco-2 cells were characterized as an intestinal permeability model in 1989. The cells were 
isolated from a colon adenocarcinoma. These intestinal epithelial cells differentiate into polarized cells 
with distinct mucosal and serosal cell membrane domains if seeded on porous polycarbonate 
membranes (32). The differentiation of the Caco-2 cells starts with reaching cell confluence between 
day 4 and 7 and is finished after 16 days in culture. Although they originate from colon cells, they have 
a lot of the properties of small intestinal absorptive cells, including microvilli, intercellular tight 
junctions, and many of the enzymes, nutrient transporters, and efflux transporters present in the small 
intestinal absorptive cells (76). Some of the most important transport proteins are expressed as 
P-glycoprotein, multidrug resistance protein, and transporters for glucose, amino acids, folic acids, 
biotin, peptides, nucleosides, and monocarboxylic acids. The cells also express enzymes for phase I 
and phase II metabolism like Cytochrome P450, sucrose isomaltase, lactase, amino-peptidase, 
alkaline peptidase, carboxylesterases, glucuronyltransferases, N-acetyltransferase, sulfotransferase, 
and gluthatione S-transferase (38). Most studies investigating mechanistic drug transport focused on 
active drug transport, but a good correlation with intestinal tissue and in vivo oral absorption data was 
found too (70, 77). 
One main disadvantage of the current Caco-2 cell model is the lack or underexpression of one of the 
most important oxidative metabolic enzyme in the gastrointestinal tract, the Cytochrome P450 3A4. 
Different approaches have been undertaken to increase Cytochrome P450 3A4 levels by transfection 
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or change of culture conditions (78, 79). Because of their nature as tumor cells, Caco-2 cells may 
possess different expression levels of transporters and metabolic enzymes and may undergo 
spontaneous mutagenesis. Morphological and biochemical properties vary with passage numbers 
(38). Standardized cell culture conditions (media, seeding density) and Transwell inserts, the use of 
marker compounds and the use of a small number of passages may help to lower inter- laboratory 
differences (35-37, 80). The long culture time of around 20 days may be disadvantageous but shorter 
protocols have been developed but not established (81). Despite these limitations, the Caco-2 cells 
constitute an excellent model to study the drug transport across the intestinal barrier, provided that its 
limitations are taken into account in interpreting the data. 
3.4.3 In Vitro Models Without Cells 
To classify compounds to their ability to simple passive membrane permeation, several methods that 
do not involve biological material have been developed. The advantages of these techniques are the 
higher throughput and better reproducibility.  
A system to study relationship between molecular structures and lipophilicity is Immobilized Artificial 
Membrane Column (IAM). It consists of a special reverse-phase liquid chromatography column, where 
the support of the solid phase is coated with lipids. The correlation between membrane permeability 
and IAM is done by the retention time. A good membrane permeable compound has a long retention. 
The use and relevance of this method to study drug absorption is limited (66). 
Parallel Artificial Membrane Permeation Assay (PAMPA) uses 96- well plates consisting of two parts. 
The bottom is a standard 96-well plate filled with buffer. A special top part contains filters impregnated 
with an organic solvent which are mimicking the cell membrane. The test compound is added to the 
top part and membrane permeation is measured. This fast and cheap method has shown a good 
correlation with Caco-2 and human absorption data (66, 82, 83). PAMPA allows studying passive 
membrane absorption only, but it ignores the possible role of active processes, enzymes, and drug 
metabolism. PAMPA and Caco-2 can be synergistically applied for efficient and rapid investigation of 
permeation mechanisms in drug discovery. During early discovery, all compounds can be rapidly 
screened using PAMPA to assess passive diffusion permeability to indicate potential for 
gastrointestinal and cell assay permeation. Later in drug discovery, a combination of PAMPA with 
Caco-2 assay for potentially interesting compounds may be reasonable to characterize completely 
permeation mechanisms (84).  
3.5 In Vitro Assessment of Drug Permeability: Data Analysis 
In vivo, several factors influence the rate of drug absorption from the intestine. Dissolution rate and 
solubility determine how fast a drug reaches its maximum plasma concentration cmax. The permeability 
coefficient Pwall determines the rate of a drug crossing the biological barrier. Together, these factors 
comprise Fick’s first law and describe the flux Jwall of a drug across a biological barrier: 
maxcPJ wallwall ⋅=  
Equation 1 
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If drug permeability is assessed with an in vitro model, the apparent permeability coefficient is 
described with the following approximated solution: 
D
RR
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V
dt
dc
P
0⋅
⋅=  
Equation 2 
 
Where Papp is the apparent permeability coefficient, dcR/dt the change of drug concentration in receiver 
compartment over time, VR the volume of the receiver compartment, A the area of the barrier surface, 
and c0D the initial drug concentration in the donor compartment (85). 
This approach has some limitations. The cell monolayer is considered as a single rate limiting barrier, 
without taking into account possible influence on permeability of a diffusion boundary layer on highly 
permeable compounds. Equation 2 is not sensitive to mass balance problems like metabolism, binding 
to cells or device surfaces, and drug stability, because it depends on the total mass transported to the 
receiver relative to initial mass. Equation 2 is accurate for an early time point, defined by linear drug 
transport with time, maintaining of sink conditions, and negligible backflow (86).  
Since this approach does not directly show any involvement of carrier mediated processes, active 
apical efflux substrates are identified by comparison of the drug permeability from apical to basal 
compartment with the drug permeability from basal to apical compartment, building the efflux ratio 
(ER).  
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Equation 3 
 
The ER is calculated with Equation 3, where Pappa_b is the apparent permeability coefficient in apical to 
basal direction and Pappb_a the apparent permeability coefficient from basal to apical compartment. For 
compounds with an ER close to one, active efflux is implausible. If ER excesses 2, involvement of 
carrier mediated efflux is presumably existent (34). This approach has some limitations and 
disadvantages. The ER is time dependent and sensitive to the extent of passive permeation, which 
means that a highly permeable compound may not be detected by this approach, because the ER is 
practically 1 compared to a low permeable compound with the same amount of carrier mediated 
transport. The approach to characterize drug transport through cell monolayer with equation 2 and 3 is 
not suitable to quantify directly the passive permeability of a substrate to carrier mediated transport. 
The common practice to calculate passive permeability for substrates to carrier mediated transport is 
to subtract passive transport curves, gained by using an inhibitor for the carrier, from the active 
transport curve. This might be an approximated semi quantitative solution at early time points, but 
neglects reversibility of transport, which is substantial over longer time periods. In the apical to basal 
direction is the calculated permeability lower than the real permeability because the carrier mediated 
transport is bigger than backdiffusion alone. In the basal to apical direction, the active transport results 
in higher drug concentrations in the apical compartment compared to passive diffusion alone leading 
to a higher permeability. 
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The use of these approximated equations still requires the establishment of the linear phase of 
permeability because the equation describes just the initial slope of the transport curve. To study 
substrates of carrier mediated transport or the influence of drug formulations on transport processes it 
is important to gain knowledge about the equilibrium conditions and the interaction with the cells. 
Further, this method does not take into account a potential cellular retention of compounds, which is 
known for lipophilic drugs (42). 
 
A more detailed model by Ho et al., describing transcellular diffusion of highly membrane interactive 
permeants and lipophilic molecules with a long membrane residence, differs from the previous 
described approximation by subdividing the transcellular transport into several single steps as shown 
in Figure 2.  
 
 
Figure 2 Sophisticated transcellular drug permeation model for highly lipophilic and membrane 
interactive drugs that takes into account protein binding of the drug, formulation to cell 
partitioning, influence of diffusion boundary layer, drug uptake and drug efflux. Legend: Highly 
lipophilic and membrane-interactive drug is denoted by D as it permeates through a cell within 
a continuous monolayer. h and h′, thicknesses of the aqueous boundary layers. kd and ka, 
dissociation and association binding constants, respectively. P, protein molecule. Permeability 
coefficients: Effective, Pe; aqueous boundary layer, PABL and P′ABL; apical membrane, Pap; 
basolateral membrane, Pbl 
 
The model describes the transcellular diffusion of a drug solution containing albumin to a receiver 
compartment containing albumin as well. The model describes the uptake of unbound drug through 
diffusion boundary layer to the cell and the efflux from the cell into the acceptor compartment. The rate 
of disappearance of a drug from donor solution can be described as 
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And the rate of appearance in the receiver sink is 
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Where the apical uptake (α, [min-1]) and basolateral efflux (γ, dimensionless) rate constants and the 
partition parameter (β, [min-1]) are 
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CD and CR are the total concentration (including free and bound drug) in the donor volume VD and in 
the receiver solution VR, respectively. Vcell is the volume of the cell monolayer, A the cross-sectional 
area of the monolayer and ε is the porosity of the filter. The effective membrane uptake permeability 
coefficient (Pe) for the apical membrane partition coefficient (K) are functions of protein concentration. 
The permeability coefficients of the basolateral membrane per se, filter support, and aqueous 
boundary layer on the filter side are Pbl, PF, and PABL, respectively. 
This model is applicable to quantify not only the transmonolayer kinetics of highly membrane 
interactive compounds but also the kinetics of less membrane interactive compounds. It also takes 
into account how a drug formulation influences the permeability (59, 87, 88). One of the disadvantages 
of this model is, that different experiments with different test assemblies are used to determine the 
permeability of a compound through a cell monolayer. The uptake experiments in apical to cell 
direction were performed in Petri dishes, whereas efflux from cell to basal compartment and 
transmonolayer permeability coefficients were determined using Transwell plates. The model was 
deduced for simple passive diffusion in the apical to basal direction but does not take into account 
substrates to carrier mediated efflux. 
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3.6 Effect of Food on Drug Absorption 
The presence of food in the gastrointestinal tract may alter the oral bioavailability of drugs. Food leads 
to secretion of gastric acid, bile, and pancreatic fluids which may alter the rate and extent of 
absorption. A slowed gastrointestinal motility and alterations in blood and lymph flow have also an 
impact on absorption. 
The digestion of dietary lipids decreases gastric motility and increases the secretion of bile and 
pancreatic fluids. Bile may improve the bioavailability of poorly water soluble drugs by enhancing the 
dissolution rate and the solubility. Bile and the products of lipid digestion (mono- and di-glycerides and 
free fatty acids) are effective emulsifying agents. Lipids and lipophilic drugs can also be absorbed by 
the lymphatic pathway, which bypasses the liver first pass metabolism and may increase the 
bioavailability. Examples for drugs with increased postprandial oral bioavailability are griseofulvin, 
danazol, and halofantrine (89). 
3.7 Absorption Enhancement by Solubility Enhancement for Oral 
Drug Delivery 
Drugs classified in BCS class II achieve high membrane permeability but a low solubility leading to a 
low dissolution, slow drug uptake, low blood and plasma levels, and poor bioavailability after oral drug 
uptake. If solubility may be increased with appropriate methods, higher dissolution accomplished by 
higher drug uptake, and increased plasma levels is achieved. Hence, a lot of strategies were 
developed in pharmaceutical technology to increase the solubility of drug solutions. Salts are used to 
increase the solubility of ionizable compounds. Some compounds were able to build complexes with 
appropriate complexing agents, e.g. cyclodextrins may be used to solubilize lipophilic compounds by 
embedding them. Cosolvents are used extensively to increase solubility of lipophilic poorly soluble 
compounds by disturbing the cluster structure of water. The use of surfactants increases the solubility 
of poorly soluble compounds by formation of micelles, which incorporate the drug molecules. 
As mentioned before, oral drug intake after a fatty meal may increase bioavailability of diverse 
lipophilic compounds. It is obvious as a strategy to improve bioavailability of poorly soluble or poorly 
absorbed compounds by the use of lipid containing dosage forms (89).  
3.8 Absorption Enhancement with Intestinal Permeation Enhancers 
3.8.1 Permeation Enhancement by Tight Junction Opening 
Hydrophilic, charged compounds are absorbed via the paracellular route. In epithelial tissues, tight 
junctions are limiting paracellular transport. A transient opening of tight junctions potentially increases 
paracellular transport and would seem less damaging than a disruption of cell membrane structure. 
Thus, it is important to develop an understanding of the mechanism of action of an absorption 
enhancing formulation or excipient. 
Various fatty acids have been shown to have membrane permeation enhancing activity. Sodium 
caprate has been the most thoroughly characterized for use as an absorption enhancing excipient. It 
increases the Caco-2 permeabilities because of dilatation of tight junctions. In vivo, absorption 
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enhancement was shown. The absorption enhancing effect was higher in colon than in jejunum. 
Chitosan acts in vitro as an intestinal permeation enhancer by opening tight junctions in a 
concentration and pH dependent way. Chitosan reduced Caco-2 TEER values and increased 
apparent permeability of mannitol. Nevertheless a vehicle containing 1.5% chitosan at pH 6.7 
increased the bioavailability of intraduodenally administered buserelin in rats (90).  
Degradation products of phospholipids like lysophosphatidylcholine decrease significantly TEER 
compared to controls in cell models, indicating tight junction opening. Lysophosphatidylcholine may be 
formed out of phospholipids by the activity of Phospholipase A2 which is expressed in the intestinal 
epithelia (91). 
3.8.2 Permeation Enhancement by Inhibition of Efflux Transporters 
An increasing number of drugs have been recognized as substrates to carrier mediated efflux, which 
may limit drug absorption. Inhibition of efflux transporters in the intestine offers a potential strategy to 
improve oral bioavailability. Strategies like coadministration of a drug with affinity to the efflux 
transporter, coadministration of a specific inhibitor without pharmacological effect, or nonspecific 
inhibition of the efflux transporter Pgp by pharmaceutical excipients are discussed. Some widely used 
pharmaceutical excipients, including surface active compounds, lipids, and polymers, are known to 
enhance the intestinal absorption by inhibiting nonspecifically efflux transporters (92). The underlying 
mechanisms of efflux inhibition of the pharmaceutical excipients are still under discussion. Several 
excipients can indirectly inhibit Pgp through effects on the lipid membrane because the activity of Pgp 
is modulated by the physical state of the lipid bilayer. For example PEG-300 alters the membrane 
fluidity by changing the microenvironment of the Caco-2 cell membranes, which perturbs the ability of 
efflux transporters to efflux substrates such as taxol and doxorubicin. PEG-300 causes almost 
complete inhibition of Pgp activity in an MDR1- transfected Madin-Darby Canine Kidney cell line (93). 
Also Tween 80 and Cremophor EL increase the membrane fluidity, whereas Vitamin E TPGS 
decreases the membrane fluidity (94). But changes in membrane fluidity alone may not be generalized 
as mechanism to reduce transporter activity (95). An alteration in the fluidity of the lipid membrane 
environment of Pgp modulates the drug efflux, by reduction of the ATPase activity (96). Other 
mechanism are discussed like energy depletion by decreasing the ATP pool available for Pgp which is 
together with membrane fluidization, that causes inhibition of Pgp ATPase activity, a critical factor 
contributing to the Pgp inhibition (97). Pluronic P85 inhibits P- glycoprotein mediated efflux of 
rhodamine 123 in Caco-2 cells (98). 
Some of these in vitro effects have been also verified in vivo (99). In vitro, D-α-tocopheryl polyethylene 
glycol 1000 succinate (TPGS) acts as a reversal agent for P-glycoprotein multidrug resistance and 
inhibits Pgp mediated drug transport of paclitaxel and rhodamine 123 in a Caco-2 cell assay (100). In 
an in vivo intraduodenal perfusion study, low TPGS concentrations (0.04%) significantly increased the 
bioavailability of talinolol (99).  
3.8.3 Permeation Enhancement by Influencing the Cell Membrane 
The easiest way to evaluate the effectiveness, mechanism, and potential for toxicity of absorption 
enhancers is to use in vitro models of the intestinal epithelium (Caco-2 models or animal intestinal 
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segments). These in vitro studies can provide an initial consideration of the possible extent of 
permeation enhancement for a drug or excipient of interest and whether this can be accomplished 
without damaging the membrane. But many of the compounds examined in vitro as membrane 
permeation enhancers cause cytotoxicity or membrane damage. Intact intestinal tissues are found to 
be more resistant to the cytotoxic effects of permeation enhancer than cell culture models, because 
intact tissue has mechanisms for recovery and an additional physical barrier like intestinal mucus.  
Various nonionic, anionic, and cationic surfactants have been investigated as intestinal permeation 
enhancers. Nonionic surfactants influence absorption enhancing activity by size and structure of both 
the alkyl chain and the polar group. Generally these seem to affect membranes by solubilizing 
membrane components. Medium chain glycerides, e.g. mono- and diglycerides of caprylic and capric 
acid, are used as pharmaceutical excipients and as nutritional agents. Diglycerides are much less 
active than monoglycerides as membrane permeation enhancers. Steroidal detergents like 
physiologically occurring bile salts have membrane permeation enhancing effects. Many investigators 
explain membrane permeation enhancing effects with reversibly damaging the intestinal mucosa. The 
colon may be more sensitive than the small intestine to the absorption enhancing effect of bile acids, 
as shown in the effects of glycocholate on insulin absorptions in rats. Physiologically, bile salts are 
present in the intestinal lumen in the form of mixed micelles. The in vitro effects of bile salt on 
epithelial membranes can be quite different when they are incorporated with other agents in mixed 
micelles. For example the permeation-enhancing effects and cytotoxicity of taurocholate on Caco-2 
monolayers was greatly reduced when incorporated with phospholipids or cholesterol in mixed 
micelles, but a mixed micelle composed of taurocholate and oleic acid had much more potent 
membrane effects than taurocholate alone (101). 
3.9 Influence of Pharmaceutical Formulations on Gastrointestinal 
Drug Absorption 
In previous chapters, the influence of different pharmaceutical excipients on gastrointestinal drug 
absorption was summarized. Similar effects have been expected, when complex pharmaceutical 
preparations have been investigated on their influence on gastrointestinal drug absorption. A 
successful strategy is the formulation of poorly water soluble drugs with lipid containing formulations 
like self emulsifying drug delivery systems (SEDDS). These orally administered lipid containing 
dosage forms generally consist of a drug dissolved in a mixture of two or more excipients like 
triglycerides, partial glycerides, surfactants and cosolvents. The underlying molecular mechanisms of 
the absorption enhancement are known partially (29, 30). It is generally agreed so far that improved 
dissolution compared to an aqueous suspension of lipophilic drug increases the absorption because 
the drug is solubilized in a lipid containing dosage form already (102-104). The dissolution is improved 
by facilitating the formation of solubilized phases from which absorption may occur. The presence of 
digestion products and bile salts in the intestine may facilitate diffusion through diffusion boundary 
layer and alter intrinsic permeability of the intestinal membrane via paracellular and transcellular 
permeation. It was observed that drug solubilization may decrease the free fraction of poorly soluble 
drugs. This could potentially lead to a decrease in absorption, if no other beneficial mechanisms are 
involved (105). 
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Lymphatic transport has been shown to be a contributor to the oral bioavailability of highly lipophilic 
drugs. The formation of lipoproteins in the intestinal tract is a prerequisite for lymphatic transport. If 
highly lipophilic drugs are formulated with suitable lipid containing vehicles, intestinal lymphatic 
transport may be promoted (106).  
Self emulsifying drug delivery systems contain large amounts of surfactants that have been described 
to have absorption enhancing effects by inhibiting drug efflux (107). 
Few commercially available products have been approved so far, where this strategy has been used 
successfully to improve the oral bioavailability of some drugs deemed to be hardly deliverable, e.g. 
Neoral® (cyclosporine), Norvir® (ritonavir), Fortovase® (saquinavir), and Agenerase® (amprenavir) (22-
28, 104). Reasons for this small amount of approved products on this basis may be the limited 
knowledge about formulation parameters that are responsible for good in vivo performance. Some 
partially successful attempts have been done for the oral administration of liposomes, most in the field 
of protein and peptide delivery like vaccine or insulin delivery, only few in the field of poorly water 
soluble drugs (108). 
Of special commercial interest are soft gelatin capsules filled with concentrates of lipid phases, that 
form fine oil in water emulsions or microemulsions when they are diluted by aqueous solutions under 
mild agitation (106).  
3.10 Mass Transfer of Lipophilic Compounds Between Lipid 
Particles or Membrane Vesicles and Cell Membranes 
As membrane biochemistry studies with liposomes as model membranes were performed, an inter-
membrane transfer phenomenon was described where lipophilic molecules were transferred from a 
liposomal carrier system to model membranes.  
Two models have been proposed to explain the transfer of lipophilic molecules between two lipid 
domains. The first model proposes molecule transfer through water phase as postulated by 
cholesterol transfer (109). This transfer is mathematically described as first order model, suggesting 
that the transfer was independent from donor and acceptor vesicle concentration (110). This model 
follows the “free fraction dogma” in pharmacokinetics, which describes that only unbound drug has a 
pharmacological effect. 
The second model proposes a transfer of lipophilic molecules from lipid domain to lipid domain by 
collision of lipid vesicles in addition to transfer through the aqueous phase. This collision-model is 
mathematically described as a second order model originally modeled for cholesterol and 
phosphatidylcholine transfer between phospholipid vesicles (111). Transfer of lipophilic drugs from 
lipid containing particles to cell membranes may be subject of the same underlying mechanism (112). 
The role of these in vitro models for the in vivo situation, has still to be discovered. 
3.11 Choice of Model Compounds 
It was the aim of this work to investigate lipophilic drugs with different properties. Literature was 
searched for lipophilic compounds with high or low permeability according to the biopharmaceutical 
classification system (BCS). We focused on BCS class I, II, and IV compounds which means high 
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permeability and high solubility in class I, low solubility and high permeability in class II, and low 
permeability and low solubility in class IV (2). 
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Figure 3 Used model compounds for the determination of the influence of lipid containing 
dosage forms on Caco-2 cell permeation. Propranolol (panel A), progesterone (panel B), 
triclabendazole (panel C), and saquinavir (panel D) were used. 
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Propranolol was chosen as model compound for BCS class I (2). Propranolol is a widely used marker 
compound for transcellular transport in the Caco-2 assay with a log P of 2.53 (42).  
Progesterone was chosen as model compound for BCS class II. It is very slightly soluble in water 
exhibiting a log P of 3.8-3.87 and no carrier mediated transport is known (42, 113).  
As a model compound for BCS class IV, triclabendazole was chosen. It is insoluble in water and 
exhibits a calculated log P of 5.969 (calculated using Advanced Chemistry Development Software 
V8.14 for Solaris [1994-2008 ACD/Labs]). The permeability classification is inconclusive and is 
described in literature as high or low (1). It undergoes strong first liver pass if orally administered 
(114). As complement, saquinavir was chosen as model compound of BCS class IV, possessing low 
solubility, exhibiting a log P of 4.1, low permeability, and it is subject of carrier mediated transport (1, 
115, 116). 
3.12 Choice of Model Formulations 
Macroscopically aqueous but microscopically structurally diverse lipid formulations were studied in this 
work. Liposomes, microemulsions and emulsions were used as model formulations.  
Liposomes are spherical vesicles consisting of one or more phospholipid bilayer that are similar to 
cellular membranes. The formation of these vesicles occur spontaneously if phospholipids were 
dispersed in aqueous media with appropriate methods. The properties of the liposomes, such as size 
can be influenced by the membrane composition and the manufacturing process. Liposomes have 
suitable properties as drug carriers, which are low systemic toxicity, ability to incorporate lipophilic and 
hydrophilic drugs, and high stability (108). The liposomes, which have been chosen for this work, were 
tested for their compatibility with the Caco-2 model in previous work of our group already (115). These 
liposomes consist mainly of Lipoid S100, which is phosphatidylcholine (>94%) isolated from soy 
lecithin.  
Microemulsions are disperse systems of two not miscible phases. They consist typically of one or 
more lipid, a surfactant, a cosolvents and an aqueous phase. The formation of microemulsions occurs 
spontaneously if the lipid phase is dispersed under mild agitation in the water phase. Microemulsions 
are optically clear or exhibit weak opalescence. Typical particle sizes are 5-140 nm (102, 105). The 
chosen microemulsion was tested already concerning cytotoxicity and compatibility with the Caco-2 
model in previous work of our group. The lipid phase was consisting of 35.05% (m/m) triglyceride 
(Captex 8000), 17.58% (m/m) mixture of mono- and diglycerides (Capmul MCM), 36.84% (m/m) 
surfactant (Cremophor EL), and 10% (m/m) ethanol (117). 
Emulsions are disperse systems of two not miscible phases and are composed of a lipid phase and 
water phase. Emulsions are stabilized by adding an emulgator. Emulsions have bigger particles than 
microemulsions, are optically turbid and their formation consumes energy. An emulsion, representing 
the third model formulation, was newly developed for this work. Regarding compatibility with the 
Caco-2 model, a formulation out of components, which were tested already for their compatibility with 
the Caco-2 model in previous work of our group, was developed using Cremophor EL, Captex 8000, 
Capmul MCM, and ethanol. Cremophor EL is a nonionic surfactant and consists of the product of the 
reaction of ethylene oxide with castor oil. It was chosen for this study because it shows no cell 
damage up to high concentrations (up to 10%) and shows an inhibiting effect on apical carrier 
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mediated efflux (94). Captex 8000 consists of >99% tricaprylin, which is a triglyceride substituted with 
three caprylic acid moieties. Caprylic acid is a C-8 fatty acid. Capmul MCM is a mixture of mono- and 
diglycerides. The fatty acids consist of 3.2 % capronic acid (C-6), 66.8% caprylic acid (C-8), 29.6% 
caprinic acid (C-10), and traces of laurinic acid and palmitinic acid. Additionally, ethanol was used as 
cosolvent. 
 
For this study, it was very important to use formulations with small influence on the tight junctions, 
because the influence of formulations on the intact membrane barrier should be studied. Since it is 
known that several formulation components may work as permeation enhancers by tight junction 
modulation, trans-epithelial electrical resistance (TEER) was used as criteria to test monolayer 
integrity.
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4 EXPERIMENTAL SECTION 
The experimental section is divided into different parts which are a publication part (section 4.1), 
preliminary experiments, and additional work. Each part is discussed separately. 
4.1 Influence of Structurally Diverse Lipid Containing Drug 
Formulations on the Transport of Lipophilic Drugs through 
Caco-2 Cell Monolayer (Publication Part) 
4.1.1 Abstract  
Introduction: To overcome poor bioavailability of poorly water soluble drugs, lipid containing drug 
formulations were used. We determined the influence of structurally diverse lipid containing drug 
formulations, including liposomes, a microemulsion, and an emulsion, on transport processes of 
lipophilic model drugs (propranolol, progesterone, saquinavir, and triclabendazole) through Caco-2 
monolayers. Methods: Drug absorption was determined in a bi-directional Caco-2 assay, using purely 
aqueous drug solutions as reference. Passive permeability coefficient of the apical (Pa) and of the 
basal membrane (Pb), formulation-to-cell partition coefficient, and carrier mediated efflux kinetics were 
deduced by fitting a mathematical model to the transport data with the software Easy Fit®. At least 
three different lipid concentrations for each formulation in the range of 0.1-50 mg/ml were tested. 
Within each lipid concentration at least three different drug concentrations were tested per drug. The 
formulations were characterized for free fraction of drug by equilibrium dialysis. Further, a biophysical 
model was developed to delineate the contribution of drug transport in the diffusion boundary layer 
and drug permeation through cell membrane to the determined apparent permeability coefficient. 
Additionally, a differentiation was introduced between permeation of free drug through the cell 
membrane and permeation following direct drug transfer from the lipid particles to the membrane upon 
collision. Results and Discussion: Pa, Pb and free fraction decreased with increasing lipid 
concentration. Within one lipid concentration, no influence of drug concentration on Pa, Pb, and free 
fraction was determined. No effect on permeability and free fraction was observed with propranolol 
emulsions and microemulsions. Triclabendazole showed lower Pb whereas permeability coefficients of 
all other drugs were equal for both membranes. Free fraction of drug plays an important role for 
intestinal cell permeation but direct transfer of lipophilic drugs from lipid phase of the formulation to cell 
membrane can also make an essential contribution to drug permeation. The relative significance of 
these two processes may depend on the drug and the formulation. These observations apply to 
structurally different lipid containing drug formulations. This could explain differences in permeability 
coefficients of the drugs. 
4.1.2 Introduction 
The modern drug discovery strategies like combinatorial chemistry and high throughput screening 
prefer lipophilic, poorly soluble compounds. These compounds show often solubility and oral 
bioavailability problems in vivo. To ensure an efficient oral delivery, a drug has to be suitable for oral 
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administration. To be absorbed from the gastrointestinal tract, a drug has to be sufficient soluble, 
because, with some exceptions, passive diffusion from high to low drug concentration of dissolved 
drug molecules is the driving force of drug absorption. Drug absorption is generally defined as the 
process by which unchanged drug proceeds from site of administration to site of measurement within 
the body (54). A general drug classification of the impact of drug solubility and membrane permeability 
on the drug absorption has been done by the framework of the biopharmaceutics classification system 
(BCS) (1, 2). Different physicochemical and physiological properties determine the reasons for poor 
drug absorption which are poor water solubility, low membrane permeability, carrier mediated drug 
efflux, drug metabolism, and pharmacological interactions. The most important cause for low 
permeability is the ability of the molecule itself to cross a biological barrier by passive diffusion. 
Several physicochemical properties are influencing the ability to cross biological barriers, which are 
lipophilicity, molecular weight, hydrogen bonding capacity, and charge (3-6). 
An increasing number of drugs has been identified to be subject of carrier mediated efflux, which is 
limiting the trans-membrane permeability and finally the oral bioavailability. Carrier mediated efflux is 
caused by proteins located in the apical cell membrane by pumping back drug molecules from the 
cellular compartment to the intestinal lumen. These efflux pumps have a broad substrate spectrum 
which is a powerful mechanism to prevent the body from the uptake of toxic alimentary ingredients 
and, unfortunately, from the oral absorption of many drugs (8). Most important efflux transporters for 
drugs belong to the ATP-binding cassette (ABC) family, e.g. P-glycoprotein (Pgp), breast cancer 
resistance protein (BCRP) and MRP2 (9-13). 
A successful strategy to improve the oral bioavailability of poorly water soluble drugs is the use of lipid 
containing dosage forms in vivo. Lipid formulation can reduce the inherent limitation of slow and 
incomplete dissolution of poorly water soluble drugs by facilitating the formation of solubilized phases 
from which absorption may occur (105). Oral administered lipid containing dosage forms generally 
consist of a drug dissolved in a mixture of two or more excipients like triglycerides, partial glycerides, 
surfactants and cosolvents (107). Some partially successful attempts have been done for the oral 
administration of liposomes, most in the field of protein and peptide delivery like vaccine or insulin 
delivery, only few in the field of poorly water soluble drugs (108). Of special commercial interest are 
soft gelatine capsules filled with concentrates of lipid phases, that form fine oil in water emulsions or 
microemulsions when they are diluted by aqueous solutions under mild agitation (106). Few 
commercially available products on this basis have been approved so far, e.g. Neoral® (cyclosporine), 
Norvir® (ritonavir), Fortovase® (saquinavir), and Agenerase® (amprenavir) (22-28, 104). Reasons for 
this small amount of approved products may be limited knowledge about formulation parameters that 
are responsible for good in vivo performance based on limited knowledge about the underlying 
mechanisms. It is generally agreed so far that improved dissolution compared to an aqueous 
suspension of lipophilic drug increases the absorption because the drug is already solubilized in a lipid 
containing dosage form (102-104). The formation of lipoproteins in the intestinal tract of highly 
lipophilic drugs formulated with suitable vehicles promotes intestinal lymphatic transport (106). The 
presence of digestion products and bile salts may facilitate diffusion through diffusion boundary layer 
and alter intrinsic permeability of the intestinal membrane via paracellular and transcellular permeation 
(105). Ingredients like surfactants are known to have an inhibitory potential on efflux (92-100, 118). 
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There is little information in the literature dealing with the effect of lipid containing dosage forms on the 
passive permeation, which is considered to be the main pathway of drug absorption of poorly water 
soluble drugs. It was observed that drug solubilization may decrease the free fraction of poorly soluble 
drugs (105). This could potentially lead to a decrease in absorption, if no other beneficial mechanisms 
are involved (4, 59, 88, 115). There is little information in literature describing a mechanism for 
lipophilic drugs that contributes to the transmembranal permeability based on mass transfer from lipid 
particles to membrane surfaces originating from membrane biochemistry studies with liposomes as 
model membranes. Two models have been proposed to explain the inter-membrane transfer of 
lipophilic molecules between two lipid domains. The first model proposes molecule transfer through 
water phase as postulated by cholesterol transfer (109). This transfer is mathematically described as 
first order model, suggesting that the transfer is independent from donor and acceptor vesicle 
concentration (110). The second model proposes a transfer of lipophilic molecules from lipid domain to 
lipid domain by collision of lipid vesicles in addition to transfer through the aqueous phase. This 
collision-model is mathematically described as a second order model (111). Lipophilic drugs may be 
subject of the same underlying mechanism (112). The role of these models for drug transport from 
lipid vesicles to cellular membranes is rarely known. 
In vitro cell models are useful tools to investigate the influence of lipid containing formulations on 
passive permeation and efflux of poorly water soluble drugs, because none of the in vivo described 
possible beneficial mechanisms, such as lymphatic transport and lipid digestion, may take place. One 
of the most frequently used and best characterized cell models for mechanistical studies on drug 
absorption is the human colon adenocarcinoma cell line Caco-2. These cells spontaneously 
differentiate into enterocyte like cells and form a cell monolayer when cultivated on a semipermeable 
filter support. The characteristics of Caco-2 cells have been well described and nicely reviewed 
elsewhere (32-39, 43, 70, 77-80). Few attempts have been undertaken to investigate complex drug 
formulations with the Caco-2 model, most of them by testing physiologically more relevant media for 
their suitability as transport media. Most of these experiments were focusing on cell viability and 
qualitative effects of the tested formulation on model drugs (44-53, 115, 117). Little systematical work 
on the quantitative interactions of lipids on cellular drug permeation has been done so far. Previous 
work of our group showed the possibility to use liposomes as tool to increase solubility of poorly water 
soluble compounds saquinavir and indinavir (115). 
Aim of the study: One of the major objectives of this work was to refine the previously published 
mathematical model for the kinetics of cellular transport, because this model predicted intracellular 
concentrations systematically too low (115). On the basis of cell permeation experiments a new 
biophysical model was developed describing the interactions between lipid containing drug 
formulation, the drugs, and the cell monolayer for a better understanding of the absorption process 
through the epithelial barrier. We focused on the influence of the formulations on passive permeability. 
Additionally we investigated the influence of microemulsions and emulsions on the carrier mediated 
efflux, because an inhibition of Pgp was observed for saquinavir liposomes in previous work of our 
group. As model formulations we chose liposomes, an emulsion, and a microemulsion. All 
components of the formulations, the liposomes, and the microemulsion were tested already for their 
compatibility with the Caco-2 cell model in previous work of our group regarding cell toxicity (115, 
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117). Since it is known that several formulation components may work as permeation enhancers by 
tight junction modulation and we wanted to study the influence of formulations on the intact monolayer, 
it was very important to use formulations with small influence on the cell monolayer integrity. In this 
context Cremophor EL was chosen as surfactant in emulsion and microemulsion for this study 
because it shows no cell damage up to high concentrations (up to 10%) and shows additionally an 
inhibiting effect on active efflux (94). To determine the influence of the different formulations, we used 
different model drugs, which had lipophilic properties in common. Propranolol was chosen as model 
compound for high water solubility and high permeability and belongs to the BCS class I (2). 
Propranolol is a widely used marker compound for transcellular transport in the Caco-2 assay with a 
log P of 2.53 (42). Progesterone was chosen as model compound for low water solubility and high 
permeability and belongs to the BCS class II. Progesterone is very slightly soluble in water exhibiting a 
log P of 3.8-3.87, no carrier mediated transport is known (42, 113). Triclabendazole was chosen as a 
model compound for BCS class IV. It is practically insoluble in water and exhibits a calculated log P of 
5.969 (calculated using Advanced Chemistry Development Software V8.14 for Solaris [1994-2008 
ACD/Labs]). The permeability classification is inconclusive and is described in literature as high or low 
(1, 114). No carrier mediated apical drug efflux has been reported. As complement saquinavir was 
chosen as model compound of BCS class IV, possessing low solubility, exhibiting a log P of 4.1, low 
permeability, and it is subject of carrier mediated transport (1, 115, 116). 
4.1.3 Material and Methods 
4.1.3.1 Material 
The human colon adenocarcinoma cell line Caco-2 was a kindly provided by Prof. H P Hauri, 
Biocenter, University of Basel, and originated from the American Type Culture Collection (ATCC, 
Rockville, MD, USA). Dulbecco’s Modified Eagle’s Medium (DMEM) (with l-glutamine, 4500 mg/l D-
glucose, without sodium pyruvate), l-glutamine 200 mM (100x), MEM non essential amino acids 
solution (100x, without l-glutamine), foetal bovine serum (FBS), Trypsin EDTA (10x) liquid, and 
Dulbecco’s Phosphate Buffered Saline (without Ca2+, Mg2+) were all purchased from Gibco 
(Gaithersburg, MD, USA). The cell culture medium was composed of DMEM supplemented with 
10% (V/V) FBS, 2 mM l-glutamine, and 1% (V/V) MEM. 
Transport media used for the permeation studies and the equilibrium dialysis experiments were 
prepared with Dulbecco’s Modified Eagle’s Medium (DMEM) base powder (without glucose, 
l-glutamine, phenol red, sodium pyruvate and sodium bicarbonate, purchased from SIGMA-Aldrich, 
Fluka Chemie GmbH, Buchs, Switzerland). DMEM base powder was dissolved in bi-distilled and 
autoclaved water and supplemented with glucose (4.5 g/l), HEPES (4.76 g/l), NaCl (1.987 g/l), and 
l-glutamine (0.876 g/l). The pH was adjusted to 7.4 and the final medium was filtered through a sterile 
filter (Supor-200, 0.2 µm pore size, Pall Corporation, Michigan, USA) under aseptic conditions. 
Glucose, HEPES, NaCl, and l-glutamine were purchased from SIGMA-Aldrich (Fluka Chemie GmbH, 
Buchs, Switzerland). Dulbecco’s Phosphate Buffered Saline (D-PBS) (with Ca2+, Mg2+) was purchased 
from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). 
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Petri dishes (56.7 cm2) were purchased from Nunc (Roskilde, Denmark) and 6-well Polycarbonate 
Membrane Transwell Plates with an insert area of 4.7 cm2 and 0.4 µm pore size were ordered from 
Costar (Corning Incorporated, Corning, NY, USA). 
Captex 8000 was purchased from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland), Capmul 
MCM was purchased from Abitec Corporation (Janesville, USA). Cremophor EL was ordered from 
Fluka (Fluka Chemie GmbH, Buchs, Switzerland). Lipoid S 100 and Lipoid EPG were kindly provided 
by Lipoid GMBH (Ludwigshafen, Germany). Saquinavir was kindly provided by Roche 
Pharmaceuticals (Basel, Switzerland). Progesterone and propranolol were purchased from Fluka 
(SIGMA-Aldrich, Fluka Chemie GmbH, Buchs, Switzerland). Triclabendazole was kindly provided by 
Phares Drug Delivery (Muttenz, Switzerland). All other chemicals were of analytical grade. 
4.1.3.2 Cell Culture Procedures 
Caco-2 cells were cultivated in Petri dishes using culture medium at 37°C in a water saturated 
atmosphere of 8% CO2. The cells were passaged by treatment with a solution of 0.25% trypsin and 
2.65 mM EDTA with a splitting ratio of 1:12 when the cell monolayer reached 90% confluence on the 
Petri dishes. Transwell were seeded at a density of 1.14*105 cells/cm2 into 6-well Transwell plates. 
The culture medium was changed every alternating day.  
4.1.3.3 Drug Quantification 
Drug quantification of all drugs was performed by HPLC-UV (Agilent series 1100, Agilent 
Technologies USA, equipped with a G1312A binary pump, an auto sampler G1367B and a variable 
wavelength detector G1314B) using a C-18 reversed phase column (CC 125/2 Lichrospher 100 RP 18 
ec, Macherey Nagel, Oensingen, Switzerland). Isocratic methods with a flow rate of 0.25 ml/min were 
used. The samples were stored at 4°C. Quantification was performed against a set of external 
standard solutions within the linear response concentration range.  
The drug concentration of progesterone was determined with the following mobile phase: distilled 
water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 40/45/15 (V/V). Ammonium 
acetate with a concentration of 0.55 g/l was added to the mobile phase. The pH-value at 25°C was 
6.9. An injection volume of 100 µl and a runtime of 7.5 min were used to detect progesterone at 
239 nm in UV. Using this method, retention time of progesterone was approximately 5 min.  
The drug concentration of propranolol was determined with the following mobile phase: distilled water 
(bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 55/20/25 (V/V). Ammonium acetate 
with a concentration of 0.55 g/l was added to the mobile phase. The pH- value at 25°C was 7.0. An 
injection volume of 100 µl and a runtime of 8 min were used to detect propranolol at 295 nm in UV. 
Using this method retention time of propranolol was approximately 3.5 min. 
The drug concentration of saquinavir was determined with the following mobile phase: distilled water 
(bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 40/45/15 (V/V). Ammonium acetate 
with a concentration of 0.55 g/l was added to the mobile phase. The pH- value at 25°C was 6.7. An 
injection volume of 100 µl and a runtime of 8 min were used to detect saquinavir at 239 nm in UV. 
Using this method retention time of saquinavir was approximately 5 min.  
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The drug concentration of triclabendazole was determined with the following mobile phase: distilled 
water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 35/40/25 (V/V). Ammonium 
acetate with a concentration of 0.55 g/l was added to the mobile phase. The pH- value at 25°C was 
6.7. An injection volume of 100 µl and a runtime of 8 min were used to detect triclabendazole at 
305 nm in UV. Using this method retention time of triclabendazole was approximately 5.6 min. 
Quantification of triclabendazole was performed against a set of external standard solutions within the 
linear response concentration range. To maintain the sample stability over time and reproducibility of 
the method, the standard solutions of triclabendazole contained the same amount of lipids as the 
samples. Samples were stored at 4°C. 
4.1.3.4 TEER Measurements 
The integrity of the Caco-2 cell monolayer in the Transwell plates was ensured with the measurement 
of the trans-epithelial electrical resistance (TEER) before and after every drug permeation study. 
After washing the cell monolayer with 37°C tempered D-PBS (with Ca2+, Mg2+), 1600 µl transport 
medium was added into the apical and 2800 µl transport medium was added into the basal 
compartment. The Transwell plate was equilibrated 60 min in the cell culture incubator before the pre-
experimental measurement. The TEER was measured with an EVOM-G-Meter (EVOM-G-Meter 
Modell -24, World Precision Instruments, Berlin, Germany) equipped with an EndohmTM tissue 
resistance measurement chamber containing 4.6 ml tempered transport media (World Precision 
Instruments, Berlin, Germany). The measurement chamber was tempered to 37°C with transport 
medium before the measurement. For the post-experimental TEER measurement, the withdrawn 
volume in the apical compartment was replaced with transport medium before TEER was measured. 
Caco-2 monolayer with TEER values exceeding 250 Ωcm2 were used for transport experiments. 
4.1.3.5 Drug Permeation Across Caco-2 Cell Monolayers 
Cells between culture days 19-23 at passage numbers 60-65 were used for the permeation studies. 
After the pre-experimental TEER measurement, the transport medium was removed and the 
formulations, tempered to 37°C, were added. In the apical to basal direction, 1600 µl of the drug 
formulation was added to the apical compartment and 2800 µl of the placebo formulation was added 
to the basal compartment. In the basal to apical direction, 1600 µl of the placebo formulation was 
added to the apical compartment and 2800 µl of the drug formulation was added to the basal 
compartment. At least three wells were used for each direction. The Transwell plate was shaken at 
37°C in a water saturated atmosphere under an incubator hood (KS15, Edmund Bühler GmbH, 
Tübingen& Hechingen, Germany) with a stirring rate of 75 rpm on an orbital shaker (KS15, Edmund 
Bühler GmbH, Tübingen& Hechingen, Germany). Permeation of drug across the cell monolayer was 
monitored by sampling the solutions of both compartments at predefined points of time during 5 h, 
except for the microemulsion experiments with 5 mg/ml lipid phase, where the permeation was 
monitored during 3 h only. 
Samples were drawn after 15, 30, 60, 90, 120, 180, and 300 min for the 5 h experiments and after 15, 
30, 45, 60, 90, 120, and 180 min for the 3 h experiments. The sample volume was 50 µl. The 
withdrawn volume was not replaced. The samples were diluted 1:10 with transport medium and 
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collected in glass vials (Schmidlin Labor& Service AG, Sarbach, Switzerland) and stored at 4°C until 
the HPLC analysis was performed. 
4.1.3.6 Cell Monolayer Drug Extraction 
Following the post-experimental TEER measurement, the 6-well Transwell plate was washed apical 
with 3 ml and basal with 4 ml of 4°C D-PBS (without Ca2+ and Mg2+). The inserts were transferred to 
Petri dishes and 0.3 ml trypsin solution (0.25% trypsin and 2.65 mM EDTA) was added to each insert. 
The inserts were incubated in the cell culture incubator for 15 min. After neutralizing the trypsin 
solution with 1 ml of cell culture medium, the cells were scraped off the polycarbonate membrane 
using a cell scraper (BD Falcon, BD Biosciences Discovery Labware, Bedford, USA), transferred into 
centrifuge tubes (BD Falcon blue max 15 ml, BD Biosciences Discovery Labware, Bedford, USA), and 
spun 5 min with 1000 rpm (Sigma 302K, Sigma Laborzentrifugen GmbH, Germany). The pellets were 
suspended in 750 µl bi-distilled water and transferred to microtubes (Treff AG, Degersheim, 
Switzerland). The microtubes were frozen at -80°C over night and thawed at 37°C under shaking with 
1400 rpm (Thermomixer comfort, Eppendorf, Hechingen, Germany) then 750 µl methanol was added 
to the samples. The samples were put on ice for 20 min, shaken at 37°C for 10 min, and spun on an 
Eppendorf centrifuge for 3 min at 14000 rpm (5415C, Eppendorf / Dr. Vaudaux AG, Schönenbuch, 
Switzerland). The supernatants of the first extraction were transferred into microtubes and stored at 
4°C. After adding 750 µl methanol, the cell pellets were disintegrated with 6 pulses of an ultrasonic 
disintegrator (Branson Sonifier 250, Model 101-063-197, SKAN AG, Basel, Switzerland, Instrument 
settings were: output control: 2, duty cycle: 30%), followed by 5 min on the thermomixer (37°C and 
1400 rpm) and centrifugation with the Eppendorf centrifuge at 14000 rpm for 3 min. After an additional 
extraction with 750 µl methanol, 5 min shaking on the thermomixer at 37°C, and centrifugation for 
3 min at 14000 rpm, the methanolic supernatant of the second extraction was united with its 
supernatant of the third extraction. Then, the methanol was evaporated under nitrogen flow. Each 
residue was merged with its supernatant of the first methanol- water extraction step on the 
thermomixer at 37°C for 3 min. Before the HPLC-analysis, the cell extracts were spun with the 
Eppendorf centrifuge for 25 min at 14000 rpm. 
4.1.3.7 Drug Extraction out of Transwell Plates 
After removal of the Caco-2 cells, the 6-well Transwell plates and the filter inserts were extracted with 
methanol to determine the surface bound amount of drug. To the apical compartment 1600 µl 
methanol was added, 2800 µl to the basal. The plate was sealed with four layers of Parafilm to avoid 
methanol evaporation and incubated at 37°C for 45 min under the incubator hood with a stirring rate of 
75 rpm. Samples of 500 µl were taken and diluted 1:1 with distilled water before drug quantification by 
HPLC. 
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4.1.3.8 Production and Characterization of Lipid Containing Drug Dosage 
Forms 
4.1.3.8.1 Preparation of Liposomes 
The liposomes were composed of Lipoid S 100 (soy lecithin, >94% phosphatidylcholine) and Lipoid 
EPG (EPG) (egg phosphatidylglycerin-sodium >98%). To prepare drug loaded liposomes, the film 
method was used. Lipoid S 100 concentrations were corresponding to the lipid concentrations. 
Additionally, the indicated amount of drug and EPG corresponding to 10% (m/m) of the drug mass 
were added. Lipoid S100, EPG, and drug were dissolved in ethanol 96% in a round bottomed flask. 
The solvent was evaporated to dryness at 40°C and the lipid film was kept under vacuum for 30 min to 
eliminate solvent traces. The lipid film was suspended with 20 ml of tempered transport medium. The 
suspension was extruded under nitrogen pressure with a filter candle through polycarbonate filters 
(Nucleopore track edge membrane filters, Whatman plc, Kent, UK) with descending pore sizes in the 
following scheme: 2 x 0.4 µm, 5 x 0.2 µm, and 20 x 0.1 µm. The addition of the drugs and the variable 
EPG concentrations had no measurable effect on the size of the liposomes. 
4.1.3.8.2 Preparation of Emulsions and Microemulsions 
The lipid phase was prepared by mixing the components at 37°C as following: 35.05% (m/m) 
triglyceride (Captex 8000), 17.58% (m/m) of a mixture of mono- and diglycerides (Capmul MCM), 
36.84% (m/m) surfactant (Cremophor EL), and 10% (m/m) ethanol for the microemulsion and 
67% (m/m) Captex 8000, 5% (m/m) Capmul MCM, 18% (m/m) Cremophor EL, and 10% (m/m) ethanol for 
the emulsion. The lipid phases were stored at 4°C. The lipid phase was warmed to 37°C before use 
and the according amount was balanced and mixed with two thirds of the final transport medium 
volume. The formulation was homogenized for 5 min at 15000 rpm with a Polytron homogenizer 
(Polytron PT 3000, Kinematica AG, Littau, Switzerland) and preheated transport medium was added 
to the final volume.  
4.1.3.8.3 Particle Size Measurement 
Particle size of the formulations was measured by dynamic light scattering. The z-average diameter of 
the liposomes was determined in disposable cuvettes (2 ml sample volume, Greiner Labortechnik, 
Kremsmünster, Austria) with a Zetasizer 1000 HSA (Malvern Instruments Ltd, Worcestershire, 
England), equipped with a 100 nm lens, at 25°C and a wavelength of 633 nm. A detector angle of 90° 
was used. Samples were diluted with sterile filtered transport media (filter pore size 0.2 µm) until 
counting rates between 100 and 300 KCts/s were reached. The resulting z-average diameter was the 
average out of 5 runs, consisting of 10 measurements each. 
The z-average particle size of the emulsions and the microemulsions were measured with a Zetasizer 
Nano ZS ZEN 3600 (Malvern Instruments Ltd, Worcestershire, England) in disposable cuvettes 
(2.5 ml sample volume, Brand GmbH & Co, Wertheim, Germany) at 37°C. The resulting z-average 
diameter was the average out of 3 runs, consisting of 10 measurements each. 
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4.1.3.9 Equilibrium Dialysis for Free Fraction Determination 
The formulations were dialyzed with glass made horizontal diffusion cells with a chamber volume of 
10 ml and a membrane surface of approximately 2 cm2. The chambers were separated by a 
SpectraPor® 7 regenerated cellulose membrane with a molecular weight cutoff of 50000 D (Spectrum 
Labs, DG Breda, Netherlands). To maintain a temperature of 37°C, a water bath was used. The 
solutions in the cells were stirred at 1000 rpm with Teflon-paddles driven by a stirring device (Janke & 
Kunkel RE162, IKA Labortechnik, Staufen, Germany). The formulations were dialyzed for at least 34-
48 h until equilibrium was reached. At least 5 samples were taken during the experiment. The samples 
were analyzed with HPLC. To avoid microbial contamination, resulting in a possible degradation of the 
drug or the formulation, 0.5% (m/V) sodium azide was added to the transport media and the 
formulations. 
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4.1.3.10 Theoretical Modeling 
4.1.3.10.1 Mathematical Model for the Determination of Drug Absorption 
Parameters in Caco-2 Cell Monolayers Including a Term Describing Drug 
Partition between Donor, Acceptor, and Cell Compartment  
Our group has introduced previously a mathematical model to describe the transport of drug between 
the apical, the basal, and the cellular compartment (115). This model enables a direct estimation of 
transport parameters from concentration-time profiles. The model takes into account passive 
permeation, described by the permeability coefficient P, and carrier mediated efflux described by the 
kinetic parameters vmax and K. 
An extension of this model including a partition coefficient from formulation to cell is derived in this 
section. The model was based on the following assumptions: 
1) Three different compartments are considered in which drug concentration varies with time, the 
apical, the cellular, and the basal compartment. 
2) Drug may move between the apical and the cellular and the basal compartment in both 
directions by passive diffusion. Permeation through the apical and the basal cell membrane 
may not be symmetrical and is characterized in both cases by a permeability coefficient, 
where Pa denotes permeability coefficient of the apical and Pb the permeability coefficient of 
the basal membrane. No effect of electrical membrane potential on the transport is 
considered. 
3) Because of their properties, lipophilic compounds may partition from an aqueous solution into 
lipophilic structures such as cell membranes. 
4) Drug may be subject to carrier mediated efflux from the cellular to the apical compartment. 
This follows saturable kinetics that may be characterized by one global parameter vk, the 
carrier mediated efflux rate. 
5) No two different orientations or conformations of the carrier at the two faces of the membrane 
are explicitly involved, the drug concentration in the apical compartment does not influence 
efflux transport and the entire mass of drug present in the cellular compartment is substrate of 
the transporter. 
6) The total mass of drug in the three compartments is preserved. 
 
The substance flux J of a drug from the apical compartment to the cellular compartment through the 
apical cell membrane in apical to basal direction can be described as 
h
ccD
h
ccD
dx
dcDJ mmmm 2112 −=−−=−=  
Equation 10 
 
where D is the diffusion coefficient of the compound in the membrane, cm1 the concentration of the 
compound at the outer membrane surface [µM], cm2 the concentration of the compound at the inner 
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membrane surface and h the membrane thickness. The partition coefficient between cell membrane 
and apical compartment (Km/a) of a drug is defined as 
a
mK
c
c
a
m
=
1
 
Equation 11 
 
where ca denotes apical total concentration. The partition coefficient between apical cell membrane 
and cell lumen (Km/C) of a drug is defined as 
C
mK
c
c
c
m
=
2
 
Equation 12 
 
where cc denotes the cellular concentration of the drug, which is homogeneous in the cellular 
compartment. Equation 11 and Equation 12 were solved after cm1 and cm2 and were inserted in 
Equation 10: 
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In Equation 13, Pa denotes the apparent permeability coefficient of the apical membrane. If the apical 
compartment is identical with the cellular compartment it follows out of Equation 13 that the ratio of the 
partition coefficient between cell membrane and apical compartment and partition coefficient between 
apical cell membrane and cell lumen is 1. It follows: 
( )caa ccPJ −=  
Equation 14 
 
If apical compartment and cellular compartment are not identical it follows out of Equation 13 that the 
partition coefficient between cell membrane and apical compartment and the partition coefficient 
between apical cell membrane and cell lumen are different. Because the membrane is the same for 
both partition coefficients, formulation-to-cell partition coefficient Ka/C is defined as 
C
a
a
m
C
m
K
K
K
=  
Equation 15 
 
It follows, out of Equation 13, that the flux of a compound from apical to cellular compartment is: 
)( caa cKcPJ Ca−=  
Equation 16 
 
The substance flux of a drug from the cellular compartment to the basal compartment through the 
basal cell membrane in apical to basal direction can be described as: 
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h
ccDJ mm 34 −−=  
Equation 17 
 
In Equation 17, D is the diffusion coefficient of the compound, cm3 the concentration of the compound 
at the inner cellular surface of the basal membrane [µM], cm4 the concentration of the compound at the 
outer membrane surface of basal membrane and h the membrane thickness. The partition coefficient 
of a drug between cell lumen and basal membrane (Km/C) is defined as  
C
mK
c
c
c
m
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3
 
Equation 18 
 
whereas partition of a drug between basal membrane and basal compartment (Km/b) is defined as 
b
mK
c
c
b
m
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4
 
Equation 19 
 
Equation 18 and Equation 19 were solved after cm3 and cm4 and were inserted in Equation 17 
( )bcbbcbbcbc ccKPccK
K
Pcc
K
K
h
KD
h
cKcK
DJ
C
b
b
m
C
m
b
m
C
m
b
m
b
m
C
m
−=








−=








−
⋅
=
−
=  
Equation 20 
 
In Equation 20, Pb denotes the apparent permeability coefficient of the basal membrane for 
non-identical cellular and basal compartment. Since the apical and the basal compartment are always 
identically composed regarding lipid formulation, it follows: 
C
b
C
a KK =  
Equation 21 
 
In Equation 16 and Equation 20, the partition coefficient Ka/C is not related to the permeability 
coefficient but depends on the composition of the media in apical and basal compartment. Pa 
describes the entire passive transport process between apical compartment and cellular compartment 
and Pb the entire passive transport process between cellular and basal compartment. These 
parameters are independent of the direction of the permeation according to the formal definition. 
Because of different membrane composition (expressed in different partition coefficients between cell 
membrane and compartment), different thickness of the cellular membranes, and different thickness of 
diffusion boundary layer, Pa and Pb may be different. The derivation in the basal to apical direction is 
analogous. 
Equation 16 and Equation 20 were implemented into the mathematical model to describe the transport 
of drug between the apical, the basal, and the cellular compartment. The resulting extended model 
allows a direct estimation of relevant transport parameters out of concentration-time profiles. These 
parameters are apparent passive permeation over the apical and basal membrane denoted by the 
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permeation coefficients Pa and Pb, carrier mediated apical efflux rate expressed by the simplified zero 
order parameter vk, and formulation-to-cell partition coefficient Ka/C. The apical and the basal 
compartment were containing the same formulation, except for the drug which was added only to the 
donor compartment according to the transport direction, resulting in the same drug partition between 
apical and cellular compartment and between basal and cellular compartment denoted both by the 
formulation-to-cell partition coefficient Ka/C. 
 
The model encompasses the following equations: 
 
apical to basal direction 
( )
a
m
k
a
m
cABaABa
aAB
V
S
v
V
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dt
dc
C
a *** +⋅−−=  
Equation 22 Change of concentration in apical compartment 
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Equation 23 Change of concentration in basal compartment 
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Equation 24 Change of mass in cellular compartment 
 
 
basal to apical direction 
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Equation 25 Change of concentration in apical compartment 
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Equation 26 Change of concentration in basal compartment 
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cBA SvSccKPScKcP
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C
a
C
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Equation 27 Change of mass in cellular compartment 
 
The molar concentration [µM] in Equation 22 to Equation 27 is denoted by c. The indices a, b, and c 
denote the apical, basal, and cellular compartment. Indices AB and BA denote the transport direction 
apical to basal and basal to apical, respectively. Pa is the apparent permeability coefficient [cm*min-1] 
of the apical membrane, Pb the apparent permeability coefficient [cm*min-1] of the basal membrane. 
These permeation coefficients were apparent because they summarize permeation through diffusion 
boundary layer and through the cellular membrane. Sm denotes the cell monolayer surface area [cm2], 
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V the compartment volume [ml], Ka/C the partition coefficient of a compound between formulation and 
cell compartment, and vk [nmol*cm-2*min-1] carrier mediated apical efflux rate. 
cAB
cAB
k
mK
mv
v
+
=
*max
 
Equation 28 
 
The carrier mediated apical efflux rate is described by the kinetic parameters vmax and K and depends 
on the molar amount of drug in the cellular compartment, which is denoted as mcAB or mcBA [nmol]. A 
cell monolayer volume of 0.00094 ml was used based on a monolayer thickness of 20 µm to calculate 
cellular drug concentrations. 
 
The reduction of the solution volume in the apical and the basal compartment due to sampling as a 
function of time was accounted for by the following relations that were determined empirically using 
regression analysis. 
3826
)0( 10247.1108457.90029681.0 tttVV ⋅⋅−⋅⋅+⋅−= −−  
Equation 29 
 
3825
)0( 100985.21063953.10042.0 tttVV ⋅⋅−⋅⋅+⋅−= −−  
Equation 30 
 
Where V(0) is volume of the respective compartment at time zero and t the time [min]. Equation 29 
applies to both compartments to a sampling volume of 50 µl over 5 h, Equation 30 applies to both 
compartments to a sampling volume of 50 µl over 3 h. 
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4.1.3.10.2 Delineating the Components of Apparent Permeability Coefficient 
Based on a Biophysical Model 
For understanding the mechanism that considers contribution of individual processes to drug 
permeation influenced by lipid containing drug formulations, contributions were expressed 
quantitatively by permeability coefficients. The relationship between individual permeability coefficients 
and measured apparent permeability coefficients was established based on a developed biophysical 
model that describes the overall process. A schematic overview of the model is given in Figure 4. 
 
 
Figure 4 Biophysical model of a drug flux over a Caco-2 cell membrane from donor 
compartment containing lipid particles to cellular lumen. 
 
This model is based on the following assumptions:  
1) Diffusional transport of free drug molecules and lipid particles takes place in solution adjacent 
to cell membrane. Kinetics of this transport is expressed by permeability coefficient of diffusion 
boundary layer. 
2) Unbound drug molecules permeate through the cell monolayer. 
3) Lipid particles do not permeate through the cell monolayer. 
4) If lipid particles collide with the cell membrane, direct drug transfer from lipid particles to the 
cell membrane may take place.  
5) The free fraction of a drug is dependent on lipid concentration and is independent of drug 
concentration except concentrations reaching saturation. 
 
Substance fluxes are defined by flux through cell membrane Jm (Equation 31) and flux through 
diffusion boundary layer JDBL (Equation 32): 
)c(c
h
DJ mm,
m
m
m 2,1 −=  
Equation 31 
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where hm denotes thickness of cell membrane, Dm diffusion coefficient of drug in cell membrane, cm,1 
drug concentration at outer cell membrane surface inside of the membrane, cm,2 drug concentration at 
inner membrane surface inside of the membrane. 
( ) ( )L,mL
DBL
w,L
w,mw
DBL
w,d
DBL cch
D
cc
h
D
J −+−⋅=  
Equation 32 
 
The flux through diffusion boundary layer is composed of the flux of the free drug molecules and the 
flux of the lipid particles, where cw,m denotes drug concentration of the water phase at membrane 
surface, cL drug concentration associated with lipid phase referring to total volume, cL,m drug 
concentration associated with lipid phase referring to total volume at membrane surface, cw drug 
concentration in water phase, hDBL thickness of diffusion boundary layer, Dw,d the diffusion coefficient 
of drug in water phase, and Dw,L diffusion coefficient of lipid particle in water phase. 
The free fraction (z) of a drug is defined as ratio of drug concentration in the water phase (cw) of the 
formulation to the total drug concentration in the formulation denoted by ctot: 
z
c
c
tot
w
=  
Equation 33 
 
Substitutions that were used to replace unknown parameters are shown in Equation 34 to Equation 
37: 
w,L
w,d
D
D
q =  
Equation 34 
 
q is defined as ratio of diffusion coefficient of drug in water phase (Dw,d) to diffusion coefficient of lipid 
particle in water phase (Dw,L). 
tot
w
V
VVF =  
Equation 35 
 
The volume fraction VF is defined as ratio of the volume of the water phase (Vw) to the volume of the 
formulation (Vtot). Because lipid phase concentrations were low in performed cell permeation 
experiments, 1-VF was assumed to be the ratio of the amount of lipid phase [g] to the volume of 
aqueous phase [ml]. 
The mass of drug in lipid phase (mL) was assumed to be the total mass of drug (mtot) minus the mass 
of drug in water phase (mw). This was used to express cL with ctot and cw. 
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Equation 36 applies to bulk, and with indices m (e.g. cw,m) at cell membrane surface.  
The unknown drug concentration at cell membrane surface inside the membrane (cm,1) was 
substituted by the following equation: 
L
m
w
m KcKcc mLmwm ⋅+⋅= ,,1,  
Equation 37 
 
where Km/w denotes the partition coefficient of the free drug between aqueous phase and membrane 
and Km/L denotes the partition coefficient between lipid associated drug in solution and cell membrane. 
Inserting Equation 37 into Equation 31 and rearranging yields: 
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Equation 38 
 
In Equation 38 denotes Pm,d the permeability coefficient of the free drug through cell monolayer, Pm,L 
the permeability coefficient of the drug because of direct drug transfer from lipid particle to the cell 
membrane, cc cellular drug concentration and Km/c the partition coefficient between cellular drug 
concentration and cell membrane.  
Inserting Equation 33 and Equation 36 into Equation 38 and rearranging yields: 
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Inserting Equation 34 into Equation 32 and rearranging yields:  
( )L,mLw,mwdbl,dDBL ccqcqcq
P
J −+−⋅=  
Equation 40 
 
where Pdbl,d denotes the permeability coefficient of the free drug through diffusion boundary layer. 
At steady state fluxes are set equal ( DBLm JJ = ), Equation 33 and Equation 36 were inserted and the 
resulting equation was rearranged and solved for the unknown concentration cw,m. 
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Equation 42 was inserted into Equation 39. Transformation of this equation after insertion resulted in:  
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Equation 43 
 
Assuming for the sake of simplicity sink conditions on the receiver (cell) side and setting cc to zero and 
dividing Equation 43 by ctot, it follows: 
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Equation 44 
 
Conversion of this formula leads to the following equation: 
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Equation 45 
 
In Equation 32 was assumed that thickness of diffusion boundary layer (hDBL) is the same for free drug 
molecules and lipid particles. However, based on hydrodynamics of lipid particles and the aqueous 
solubilized drug, hDBL is proportional to D1/3 (119). Therefore, it follows for the ratio of diffusion 
boundary layer thicknesses: 
3
1
3
1
,
,
,
, q
D
D
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h
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=  
Equation 46 
 
Where hDBL,d is the thickness of diffusion boundary layer of the unbound drug and hDBL,L the thickness 
of diffusion boundary layer of the lipid particles in water phase. 
Accordingly, for the ratio of diffusion coefficient of the lipid particle in water phase to thickness of 
diffusion boundary layer of the lipid particles holds: 
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Since it holds that  
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Equation 48 
 
q2/3 instead of q must be used as conversion term in Equation 40 through Equation 45. The parameter 
q was calculated by experimentally determined diffusivity coefficients. The diffusivity coefficients of the 
lipid particles of the formulations were determined by PCS during particle size measurements and 
were 1.37*10-7 cm2*s-1 for microemulsion, 0.27*10-7 cm2*s-1 for emulsion, and 0.42*10-7 cm2*s-1 for 
liposomes. A representative diffusivity coefficient for all drugs, 7.8*10-6 cm2*s-1 deduced for 
testosterone (molecular weight 288.42 g/mol) at 37°C in aqueous solution was used (119). The 
different molecular weights of the compounds were not taken into account, because the molecule 
radius corresponds to the molecular weight with the cube root causing a small effect on the diffusivity 
coefficient D and the effect of the molecular weight is additionally minimized by the conversion of q. 
 
Because of the dependence of the permeability coefficient through diffusion boundary layer on 
different particle diffusivities, q was converted by squaring and taking the cube root before inserting 
the parameter into the model. In Equation 45 q2/3 instead of q was used as conversion term. Finally 
inserted values into the model (Equation 45) were 14.79 for the microemulsions, 43.70 for the 
emulsions, and 32.55 for the emulsions.  
 
The resulting Equation 45 was applied to delineate the components of the estimated apparent 
permeability coefficients Pa and Pb out of the transport studies. Either Pa or Pb were inserted for P, 
depending on which of them is representing the rate determining apparent permeability coefficient. 
 
4.1.3.10.3 Analysis of the Permeation Data 
The system of differential equations, Equation 22 to Equation 27, was fitted to the experimental data 
with Easy Fit® to deduce optimal values for the kinetic parameters Pa, Pb, vk, and Ka/C. A two step 
fitting procedure was performed. In the first step, the data was fitted to the model and the results were 
analyzed: For the substances where we expected no apical carrier mediated efflux and a very low 
value for vk was estimated by EasyFit® too, vk was set zero for a second fitting. The Pa and Pb values 
were compared and if they were for a drug over all experiments equal, they were set equal for a 
second fitting. 
The regression analysis of the transport experiments with Easy Fit® was performed generally with the 
model type ODE, the numerical method DFNLP, a scaling of 1, an initial stepsize of 0.0001 to 
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0.000001, a final accuracy (absolute and relative) of 0.000001 and a termination tolerance of 1*10-18. 
The transport parameters were determined for every single transport experiment, taking into account 
the mentioned volume reduction. 
 
Equation 45 was fitted with Easy Fit® to data of apparent permeability coefficients versus free fractions 
for different volume fractions to deduce optimal values for Pm,d, Pm,L, and Pdbl,d. Using “explicit” model, 
the numerical method DFNLP, a scaling of 1, an initial stepsize of 0.0001 to 0.000001, a final accuracy 
(absolute and relative) of 0.000001 and a termination tolerance of 1*10-18 were used. 
 
4.1.4 Results 
4.1.4.1 Formulation Characterization 
The optical aspect of the milky liposomes and emulsions differed strongly from the microemulsions 
that were optically clear, exhibiting a weak opalescence. The obtained formulations were insensitive 
for phase separation and coalescence for at least 48 h in all used dilutions and with all used drugs, 
indicating physical stability during experimental procedures. The z-average particle sizes of the 
formulations are shown in Table 1. 
 
Table 1 Determined z-average particle sizes of the formulations, measured with PCS 
Formulation Particle Size ± Standard Deviation [nm] (number of measurements) 
Liposomes 128.5± 14.7 (n=95) 
Microemulsion 53.8± 12.7 (n=51) 
Emulsion 176.2±34.4 (n=66) 
 
 
Figure 5 Equilibrium dialysis of progesterone liposome formulation containing 0.5 mg/ml 
lipids and 159 µM (corresponding to 0.05 mg/ml) progesterone.  
Legend: donor compartment (●), acceptor compartment (■) 
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Free fractions of the formulations were determined by equilibrium dialysis. A representing example of 
an obtained time dependent concentration curve is shown in Figure 5. Owning a molecular weight of 
2515 D, Cremophor EL was theoretically able to pass the dialysis membrane (120). In a preliminary 
experiment a microemulsion was dialyzed with a dialysis membrane with a molecular weight cut of 
2000 D, which does not allow Cremophor EL to pass. No difference in free fraction (z) was found 
when this experiment was compared with the free fraction obtained by an equilibrium dialysis using a 
50000 D membrane (data not shown/see Chapter 4.5).  
No influence of the drug concentration on the free fraction was observed with the liposome 
formulations of all drugs within the same lipid concentration (see Table 2, Table 3, and Table 5). This 
was true for a wide range of lipid and drug concentrations. For this reason, one dialysis per lipid 
concentration for emulsions and microemulsions was considered to be appropriate to determine the 
influence of the lipid concentration on the free fraction. Generally, the free fraction decreased with 
increasing lipid concentration. When the lipid concentration was plotted versus the inverse of z, a 
linear relationship resulted for all drugs and all formulations. Figure 6 shows a typical, representative 
example. If no experimental data for a certain lipid concentration was available, this linear relationship 
was used to calculate singular free fractions of progesterone liposomes (0.1 mg/ml and 1 mg/ml lipid 
phase) by applying linear regression analysis.  
The obtained free fractions by equilibrium dialysis are enclosed in Table 2 to Table 5. No decrease 
was observed with propranolol emulsions and microemulsions.  
 
 
Figure 6 Plot of lipid concentration versus 1/z for progesterone liposomes. Linear regression 
analysis resulted in the following equation: y=4.7059x+1 (r2=0.9921).  
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4.1.4.2 Cell Permeation of Drugs from Aqueous Solutions and Formulations 
Measurement of drug permeation in the Caco-2 model was possible with purely aqueous solutions of 
all drugs except triclabendazole, where a strong adsorption to the Transwell surfaces was observed 
(data not shown). Tested liposome and emulsion formulations were well tolerated by the cell 
monolayer. Microemulsions were well tolerated up to 5 mg/ml lipid phase and 3 h of incubation as 
monitored by TEER measurements. Higher microemulsion lipid phase concentrations as well as 
longer incubation times were resulting in a damage of the cell monolayer expressed as decrease of 
TEER below 200 Ohm*cm2. 
Permeation data were analyzed using the mathematical model for the determination of drug 
absorption parameters in Caco-2 cell monolayers presented in the method section 
(Section 4.1.3.10.1). The concentration variables defined by the system of differential equations, 
Equation 22 to Equation 27, were fitted to the experimental concentration data and cell monolayer 
drug extraction data and optimal values for Pa, Pb, vk, and Ka/C were deduced using Easy Fit®. Initial 
concentration values, c0aAB and c0bBA corresponding to t=0 for both transport directions were treated as 
adjustable parameters in the regression analysis. Concentration data of both compartments and cell 
extraction data obtained from apical to basal and basal to apical direction of permeation of three wells 
each were used simultaneously in the fitting, resulting in a more stable regression analysis compared 
to the separate calculation of each permeation direction as shown in previous work (115). A subset of 
the resulting plots of simultaneously data fitting is shown in Figure 7 to Figure 12. These plots were 
typical for all formulations and drugs. 
 
 
Figure 7 Apical to basal drug permeation of liposome formulations containing 159 µM 
progesterone and 0.1 mg/ml and 10 mg/ml phospholipids. The solid line represents the best 
obtained fit. Legend: apical (○) and basal (●) compartment containing 0.1 mg/ml phospholipids, 
apical (□) and basal (■) compartment containing 10 mg/ml phospholipids. 
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Figure 8 Basal to apical drug permeation of liposome formulations containing 159 µM 
progesterone and 0.1 mg/ml and 10 mg/ml phospholipids. The solid line represents the best 
obtained fit. Legend: apical (○) and basal (●) compartment containing 0.1 mg/ml phospholipids, 
apical (□) and basal (■) compartment containing 10 mg/ml phospholipids. 
 
 
A  
 
B 
Figure 9 Time dependent drug mass in cellular compartment during cell permeation 
experiments of liposomes containing 159 µM progesterone. Panel A shows liposome 
formulations containing 0.1 mg/ml phospholipids for apical to basal direction (○) and basal to 
apical direction (●). Panel B shows liposome formulations containing 10 mg/ml phospholipids 
for apical to basal direction (□) and basal to apical direction (■). The solid line represents fitted 
curve and points represent experimental data. 
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Figure 10 Apical to basal drug permeation of liposome formulations containing 63 µM 
triclabendazole and 0.1 mg/ml, 1 mg/ml, and 10 mg/ml phospholipids. The solid line represents 
the best obtained fit. Legend: apical (○) and basal (●) compartment containing 0.1 mg/ml 
phospholipids , apical (∇) and basal (x) compartment containing 1 mg/ml phospholipids apical 
(□) and basal (■) compartment containing 10 mg/ml phospholipids. 
 
 
Figure 11 Basal to apical drug permeation of liposome formulations containing 63 µM 
triclabendazole and 0.1 mg/ml, 1 mg/ml, and 10 mg/ml phospholipids. The solid line represents 
the best obtained fit. Legend: apical (○) and basal (●) compartment containing 0.1 mg/ml 
phospholipids, apical (∇) and basal (x) compartment containing 1 mg/ml phospholipids apical 
(□) and basal (■) compartment containing 10 mg/ml phospholipids 
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Figure 12 Time dependent drug mass in cellular compartment of liposome formulations 
containing 63 µM triclabendazole. Panel A shows liposome formulations containing 0.1 mg/ml 
phospholipids for apical to basal direction (○) and basal to apical direction (●). Panel B shows 
liposome formulations containing 1 mg/ml phospholipids for apical to basal direction (∇) and 
basal to apical direction (x), and panel C shows liposome formulations containing 10 mg/ml 
phospholipids for apical to basal direction (□) and basal to apical direction (■). Solid line 
represents fitted curve and points represent experimental data. 
 
The estimated transport parameters are displayed in Table 2 to Table 5. The model provides values of 
permeability coefficients of the apical membrane Pa and of the basal membrane Pb of the cell 
monolayer. Consistent values of the passive apical and basal permeability coefficients were always 
obtained. For all drugs, except triclabendazole, estimated Pa and Pb, representing the best fit, were 
equal. All transport studies with triclabendazole showed that Pb was smaller than Pa. For further 
calculations the rate limiting parameter Pb was taken. With increased lipid concentrations, the passive 
permeability coefficient decreased generally. Within one lipid concentration no influence of the drug 
concentration was observed. 
The simplified parameter vk, describing carrier mediated efflux rate, was introduced to eliminate the 
correlation between parameters in the regression analysis, as observed in previous work (115). Using 
this parameter, the model was still able to differentiate between compounds that are subject to carrier 
mediated efflux and compounds that are not subject of carrier mediated efflux. Deduced vk parameters 
of compounds that are not subject to carrier mediated efflux were localized at the lower bound defined 
for fitting procedure. Additionally, these very low vk values were independent of drug and lipid phase 
concentration. No effect on fitting quality and the other estimated parameters was obtained if vk was 
set to zero in these cases. Contrary to these findings, the compounds that have been subject to carrier 
mediated efflux showed a deduced value for vk that was dependent on drug and lipid concentration. 
Carrier mediated efflux was found for saquinavir and propranolol. Propranolol showed exiguous carrier 
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mediated efflux rate only, whereas high carrier mediated efflux rate was found for saquinavir. Figure 
13 shows the influence of the lipid concentration on the carrier mediated efflux rate of saquinavir in 
microemulsion and emulsion formulations. The same qualitative effect for both of the formulations was 
observed. The carrier mediated efflux decreased with increasing lipid concentration but within the 
same lipid concentration a drug concentration dependent increase of the carrier mediated efflux was 
observed, indicating first order kinetics and drug concentrations below saturation of the involved 
transporter. 
The impact of the microemulsion on the carrier mediated efflux appears also if the permeated fractions 
of saquinavir microemulsion experiments are compared. Permeated fraction is the molar amount of 
drug at endpoint of the cell permeation experiment in acceptor compartment divided by initial molar 
amount of drug in apical to basal direction. Permeated fraction of saquinavir microemulsion containing 
0.5 mg/ml lipid phase and 14.5 µM saquinavir was 1.88% and increased to 7.43% when lipid phase 
concentration was increased to 5 mg/ml and contains the same drug concentration.  
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Figure 13 Influence of lipid phase concentration on the carrier mediated efflux rate vk of 
saquinavir. Open columns represent the saquinavir emulsions, closed columns saquinavir 
microemulsions. Upper row numbers on x-axis indicate used drug concentration [µM]; lower 
row numbers indicate used lipid phase concentration [mg/ml]. 
 
The initial drug concentrations, c0aAB and c0bBA, obtained from the best fit were generally lower than the 
theoretical concentration of the prepared aqueous solutions and the formulations. This was because 
some loss of drug firstly during preparation, which was confirmed by measuring the drug concentration 
of the formulations before their use, and secondly at the onset of the transport experiment possibly 
because of an initial adsorption of the drug to the plastic made surface of the Transwell plates. Time 
dependent mass balance demonstrates, that total drug mass was constant after the first sampling 
point. Therefore, the estimation of the kinetic parameters was not affected by this initial decrease of 
drug content of the drug formulations. Furthermore the adsorption decreased with increasing lipid 
phase concentration. 
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Estimated drug mass in the cellular compartment obtained from model simulation was the same at the 
endpoint of the experiment as the drug mass determined by cell extraction. The introduction of Ka/C, 
the formulation-to-cell partition coefficient, improved the fitting quality. Without this coefficient, the drug 
mass in cellular compartment obtained from model simulation was systematically much lower than the 
drug mass measured by cell extraction. Simultaneous increase of Ka/C with increasing lipid phase 
concentration was observed indicating that the lipophilic drugs remain in the formulation rather than 
diffusing out of the lipid particles to cross the cell monolayer. No systematic effect of the drug 
concentration on Ka/C was observed.  
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Table 2 Kinetic parameters of transport of progesterone as solution and diverse drug 
formulations across Caco-2 cell monolayer 
Formulation 
Lipid 
Content 
[mg/ml] 
Drug Conc. 
[µM] 
Px105 
[cm/s] 
Free 
Fraction 
vk 
[nmol*cm-2*min-1] Ka/C 
c0aAB 
[µM] 
c0bBA 
[µM] 
Solution 0 4.45 30.3 1 0 0.0626 2.59 2.59 
  14.63 26.2 1 0 0.126 9.57 9.71 
  31.80 38.0 1 0 0.0655 20.80 22.94 
  63.60 29.1 1 0 0.0255 53.38 49.13 
Liposomes 0.1 31.80 29.6 0.680# 0 0.0717 25.11 23.80 
  63.60 34.6 0.680# 0 0.0289 64.87 58.70 
  159.00 35.8 0.680# 0 0.398 115.75 132.82 
 0.5 31.80 14.3 0.297 0 0.0670 24.93 25.04 
  63.60 18.5 0.305 0 0.0748 45.88 47.36 
  159.00 15.7 0.271 0 0.0923 125.73 130.99 
 1 31.80 15.4 0.175# 0 0.117 27.50 29.71 
  63.60 16.3 0.175# 0 0.151 59.35 54.96 
  159.00 15.0 0.175# 0 0.0752 131.36 143.74 
 5 159.00 4.59 0.0356 0 0.120 151.87 151.44 
  318.00 6.35 0.0364 0 0.170 318.83 346.18 
  794.99 4.50 0.0231 0 0.223 750.41 743.60 
 10 63.60 2.69 0.0195 0 2.84 63.00 63.00 
  159.00 3.56 0.0197A 0 0.955 142.06 146.51 
  318.00 3.58 0.0189 0 0.739 276.05 297.68 
  794.99 3.62 0.0197 A 0 0.673 846.42 846.42 
  1589.98 3.04 0.0207 0 0.991 1547.34 1591.60 
 25 63.60 2.35 0.00847 0 8.40 58.01 56.08 
  159.00 2.37 0.00764 A 0 0.900 144.65 145.74 
  318.00 1.81 0.00702 0 4.15 304.54 304.54 
  794.99 1.68 0.00742 0 2.18 762.61 762.61 
  1589.98 1.91 0.00764 A 0 1.68 1344.85 1343.93 
  3307.15 1.64 0.00764 A 0 1.42 3137.28 3233.73 
 50 63.60 2.04 0.00437 A 0 0.627 68.19 88.88 
  159.00 1.35 0.00455 0 3.69 146.00 154.84 
  318.00 1.05 0.00437 A 0 4.19 283.57 288.83 
  794.99 1.00 0.00437 A 0 4.56 802.35 732.85 
  1589.98 1.27 0.00377 0 1.83 1394.30 1490.86 
  3307.15 0.94 0.00437 A 0 2.22 4312.91 4337.57 
  6709.70 0.92 0.00437 A 0 1.91 6126.27 6249.31 
  11193.44 0.85 0.00479 0 2.67 11011.91 11745.82 
Emulsion 0.5 3 25.6 0.436 0 0.560 2.30 2.54 
  14.5 19.5 0.436 0 0.115 10.44 10.43 
  31.8 20.0 0.436 0 0.108 23.48 23.91 
 1 3 14.0 0.266 0 1.07 2.42 2.16 
  14.5 11.4 0.266 0 0.498 14.98 14.05 
  31.8 10.3 0.266 0 0.410 20.77 21.30 
 5 63.6 3.71 0.0672 0 3.23 53.96 53.29 
  14.5 4.33 0.0672 0 4.28 13.77 13.62 
  31.8 5.01 0.0672 0 2.19 38.32 34.02 
Micro- 0.5 3 36.1 0.396 0 0.0468 3.92 7.41 
emulsion  14.5 19.1 0.396 0 0.0782 7.18 5.99 
  31.8 29.1 0.396 0 0.0153 26.58 28.35 
 1 14.5 14.6 0.195 0 0.0748 9.76 9.59 
  31.8 13.7 0.195 0 0.0281 30.84 25.84 
  63.6 14.0 0.195 0 0.167 32.98 31.38 
 5 14.5 4.47 0.0656 0 0.277 11.35 11.76 
  31.8 7.14 0.0656 0 0.266 38.33 41.66 
  63.6 4.55 0.0656 0 0.256 58.07 54.93 
# Calculated value by using linear regression analysis 
A
 Calculated value by taking the average out of the measured free fractions inside this particular lipid 
concentration  
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Table 3 Kinetic parameters of transport of propranolol as solution and diverse drug 
formulations across Caco-2 cell monolayer 
Formulation 
Lipid 
Content 
[mg/ml] 
Drug 
Conc. 
[µM] 
Px105 
[cm/s] 
Free 
Fraction 
vk 
[nmol*cm-2*min-1] 
Ka/C 
c0aAB 
[µM] 
c0bBA 
[µM] 
Solution 0 4.10 35.8 1 4.13*10-3 0.0791 3.64 3.98 
 0 13.75 33.1 1 2.26*10-2 0.0791 11.82 11.41 
 0 30.63 27.1 1 3.13*10-2 0.0791 27.15 26.13 
 0 60.71 32.9 1 6.95*10-1 0.0742 50.06 52.66 
Liposomes 0.1 31.8 45.8 0.8061 1.00*10-10 0.0674 25.44 28.51 
 0.1 63.6 35.7 1 3.21*10-2 0.0669 53.84 55.46 
 0.1 159 31.7 0.9416 1.00*10-10 0.1876 127.86 139.71 
 1 31.8 20.9 0.5723 2.36*10-3 0.1805 25.57 25.94 
 1 63.6 21.2 0.6211 1.00*10-10 0.0617 42.55 46.72 
 1 159 24.6 0.6746 1.00*10-10 0.1244 111.85 123.65 
 10 63.6 6.11 0.1158 5.75*10-3 0.2921 40.20 46.81 
 10 159 6.64 0.1356 1.08*10-2 0.3643 90.15 97.00 
 10 794 7.08 0.1644 1.47*10-1 0.2985 655.02 669.08 
Emulsion 0.5 14.5 44.0 0.9152 5.81*10-3 0.0422 18.03 19.62 
  31.8 52.8 0.9152 2.48*10-2 0.0444 33.32 39.43 
  63.6 32.8 0.9152 8.77*10-3 0.0653 66.78 66.89 
 1 14.5 42.1 1 9.39*10-3 0.0141 13.91 15.80 
  31.8 39.4 1 1.00*10-10 0.0318 28.23 32.89 
  63.6 34.6 1 1.94*10-2 0.1597 56.62 60.01 
 5 14.5 46.8 0.7829 1.00*10-10 0.1116 16.95 20.37 
  31.8 34.4 0.7829 1.00*10-10 0.0756 32.01 33.83 
  63.6 32.2 0.7829 1.00*10-10 0.1313 59.82 66.58 
Micro- 0.5 14.5 50.2 0.8568 1.81*10-3 0.0601 11.72 14.16 
emulsion  31.8 25.0 0.8568 2.65*10-3 0.0595 40.78 35.00 
  63.6 30.9 0.8568 1.00*10-10 0.0590 58.68 60.16 
 1 14.5 36.0 0.9056 1.00*10-10 0.0560 13.74 14.20 
  31.8 20.5 0.9056 1.64*10-2 0.0621 60.34 50.00 
  63.6 33.5 0.9056 1.00*10-10 0.0682 55.97 64.69 
 5 14.5 37.8 0.8090 6.90*10-3 0.1051 15.20 18.18 
  31.8 30.1 0.8090 8.90*10-3 0.1264 26.07 27.86 
  63.6 30.1 0.8090 2.02*10-2 0.1477 65.26 64.23 
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Table 4 Kinetic parameters of transport of saquinavir as solution and diverse drug formulations 
across Caco-2 cell monolayer 
Formulation 
Lipid 
Content 
[mg/ml] 
Drug 
Conc. 
[µM] 
Px105 
[cm/s] 
Free 
Fraction 
vk 
[nmol*cm-2*min-1] 
Ka/C 
c0aAB 
[µM] 
c0bBA 
[µM] 
Solution 0 4.5 8.790 1 - - - - 
  5 16.3 1 - - - - 
  10.4 8.83 1 - - - - 
  14.5 14.3 1 - - - - 
Emulsion 0.5 3 5.32 0.2718 5.82*10-3 0.2792 1.85 2.03 
  7 3.90 0.2718 6.28*10-3 0.8385 2.84 2.95 
  14.5 4.30 0.2718 1.96*10-2 0.2331 7.78 8.24 
 1 3 3.27 0.1534 4.82*10-3 0.9034 2.68 2.73 
  7 3.86 0.1534 7.67*10-3 0.5403 3.59 3.60 
  14.5 2.74 0.1534 1.71*10-2 0.3612 10.68 11.24 
 5 3 1.44 0.0524 1.85*10-3 1.8330 2.77 2.76 
  7 1.16 0.0524 2.81*10-3 2.3992 5.36 5.54 
  14.5 0.901 0.0524 6.39*10-3 1.9203 13.56 13.70 
Micro- 0.5 3 3.28 0.1770 1.95*10-3 0.1793 1.00 1.08 
emulsion  7 2.74 0.1770 4.41*10-3 0.1607 2.66 2.93 
  14.5 3.72 0.1770 4.31*10-2 0.1700 19.51 19.62 
 1 3 2.15 0.0963 2.79*10-3 0.5671 2.27 2.29 
  7 2.25 0.0963 7.31*10-3 0.9196 5.98 5.80 
  14.5 1.91 0.0963 2.33*10-2 0.7434 20.01 20.81 
 5 3 1.51 0.0205 1.14*10-3 0.8794 3.44 3.56 
  7 1.05 0.0205 2.12*10-3 1.1951 5.82 5.97 
  14.5 0.967 0.0205 6.79*10-3 1.0373 20.54 19.95 
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Table 5 Deduced kinetic parameters of transport of triclabendazole of diverse drug 
formulations across Caco-2 cell monolayer 
Formulation 
Lipid 
Content 
[mg/ml] 
Drug 
Conc. 
[µM] 
Pax105 
[cm/s] 
Pb x105 
[cm/s] 
Free 
Fraction 
x103 
vk 
[nmol 
*cm-2 
*min-1] 
Ka/C 
c0aAB 
[µM] 
c0bBA 
[µM] 
Liposomes 0.1 14.5 8.45 2.02 39.4 0 0.0086 7.35 6.83 
  31.8 14.6 1.46 52.7 0 0.0194 17.33 18.85 
  63.6 18.2 1.81 56.7 0 0.0216 52.40 46.82 
 0.5 31.8 4.28 0.593 13.4 0 0.0741 31.83 32.43 
  63.6 4.46 0.585 7.13 0 0.0523 42.68 43.96 
  159 3.33 0.581 5.66 0 0.0753 112.12 119.64 
 1 31.8 2.38 0.438 2.68 0 0.1849 30.67 30.84 
  63.6 1.58 0.472 2.49 0 0.1426 48.54 50.64 
  159 1.53 0.478 2.08 0 0.1742 127.30 127.61 
 10 63.6 0.665 0.115 0.338 0 1.2493 54.14 54.20 
  159 0.410 0.211 0.161 0 1.3079 156.11 149.69 
  794 0.777 0.165 0.201 0 0.7244 633.92 665.68 
Emulsion 0.5 14.5 3.04 0.703 2.38 0 0.1166 15.47 19.21 
  31.8 1.68 0.777 2.38 0 0.0917 23.54 26.95 
  63.6 3.63 0.676 2.38 0 0.0716 37.62 41.82 
 1 14.5 1.63 0.697 1.80 0 0.1499 13.74 14.62 
  31.8 1.08 0.471 1.80 0 0.1368 28.12 30.65 
  63.6 1.96 0.608 1.80 0 0.1917 54.30 59.41 
 5 14.5 0.339 0.264 0.160 0 0.3644 18.00 18.00 
  31.8 0.685 0.367 0.160 0 0.4752 32.61 35.69 
  63.6 1.10 0.519 0.160 0 0.5816 70.13 69.84 
Micro- 0.5 14.5 4.02 0.924 1.95 0 0.0671 12.24 13.27 
emulsion  31.8 3.39 0.925 1.95 0 0.0597 28.74 32.98 
  63.6 6.34 0.884 1.95 0 0.0524 42.81 45.96 
 1 14.5 2.73 0.936 1.55 0 1.3090 13.91 14.53 
  31.8 1.59 1.12 1.55 0 1.2777 51.70 54.57 
  63.6 3.45 0.840 1.55 0 1.2464 56.43 59.17 
 5 14.5 1.41 0.609 0.178 0 0.3929 21.35 21.18 
  31.8 1.23 0.577 0.178 0 0.7228 41.08 42.30 
  63.6 1.43 0.544 0.178 0 0.3549 69.15 70.45 
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No relevant metabolism of the drugs was found in the Caco-2 cells. It is known from previous work of 
our group that saquinavir undergoes phase I metabolism in Caco-2 cells by hydroxylation. The main 
metabolite was detectable by HPLC-MS but contributed less than 2% to the mass balance and was 
therefore neglected in this study (115). Propranolol is known to be subject of phase I metabolism by 
ring hydroxylation, mainly by Cyp 450 2D6 and N-desisopropylation by Cyp 450 1A2, as well as phase 
II metabolism by glucuronidation (121). No evidence for metabolism, expected to be found in an 
additional peak in HPLC analysis, was observed in our experiments. No reports have been found 
concerning progesterone metabolism in Caco-2 cells as well as no evidence for progesterone 
metabolism has been found in our experiments. Triclabendazole is known to be subject of phase I and 
II metabolism. In sheep, the flavin monooxigenase system is the main metabolic pathway (122). 
Phase II metabolism to sulpho-metabolites by metabolism over gluthatione-S-transferase is reported 
in literature (123). Nevertheless, no evidence of triclabendazole metabolism by the Caco-2 cells was 
found in our experiments. 
4.1.4.3 Qualitative Influence of Lipid Phase Concentration on Apparent 
Permeability Coefficient 
A strong influence of the lipid phase concentration on the permeability coefficient was observed, 
where the passive apparent permeability coefficient decreased with increasing lipid concentrations. 
Within the same lipid concentration no influence of the drug concentration on apparent permeability 
coefficient was observed, since the free fraction is determined by the lipid phase concentration and 
apparent permeability coefficient depends on free fraction. An example is given in Figure 14 that 
shows the influence of lipid phase concentration and drug concentration of the different progesterone 
formulations. Shown results were typical for the other used drugs and formulations too, except for 
propranolol emulsion and microemulsion. These exceptions showed no effect of the lipid concentration 
on the permeability coefficient and on free fraction. 
Thus, formulation of the drugs with a lipid containing system appears to profoundly influence their 
permeation behavior through Caco-2 cell monolayer when an interaction of the drug with the vehicle 
was present. 
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Figure 14 Qualitative influence of the lipid concentration and the drug concentration on 
apparent permeability coefficient of progesterone formulations. Panel A shows the liposome 
formulations, panel B shows the emulsion formulations, and panel C shows the microemulsion 
formulations. Each column represents the determined apparent permeability coefficient out of 
one transport experiment. Same pattern or color indicates same drug concentration. 
 
 
4.1.4.4 Quantitative Influence of Free Fraction on Apparent Permeability 
Coefficient 
Both, the determined free fractions and the deduced apparent permeability coefficients are dependent 
individually on the lipid concentration. The apparent permeability coefficient may be seen as function 
of the free fraction because it is generally agreed that the unbound drug concentration permeates 
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through the cell membrane and determines drug permeation. Equation 45 that was derived from the 
biophysical model expresses the apparent permeability coefficient as a function of free fraction. In this 
equation, the effect of the diffusion boundary layer and the contribution of firstly of permeation of free 
drug through the membrane and secondly of permeation of lipid bound drug through the membrane 
following direct transfer of drug upon collision of lipid particles with the membrane are taken into 
account. These processes are expressed as permeability coefficients. This equation was used to 
analyze the measured permeability coefficients. This equation was at first fitted to apparent 
permeability coefficient versus free fraction data for different volume fraction (VF) values of each drug 
with each formulation. Although, similar values of permeability coefficient of the free drug through the 
membrane (Pm,d) and permeability coefficient delineating transport through diffusion boundary layer 
(Pdbl,d) for all formulations of the same drug were generally deduced. From the fit, individual values of 
these parameters showed rather strong deviation. This was either because of the experimental 
variability of the data or because of the domination of one parameter over the process. Therefore, in 
order to alleviate these deviations and to obtain more universally valid values of the deduced 
parameters, data of each drug with all formulations were simultaneously used in the fitting. In this, the 
same Pm,d and Pdbl,d were used for all formulations. A different Pm,L for each formulation was used. 
This fitting procedure improved the quality of the resulting fit compared to above first option. Figure 15 
to Figure 25 show plots of apparent permeability coefficient as function of the free fraction. The array 
of curves in Figure 15 to Figure 25 represents the best fits corresponding to the different VF values. 
For a better clarity no z-axis was used. The model explained the data satisfactorily. 
 
 
Figure 15 Plot of the apparent permeability coefficient as function of the free fraction of 
triclabendazole emulsion including best obtained fit  
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Figure 16 Plot of the apparent permeability coefficient as function of the free fraction of 
triclabendazole microemulsion including best obtained fit. 
 
 
 
Figure 17 Plot of the apparent permeability coefficient as function of the free fraction of 
triclabendazole liposomes including best obtained fit. 
 
 
 
Figure 18 Plot of the apparent permeability coefficient as function of the free fraction of 
progesterone emulsion including best obtained fit. 
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Figure 19 Plot of the apparent permeability coefficient as function of the free fraction of 
progesterone microemulsion including best obtained fit. 
 
 
 
Figure 20 Plot of the apparent permeability coefficient as function of the free fraction of 
progesterone liposomes including best obtained fit. 
 
 
 
Figure 21 Plot of the apparent permeability coefficient as function of the free fraction of 
propranolol emulsion including best obtained fit. 
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Figure 22 Plot of the apparent permeability coefficient as function of the free fraction of 
propranolol microemulsion including best obtained fit. 
 
 
 
Figure 23 Plot of the apparent permeability coefficient as function of the free fraction of 
propranolol liposomes including best obtained fit. 
 
 
 
Figure 24 Plot of the apparent permeability coefficient as function of the free fraction of 
saquinavir emulsion including best obtained fit. 
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Figure 25 Plot of the apparent permeability coefficient as function of the free fraction of 
saquinavir microemulsion including best obtained fit.  
 
 
The estimated parameters of all drugs and formulations by fitting the model to the experimental 
determined apparent permeability coefficients and determined free fractions are given in Table 6.  
 
Table 6 Estimated parameters of all drugs and formulations by fitting Equation 45 to the 
experimental determined apparent permeability coefficients and free fractions. 
Drug Type of Formulation 
Pm,d 
[cm*s-1] 
Pm,L 
[cm*s-1] 
Pdbl,d 
[cm*s-1] 
Triclabendazole A Emulsion 8.16±3.38*10-6 
 Microemulsion 8.19±1.73*10-6 
 Liposomes 
4.48±1.54*10-3 
6.07±4.50*10-7 
2.72±0.40*10-4 
Progesterone Emulsion 1.31±0.90*10-3 
 Microemulsion 9.80±33.0*10-3 
 Liposomes 
6.74±0.83*10-4 
5.49±4.40*10-3 
5.71±0.52*10-4 
Propranolol Emulsion 1.01±1.12# 
 Microemulsion 5.10±3.84*10-3# 
 Liposomes 
1.02±0.20*10-3 
4.90±9.20*10-4 
4.77±0.31*10-4 
Saquinavir Emulsion 2.01±12.9*10-4 
 Microemulsion 
3.00±5.17*10-4 
4.54±9.24*10-5 
2.02±2.50*10-4 
#
 no interaction between formulation and drug, values not meaningful  
A
 to improve fitting quality, a scaling of -1 instead of 1 was used 
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Similar values for all drugs were obtained for the permeability coefficient of the diffusion boundary 
layer. Big differences between Pm,d and Pm,L depending on the drug and the formulation were found. 
For example triclabendazole showed a Pm,d that is much larger than the Pm,L. In contrast to that, for 
progesterone, the Pm,L was larger than the Pm,d. 
 
To verify that lipid particles contribute to the total membrane permeability coefficient, as proposed in 
this work, depending on the drug and the formulation, a simplified model was fitted, where Pm,L, was 
not taken into account to the same datasets. The resulting estimations for the Pdbl,d are in the same 
order of magnitude as the values obtained by the full equation. Except for the triclabendazole 
formulations, however, very poor fitting quality was obtained resulting in unrealistically high values for 
Pm,d (data not shown/detailed results can be found in appendix, section 6.6.2.1). This confirms the 
importance to introduce the contribution of permeability caused by direct mass transfer from lipid 
particle to the cell membrane. 
 
4.1.4.5 Effect of Lipid Containing Drug Formulations on Drug Fluxes  
Drug flux is defined as product of apparent permeability coefficient and drug concentration. Flux is 
relevant for drug amount delivered and hence bioavailability. Whereas apparent permeability 
coefficient correlates directly with the free fraction (see Equation 45), flux correlates with the absolute 
free drug concentration in water phase. By calculating fluxes of all cell permeation experiments we 
observed that within one lipid concentration the drug flux increases with increasing drug concentration, 
because permeability coefficient remains constant. Within the same drug concentration drug flux 
decreases with increasing lipid concentration because the permeability coefficient decreases with 
increasing lipid concentration. The above is demonstrated in the example of progesterone liposomes 
(see Figure 26) and is considered to apply also to the other formulations and drugs. 
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Figure 26 Qualitative influence of lipid concentration and drug concentration of progesterone 
liposomes on drug flux through Caco-2 cell monolayer. Each column represents the calculated 
flux of apparent permeability coefficient and total drug concentration of one transport 
experiment. Same pattern or color indicates same drug concentration and is the same as in 
Figure 14 panel A.  
 
Because of the wide drug and lipid phase concentrations tested, progesterone liposome series offered 
the possibility to compare experiments exhibiting the same free drug concentration. If experiments 
exhibiting the same free drug concentration were considered, an increase of total drug concentration 
is needed to maintain same free drug concentration with higher lipid concentration. Figure 27, Panel A 
demonstrates a linear relationship of total drug concentration as a function of lipid concentration of 
formulations having the same free drug concentration in water phase. Since drug flux correlates with 
absolute free concentration, it follows that the flux should be constant for these formulations if free 
drug alone is responsible for membrane permeation. Calculated drug fluxes of the experiments with 
equal unbound drug concentration, however, showed an increased drug flux with increasing lipid and 
drug concentration, using total drug concentration and apparent permeability coefficients for the 
calculation. The resulting increasing relationship is shown in Figure 27, Panel B. In this plot the 
apparent permeability is the slope. 
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B 
 
Figure 27 Resulting plots if experiments of progesterone liposomes in which the drug 
concentration in the water phase (free drug concentration) were equal are compared. Panel A 
shows the resulting linear relation of experiments with the same drug concentration in the 
water phase, if the total drug concentration of these formulations is plotted against the lipid 
concentration. Panel B shows the influence of the lipid concentration on the drug flux of the 
same experiments, resulting in a non-linear relationship with decreasing slope. 
 
4.1.5 Discussion 
4.1.5.1 Cell Permeation Kinetics 
The model based evaluation of the experimental results of this study shows that the developed 
mathematical model for the determination of drug absorption parameters in Caco-2 cell monolayers 
distinguishes in a quantitative fashion between the permeability coefficients of the apical and the basal 
membrane. The model allows calculating a formulation-to-cell partition coefficient, which enables to 
gain information about cellular retention and accumulation of a drug. Additionally the model enables to 
quantify the contributions of passive permeation and carrier mediated efflux. Carrier mediated efflux 
was determined for propranolol and saquinavir which was in agreement with the literature (21, 115, 
124). 
 
The used drugs were classified by the model as expected based on literature, taking aqueous 
solutions (or low lipid concentrations in the case of triclabendazole) as reference. Obtained 
permeability coefficients of all drugs were not dependent on the used drug concentrations within one 
lipid concentration, which is in agreement with the diffusion theory. 
 
The definition of different apparent permeability coefficients for the apical and the basal membrane 
permits to differentiate between the two sides of polarized cells and allows concluding on the possible 
effect of different membrane properties on cellular permeation of drugs.  
Progesterone showed no differences of apparent permeability coefficient of the apical membrane and 
the basal membrane. If no difference between apical and basal membrane permeability coefficient 
exists, it may be sensible to replace the two different parameters by a common apparent permeability 
coefficient (P) to lower the numbers of parameters estimated by data fitting to optimize the estimation 
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of all other parameters. This approach makes sense especially if a carrier mediated transport is 
involved.  
Concerning propranolol and saquinavir, a high correlation level (~0.95-1) of Pa and Pb in the 
regression analysis of most of the data sets was obtained. There were some data sets showing no 
correlation, but Pa and Pb were estimated equal in these cases, indicating no difference of Pa and Pb. 
For these reasons a common apparent permeability coefficient was used. 
All tested triclabendazole formulations showed a distinct difference between Pa and Pb, whereas Pb 
was always smaller. Lower apparent permeability coefficient of the basal membrane may be a 
consequence of different interactions of triclabendazole with the apical and the basal membrane 
caused by different membrane composition. It is known that the basolateral membrane is composed 
different, e.g. enriched in sphingomyelin and phosphatidylcholine (64, 65). 
 
The deduced permeability coefficients of aqueous solutions in this work were systematically higher 
compared to apparent permeability coefficients from literature. Several parameters like hydrodynamics 
inside the Transwell inserts, caused by different oscillation and stirring rate of the shaker, or cell 
culture conditions may be responsible for this, but the different calculation method for apparent 
permeability coefficients in the literature compared to the proposed model in this work mainly causes 
this effect. The standard literature model for the calculation of the transcellular apparent permeability 
coefficient takes into account the whole cell monolayer as barrier (34). In contrast to the standard 
approach, the model proposed in this study takes into account two permeability coefficients to 
describe the transcellular permeability, where Pa describes drug permeation through the apical 
membrane between formulation and cellular compartment in both directions, and Pb describes the 
same for the basal membrane. This different definition of permeability coefficients mainly causes the 
obtained differences compared to literature.  
 
The introduction of the formulation-to-cell partition coefficient Ka/C is very useful for a better 
understanding of the mechanism responsible for the impact of a drug formulation on drug permeation. 
Misinterpretation of the data is diminished because Ka/C is important for a precise assessment of the 
time dependent concentration change in the cellular compartment. The partition coefficient additionally 
explains, in addition to independent prediction of Pa and Pb, cellular accumulation of a compound that 
could otherwise be interpreted wrongly as adsorption to the Transwell device, not detectable 
metabolism, or substance loss because of degradation. 
 
4.1.5.2 Influence of Lipid Containing Formulations on Carrier Mediated Efflux 
A low carrier mediated apical efflux rate was estimated for propranolol, which is consistent with the 
literature where a slightly higher permeability coefficient from basal to apical transport direction is 
reported (21, 124). Saquinavir showed an extensive carrier mediated apical efflux, which was 
expected and consistent with previous work of our group. The qualitative effect on the carrier mediated 
efflux of saquinavir of microemulsions and emulsions, shown in Figure 13, indicates a common 
underlying mechanism. The decrease of the carrier mediated efflux with increasing lipid concentration 
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may be explained by the decreasing amount of free drug able to cross the cellular membrane. This is 
expressed as well in the increase of the formulation-to-cell partition coefficient, indicating a lower 
intracellular concentration compared to the donor and the acceptor with increasing lipid concentration. 
Furthermore, the concentration dependence of the carrier mediated efflux within one lipid 
concentration may be evidence that the amount of drug crossing the cellular membrane is below that 
required for saturation of the involved carrier. Hence, a first order kinetics of apical efflux is implied. 
Inhibition of the apical efflux rate by Cremophor EL is described in literature (94, 95, 125). While 
containing the double amount of Cremophor EL in the lipid phase, no additional inhibition of the efflux 
by the microemulsion compared to the emulsion was determined in the experiments of this work. 
Maybe the difference in Cremophor EL content was too low or the influence of the surfactant is low in 
the used experimental setting. However, significant effect of the used concentration range of 
Cremophor EL (0.005%-0.1% (m/V)) on drug transport by inhibiting active efflux has been reported 
(94, 125). It is assumed that the amount of Cremophor EL available to inhibit active efflux was very 
low, because of the evidence, provided by equilibrium dialysis experiments, that Cremophor EL is 
strongly associated with the lipid particles. No differences could be found in free fraction, caused by 
free Cremophor EL molecules available to solubilize drug in the acceptor compartment, when 
experiments using a dialysis membrane that was not permeable for Cremophor EL, were compared 
with experiments using a dialysis membrane that was permeable for Cremophor EL. Therefore, a very 
small concentration of monomeric Cremophor EL can be assumed in tested lipid formulations. 
 
4.1.5.3 Influence of Formulation and Free Fraction on Apparent Permeability 
Coefficient 
The results of the study showed that free fraction generally determines apparent permeability. High 
free fractions of drugs in a lipid containing dosage form results in similar permeability coefficients as 
aqueous solutions, whereas low free fractions have low apparent permeability coefficients as a 
consequence. All drugs showed strong interaction with lipid formulation regardless of structure of the 
formulation. This was because of the lipophilicity of the used drugs. In contrast to all other drugs, 
propranolol showed no interaction with the microemulsion and the emulsion causing apparent 
permeability coefficients equal to the aqueous solutions which can be explained by its low solubility in 
the lipid phase of the emulsion and the microemulsion, which is caused by its moderate lipophilicity 
and its occurrence as mainly charged ion at pH 7.4. Propranolol is known to interact with cellular 
membranes and model membrane systems. The naphthalene moiety of propranolol partitions into the 
hydrocarbon core of the lipid bilayer and the charged amine side chain is most likely positioned in the 
aqueous phospholipid head group region which may explain strong interaction of propranolol with the 
liposomes and the cells (126). This may explain the observed strong interaction of propranolol with the 
liposomes. 
Besides the influence of the free fraction, the need of an additional mechanism to describe trans-
membranal drug permeability was evident, because a model taking into account only permeation of 
free drug molecules did not adequately explain the data. Excluding paracellular permeation by 
monitoring TEER and excluding phagocytotic activity of Caco-2 cells, it was obvious to assume a 
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beneficial effect caused by the lipid containing drug formulations to the passive permeation. 
Considering this effect, permeation caused by direct drug transfer from lipid particle to the cell 
membrane was taken into account additionally to the permeability coefficient of the free drug through 
the cell membrane, because direct drug transfer from lipid domain to lipid domain has been described 
in literature.  
The resulting model, proposed in this work, described the data satisfactorily. Standard error was 
relatively large, because of experimental variation and depending on drug, cases of extremely high or 
low free fractions making fitting difficult. Big differences were found regarding the Pm,L depending on 
the drug and the formulation. Depending on the drug, mass transfer caused by direct drug transfer 
from lipid particle to cellular membrane has high or low contributions to substance flux over the cellular 
membrane.  
Generally high Pm,L were found for all progesterone formulations indicating an important contribution of 
the “lipid pathway” to the trans-membranal permeability. Progesterone is a physiologically occurring 
compound and has the same scaffold and similar physicochemical properties as cholesterol that 
occurs physiologically in the cellular membranes. This physicochemical similarity and even more the 
physiological relevance for progesterone to cross membranes easily, because of the intracellular 
localization of the steroid hormone receptor, may explain why progesterone may easily be transferred 
between lipid particles and membrane. While progesterone is possessing a low free fraction, the 
resulting apparent permeability coefficient is high compared to other drugs, because high Pm,L partially 
compensates the effect of low permeability on drug permeation. 
 
The lowest Pm,L was resulting for triclabendazole for all formulations, indicating a small contribution of 
the lipid particles to the trans-membrane transport of the drug. Compared to progesterone and 
saquinavir, which had both similar free fractions, the free fractions of triclabendazole were more than 
one order of magnitude lower, indicating a strong interaction of the formulations with the drug. This 
implies a low tendency of triclabendazole to leave the lipid phase of the formulations. The interaction 
of the drug with the formulation seems to be stronger than the interaction of the drug with the cell, 
causing low contribution of the “lipid pathway” to the trans-membranal permeability resulting in a low 
apparent permeability. 
Regarding the dataset used for this work, too little data were collected with only four drugs to conclude 
on concrete molecular properties important to direct lipid-lipid transfer. Nevertheless, several general 
points may be important for a contribution of lipid-lipid transfer to transcellular permeation. For 
liposomes, the localization of the drug inside the bilayer may be important for lipid-lipid transfer from 
liposomes to cell membrane. Less lipid-lipid drug transfer would be expected if a drug is located in the 
core region of the bilayer compared to the localization of a drug in the surface region. Very high drug 
solubility in the used lipid phase combined with a high lipophilicity may be disadvantageous, because 
the drug is then trapped inside the lipid particles causing a low free fraction and a high affinity of the 
drug to the lipid phase, which impedes together transcellular permeation. 
 
The obtained permeability coefficients of the free drug through cell monolayer (Pm,d) were independent 
of the formulations for all drugs. A classification of the used drugs results in the following order from 
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highest to lowest Pm,d: triclabendazole > propranolol > progesterone > saquinavir. Surprisingly, 
triclabendazole was found to be the compound with the highest Pm,d, indicating a high permeability 
coefficient out of an aqueous solution. In vivo data of triclabendazole showed an increase of 
bioavailability after oral triclabendazole administration together with a fatty meal (127). This is a typical 
BCS class II substance behavior by which the permeability coefficient is high but the flux through the 
epithelial barrier is limited because of low solubility. With an increase of the solubility an increase of 
the flux is obtained. Additional indication of high membrane permeability of triclabendazole is a high 
apparent permeability coefficient determined in our lab for albendazole, a structurally very similar 
compound (unpublished results). Due to unspecific adsorption to the Transwell surfaces it was not 
possible to measure the permeability of a purely aqueous triclabendazole solution as reference. If 
triclabendazole is formulated with small amounts of lipids the permeability coefficient decreases 
rapidly because of a very low free fraction caused by high lipophilicity.  
 
All obtained Pdbl,d are in the same order of magnitude, but the resulting differences are bigger than 
expected. It was expected that saquinavir resulted in the lowest Pdbl,d, because of its size. It was 
expected further to find similar Pdbl,d for all other drugs because of nearly equal molecular weights. 
There is very recently published work dealing with drug transport of bile micelle containing drug 
formulations through diffusion boundary layer that shows, that the assumptions made in the present 
work describes drug transport through diffusion boundary layer most appropriately (128).  
Unspecific adsorption to the filter insert may contribute to determined differences because Pdbl,d of 
triclabendazole and saquinavir were similar, but different from the other drugs. Both drugs undergo 
unspecific adsorption to the Transwell device. It may be possible that triclabendazole and saquinavir 
would be slightly retarded during diffusion through the polycarbonate filter caused by the tendency of 
these drugs to adsorb to surfaces. The unspecific adsorption of triclabendazole was more distinctive 
than the absorption of saquinavir and could explain the slow permeation through the basal diffusion 
boundary layer.  
 
It is often encountered in literature that for most lipophilic compounds that exceed log D 2-3 cell 
membrane permeation is very rapid. Therefore, permeation through diffusion boundary layer would be 
the rate limiting step for lipophilic compounds (85, 128-132). If aqueous solutions of the model drugs 
tested in this work were regarded, this is confirmed for all compounds (see Table 6). If lipid containing 
formulations of the tested model compounds are considered, one has to take into account, that the 
resulting permeability coefficients are also dependent on the free fraction. Out of this follows that a low 
free fraction decisively influences the apparent permeability coefficient of a drug through the 
membrane. Depending on free fraction, lipid concentration, and the drug, the diffusion boundary layer 
or the membrane may be rate determining. This is also expressed in the shape of apparent 
permeability versus free fraction plots. 
 
Taken together, lipid containing drug formulations influence transcellular drug permeation with 
different mechanisms. Lipid containing formulations decrease the free fraction of a lipophilic drug and 
decrease the apparent permeability coefficient. Depending on the drug, contribution of drug 
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permeation because of direct drug transfer from lipid particle to cell membrane may compensate the 
decrease of apparent permeability coefficient partially, as observed for progesterone. On the other 
hand, very low apparent permeability coefficients may result if a highly lipophilic and highly membrane 
permeable compound does not permeate by direct drug transfer from lipid particle to cell membrane. 
In this case, the extremely low free fraction determines the permeation totally, such as observed for 
triclabendazole. 
 
4.1.5.4 Drug Flux: Consequences for In-Vivo Drug Delivery?  
Drug flux depends on total drug concentration and apparent permeability coefficient and correlates 
directly with the absolute free drug concentration. If a single drug concentration is considered with 
different lipid concentrations, drug flux decreases with increasing lipid concentration because 
decreasing apparent permeability coefficient with increasing lipid concentration. If free drug 
concentration alone is responsible for membrane permeation, the flux of a drug of different lipid 
containing formulations with the same absolute free concentration should be constant and 
independent of lipid concentration. As displayed in Figure 27, Panel B, flux of progesterone increases 
with increasing lipid concentration if experiments with the same absolute unbound drug concentration 
were regarded. The fact that this plot, where the apparent permeability is the slope, does not show a 
constant flux but an increase with increasing lipid concentration shows indirectly the contribution of the 
lipid particles to the transmembranal drug permeation. This is consistent with the high Pm,L compared 
to Pm,d obtained for progesterone. Drug fluxes of experiments with equal unbound drug concentration 
showed an increased flux with increasing drug and lipid concentration, but the benefit for drug flux 
leveled off at high lipid concentrations. Because apparent permeability coefficient remains constant 
within one lipid concentration, the drug flux may be increased by augmenting the total drug 
concentration to compensate the decrease of apparent permeability coefficient, if drug solubility in that 
formulation is high enough. It is a precondition that the lipid containing formulation allows a large drug 
solubility enhancement. This may lead to absorption enhancement in vivo. Since drug flux is time 
dependent, a time independent parameter to characterize the influence on drug transport is the 
situation in equilibrium. Regarding cell permeation experiments with different progesterone 
formulations, the extent of drug permeation was always the same in equilibrium in apical to basal 
direction, but time to reach equilibrium was prolonged with increasing lipid concentrations. If no active 
efflux, degradation, and metabolism are involved, even formulations with high lipid concentrations 
would equilibrate, but it is a question of time. Regarding a given amount of drug, this would result in 
vivo in same area under the curve (AUC), but prolonged time to attain the maximal plasma 
concentration. The maximal plasma concentration would be lowered because drug flux and 
permeability were decreased with increasing lipid concentration resulting in slower drug invasion. Lipid 
systems offer the possibility to compensate lower maximal plasma concentration by increasing drug 
concentration in the formulation, which is not affecting the permeability coefficient of the drug and 
would entail, assuming same permeated fraction, to increased AUC and maximal plasma 
concentration. That again may cause longer time period exceeding the minimal effective drug 
concentration. 
Marcel Schneider Page 82 of 172 University of Basel, 2008 
 
After peroral administration, the lipid formulations are altered by lipid digestion, presence of bile salts, 
and phospholipids, but drug solubilization in colloidal systems may still take place in the intestine. 
Because similar effects of structurally different formulations on drug permeation have been shown, 
similar effects of the digested product were expected, if the particles are able to interact physically with 
the cellular membrane.  
There is a mucus layer present, which is first of all an additional hydrophilic diffusion barrier for drug 
permeation itself. It was shown that mainly the lipid components of the mucus lower the diffusion of 
lipophilic compounds (133). Additionally, the mucus layer is a barrier with unknown influence on the 
mass transfer caused by direct drug transport from lipid particle to the cell membrane upon collision. 
Few data are available dealing with small particles diffusing through mucus. These data indicate that, 
depending on particle properties, diffusion of particles through mucus is possible (106, 134-136). 
Alternatively, a drug transfer from lipid particles to lipophilic mucus components may be thinkable 
since human intestinal mucus is containing glycolipids, lipids, and phospholipoidal constituents 
0.5-5%[w/w] overall (58).  
There is evidence, that lipid containing formulations have the ability to affect the pharmacokinetics of 
an orally administered drug. Particularly for highly lipophilic molecules, lipid containing dosage forms 
provide a good possibility to improve bioavailability. In vivo, different mechanisms like uptake of lipid 
vesicles by the lymphatic tissue are involved and may contribute additionally to the absorption 
enhancement which makes it difficult to estimate the importance of the drug permeation because of 
direct drug transfer from lipid particle to the cell membrane out of the in vitro data of this work. It would 
be challenging to asses the in vivo quantification of this transfer because other involved mechanisms 
have to be excluded somehow. Another possibility to investigate on this open question would be to 
use a suitable in vitro model e.g. to put a layer of mucus or artificial mucus on Caco-2 cell monolayer 
or to use a mucus producing cell model. 
4.1.6 Conclusions 
The refined mathematical model, which is proposed in this study for the determination of drug 
absorption parameters in Caco-2 cell monolayers, is able to differentiate between active and passive 
transported compounds. The model is able to divide trans-monolayer permeability into independent 
permeability coefficients of the apical membrane and the basal membrane. It allows deducing 
formulation-to-cell partition coefficient, intracellular time dependent concentration, and quantification of 
carrier mediated efflux rate directly out of time dependent experimental concentration data. The 
analysis of the transcellular permeation experiments with this model indicated a decrease of apparent 
permeability with increasing lipid concentration, if an interaction of a drug and a lipid containing 
formulation is given.  
A biophysical model for delineating contribution of different transport steps to the apparent 
permeability coefficient was developed taking into account transport of lipid particles and free drug 
molecules through diffusion boundary layer, permeation of free drug molecules through cell 
membrane, and drug permeation because of direct drug transfer from lipid particles to the cell 
membrane. This evaluation of the apparent permeability coefficient confirmed that the free fraction of a 
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drug is the major determinant of intestinal cell permeation. Additionally, the direct transfer of lipophilic 
drugs from lipid phase of the formulation to cell membrane can also make an essential contribution to 
drug permeation. The relative significance of these two processes may depend on the drug and the 
formulation. These observations apply to structurally different lipid containing drug formulations.  
Since drug flux is relevant for the amount delivered and hence bioavailability, simultaneous increase of 
drug and lipid concentration provides an undiminished flux which may improve bioavailability by 
prolonged intestinal absorption at a sustained rate. The results of this study may be used for the 
development of efficient oral dosage forms to improve bioavailability of poorly water soluble drugs. 
 
4.1.7 Acknowledgements 
We would like to thank Lipoid GmbH for the generous supply with Lipoid S 100 and Lipoid EPG. We 
would like to thank Roche Pharmaceuticals for the kind gift of saquinavir and Phares Drug Delivery for 
the kind gift of triclabendazole. 
 
Marcel Schneider Page 84 of 172 University of Basel, 2008 
4.2 Screening of Several Lipophilic Compounds to Find a Poorly 
Soluble Compound with Low Membrane Permeability and No 
Carrier Mediated Efflux 
To investigate the influence of lipid containing dosage forms on drugs with different properties, a drug 
exhibiting poor water solubility and low membrane permeability had to be chosen. Furthermore the 
drug should be no subject of carrier mediated efflux. Ideally, the compound should have been used in 
Caco-2 permeation studies already and drug metabolism should be known.  
In a log D range from 0 to 5 and a molecular weight up to 500 D, high lipophilicity and good membrane 
permeability are usually connected properties if the compound is no subject of carrier mediated 
efflux (5). If log D exceeds 5 or the molecular weight exceeds 500 D membrane permeability 
decreases (7).  
After extensive literature study, some compounds were chosen to test their suitability with the Caco-2 
model: Carbamazepine was chosen because of its poor solubility and high lipophilicity (log D 2.6), a 
known moderate to low Caco-2 permeability, and no reported carrier mediated transport in the Caco-2 
model (33, 84, 137).  
The moderately lipophilic triamterene (log D 1.26) was chosen because of its poor solubility and 
because it was one order of magnitude less permeable than propranolol in the mdr1-mdck cell 
model (138).  
A permeability coefficient in the Caco-2 model of 1.3*10-6 cm/s indicated that the poor soluble and 
moderately lipophilic bendroflumethiazide (log D 1.91) may have the desired properties (33). 
Poorly soluble proscillaridine was chosen because of its molecular weight of 531 D, a log D of 2.48, 
and a reported permeability of 0.63*10-6 cm/s in the Caco-2 cell model (60).  
Albendazole and triclabendazole were chosen because of their low solubility and their high lipophilicity 
(log D of 3.01 and of 5.9, respectively). Both compounds achieve a low bioavailability if orally 
administered in vivo (1).  
4.2.1 Material and Methods 
4.2.1.1 Material 
Carbamazepine, triamterene, bendroflumethiazide, and albendazole were purchased from SIGMA-
Aldrich, Fluka Chemie GmbH, Buchs, Switzerland and were of analytical grade. Proscillaridine 
(minimum 80%) was purchased from SIGMA-Aldrich, Fluka Chemie GmbH, Buchs, Switzerland. 
Triclabendazole was kindly provided by Phares Drug Delivery, Muttenz, Switzerland. Transport media 
used for the permeation studies were prepared with Dulbecco’s Modified Eagle’s Medium (DMEM) 
base powder (without glucose, l-glutamine, phenol red, sodium pyruvate and sodium bicarbonate, 
purchased from SIGMA-Aldrich, Fluka Chemie GmbH, Buchs, Switzerland). DMEM base powder was 
dissolved in bi-distilled and autoclaved water and supplemented with glucose (4.5 g/l), HEPES 
(4.76 g/l), NaCl (1.987 g/l), and l-glutamine (0.876 g/l). The pH was adjusted to 7.4 and the final 
medium was filtered through a sterile filter (Supor-200, 0.2 µm pore size, Pall Corporation, Michigan, 
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USA) under aseptic conditions. Glucose, HEPES, NaCl, and l-glutamine were purchased from SIGMA-
Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). Dulbecco’s Phosphate Buffered Saline (D-PBS) 
(with Ca2+, Mg2+) was purchased from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). 
 
4.2.1.2 Drug Quantification 
The drug quantification of cell permeation experiments with aqueous solutions of the drugs was 
performed with HPLC-UV (Agilent series 1100, Agilent Technologies USA, equipped with a capillary 
pump G1376A, an auto sampler G1377AµWPS and a variable wavelength detector G1314a). A C-18 
reversed phase column was used (CC 125/2 Lichrospher 100 RP 18 ec, Macherey Nagel, Oensingen, 
Switzerland). 
The drug concentration of albendazole was determined using the following mobile phase: distilled 
water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 40/45/15 (V/V). Ammonium 
acetate with a concentration of 0.55 g/l was added to the mobile phase. pH-value at 25°C was 7.30. 
An isocratic method was used for quantification with a flow of 0.2 ml/min, an injection volume of 40 µl 
and a runtime of 7 min. Albendazole was detected at 254 nm in UV. Quantification was performed 
against a set of external standard solutions within the linear response concentration range. Samples 
were stored at 4°C. 
 
The drug concentration of bendroflumethazide was determined with the following mobile phase: 
distilled water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 50/35/15 (V/V). 
Ammonium acetate with a concentration of 0.55 g/l was added to the mobile phase. pH-value at 25°C 
was 6.95. An isocratic method was used for quantification with a flow of 0.2 ml/min, an injection 
volume of 40 µl and a runtime of 8 min. Bendroflumethazide was detected at 254 nm in UV. Using this 
method, retention of bendroflumethazide was approximately 4.7 min. Quantification was performed 
against a set of external standard solutions within the linear response concentration range. Samples 
were stored at 4°C. 
 
The drug concentration of carbamazepine was determined with the following mobile phase: distilled 
water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 55/35/10 (V/V). Ammonium 
acetate with a concentration of 0.55 g/l was added to the mobile phase. pH-value at 25°C was 6.9. An 
isocratic method was used for quantification with a flow of 0.2 ml/min, an injection volume of 40 µl and 
a runtime of 6 min. Carbamazepine was detected at 284 nm in UV. Using this method, retention of 
carbamazepine was approximately 3.7 min. Quantification was performed against a set of external 
standard solutions within the linear response concentration range. Samples were stored at 4°C. 
 
The drug concentration of proscillaridine was determined with the following mobile phase: distilled 
water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 45/45/10 (V/V). Ammonium 
acetate with a concentration of 0.55 g/l was added to the mobile phase. pH-value at 25°C was 7.21. 
An isocratic method was used for quantification with a flow of 0.2 ml/min, an injection volume of 40 µl 
and a runtime of 7 min. Proscillaridine was detected at 300 nm in UV. Using this method, retention of 
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proscillaridine was approximately 4.7 min. Quantification was performed against a set of external 
standard solutions within the linear response concentration range. Samples were stored at 4°C. 
 
The drug concentration of triamterene was determined by HPLC-UV with the following mobile phase: 
distilled water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 60/35/5 (V/V). 
Ammonium acetate with a concentration of 0.55 g/l was added to the mobile phase. pH-value at 25°C 
was 6.81. An isocratic method was used for quantification with a flow of 0.2 ml/min, an injection 
volume of 40 µl and a runtime of 8 min. Triamterene was detected at 233 nm in UV. Using this 
method, retention of triamterene was approximately 5.5 min. Quantification was performed against a 
set of external standard solutions within the linear response concentration range. Samples were 
stored at 4°C. 
 
The drug concentration of triclabendazole was determined with the following mobile phase: distilled 
water (bi distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 35/40/25 (V/V). Ammonium 
acetate with a concentration of 0.55 g/l was added to the mobile phase. pH-value at 25°C was 6.7. An 
isocratic method was used for quantification with a flow of 0.25 ml/min, an injection volume of 40 µl 
and a runtime of 8 min. Triclabendazole was detected at a wavelength of 305 nm. Using this method 
retention of triclabendazole was approximately 5.6 min. Quantification was performed against a set of 
external standard solutions within the linear response concentration range. To maintain the stability 
and reproducibility, the standard solutions contained the same amount of lipids as the samples. Lipid 
containing samples were diluted 1:10 with transport media before injection. Samples were stored at 
4°C. 
4.2.1.3 TEER Measurements 
The integrity of the Caco-2 cell monolayer in the Transwell plates was ensured with the measurement 
of the trans-epithelial electrical resistance (TEER) before and after every transport study. 
After washing the cell monolayer with 37°C tempered D- PBS (with Ca2+, Mg2+), 1600 µl transport 
medium was added into the apical and 2800 µl transport medium was added into the basal 
compartment. The Transwell plate was equilibrated for 60 min in the cell culture incubator before the 
pre-experimental measurement. The TEER was measured with an EVOM-G-Meter (EVOM-G-Meter 
Modell -24, World Precision Instruments, Berlin, Germany) equipped with an EndohmTM tissue 
resistance measurement chamber containing 4.6 ml tempered transport media (World Precision 
Instruments, Berlin, Germany). The measurement chamber was tempered to 37°C with transport 
medium before the measurement. For the post-experimental TEER measurement, the withdrawn 
volume in the apical compartment was replaced with transport medium before TEER was measured. 
Caco-2 monolayer exceeding TEER values of 250 Ωcm2 were used for transport experiments. 
4.2.1.4 Drug Permeation Across Caco-2 Cell Monolayers 
Cells between culture days 19-23 at passage numbers 60-65 were used for the permeation studies. 
After the pre-experimental TEER measurement, the transport medium was removed from the donor 
compartment and replaced by the tempered (37°C) drug solutions. In the apical to basal direction, 
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1600 µl of the drug solution was added to the apical compartment whereas the basal compartment 
contained 2800 µl of transport media. In the basal to apical direction, the apical compartment 
contained 1600 µl transport media and 2800 µl of the drug formulation was added to the basal 
compartment. Triclabendazole was tested additionally as liposomal formulation. After the pre-
experimental TEER measurement, transport medium was completely removed. In the apical to basal 
direction, 1600 µl drug formulation was added to the apical compartment and 2800 µl placebo 
formulation (same lipid concentration as donor) was added to the basal compartment. In the basal to 
apical direction, 1600 µl placebo formulation was added to the apical compartment and 2800 µl drug 
formulation was added to the basal compartment. 
At least three wells were used for each direction. The Transwell plate was shaken at 37°C in a water 
saturated atmosphere under an incubator hood (KS15, Edmund Bühler GmbH, Tübingen& Hechingen, 
Germany) with a stirring rate of 75 rpm on an orbital shaker (KS15, Edmund Bühler GmbH, Tübingen& 
Hechingen, Germany). Permeation of drug across the cell monolayer was monitored by sampling the 
solutions in both compartments at predefined points of time during 5 h, which were 15, 30, 60, 90, 
120, 180, and 300 min. The sample volume was 50 µl. The withdrawn volume was not replaced. The 
samples were collected in glass vials (Schmidlin Labor& Service AG, Sarbach, Switzerland) and 
stored at 4°C until the HPLC analysis was performed. 
4.2.1.5 Data Analysis 
The kinetic model describing cell permeation described by Kapitza et al. (115) was fitted to the time 
dependent concentration data with the software Easy Fit® to deduce parameters describing cell 
permeation. Easy Fit® deduced apparent permeability coefficient (P), carrier mediated efflux parameter 
(vk), initial concentration in apical compartment in apical to basal direction (c0a_ab), and initial 
concentration in basal compartment in basal to apical direction (c0b_ba). 
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4.2.2 Results and Discussion 
Table 7 gives an overview of the determined transport parameters out of the concentration versus time 
curves fitted by Easy Fit® using the kinetic model describing cell permeation described by Kapitza et 
al. (115). Albendazole showed high apparent permeability coefficients, equilibrium was reached after 
90 min independent of drug concentrations and transport direction. No carrier mediated efflux was 
observed. Similar observations were made with carbamazepine. Albendazole and carbamazepine 
were not suitable as model compound because their membrane permeability was similar to 
progesterone and propranolol, which were model compounds for high membrane permeability. 
 
Table 7 Kinetic parameters by fitting the concentration versus time profiles to the diffusion 
model with Easy Fit®. Abbreviations: P indicates apparent permeability coefficient, vk carrier 
mediated efflux rate, C0a_AB fitted apical concentration in apical to basal direction at t=0, C0b_BA 
fitted basal concentration at t=0 in basal to apical direction. 
Drug Drug 
concentration 
[µM] 
P *105 
[cm/s] 
vk 
[nmol*cm-2*min-1] 
C0a_AB 
[µM] 
C0b_BA 
[µM] 
Albendazole 0.45 34.0 0.00027 0.61 0.52 
 3.18 44.1 1*10-10 3.55 3.24 
Bendroflumethiazide 4.6 8.33 0.01353 3.25 3.28 
 31.8 5.31 0.06749 23.82 24.43 
Carbamazepine  4.6 30.3 0.00512 30.58 29.88 
 31.8 33.4 1*10-10 4.15 4.36 
Proscillaridine  4.6 8.49 0.01847 4.27 4.1421 
 31.8 8.03 0.13066 30.15 28.39 
Triamterene  4.6 8.30 0.01073 4.79 4.41 
 31.8 5.52 0.04651 32.14 30.59 
Triclabendazole#  4.6 5.27 1*10-10 0.23600 0.61 
 14.9 4.1 1*10-10 1.13 2.33 
Triclabendazole liposomes 
(0.1 mg/ml lipid) 63 2.84 1*10
-10
 45.363 43.17 
Triclabendazole liposomes 
(10 mg/ml lipid) 63 0.298 1*10
-10
 97.220 95.25 
# poor fitting quality due to high adsorption of triclabendazole to the Transwell surfaces. 
 
For bendroflumethiazide, proscillaridine, and triamterene moderate to low passive permeability 
coefficients were obtained. These drugs showed asymmetric cell permeation because they were 
subject to carrier mediated apical efflux. For that reason they were not suitable as model drug. 
Triclabendazole permeation data suggested an apparent permeability coefficient that was one order of 
magnitude lower than the apparent permeability coefficients of chosen highly membrane permeable 
model drugs progesterone and propranolol, which attained an apparent permeability coefficient 
exceeding 1*10-4 cm/s. No active carrier mediated efflux was observed. Cell permeation experiments 
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with aqueous solutions of triclabendazole showed a poor recovery because of extensive unspecific 
drug adsorption to the Transwell surface. In an additional experiment, where liposomes with low lipid 
phase concentrations were used, the unspecific adsorption of triclabendazole disappeared. Because 
of the disappearance of adsorption to the surfaces in presence of lipids, triclabendazole could be used 
to determine the influence of lipid containing drug formulations on passive permeation. 
4.2.3 Conclusion 
Despite the lack of reliable permeation data because of unspecific adsorption of aqueous 
triclabendazole to Transwell surface, triclabendazole was the most suitable drug inside the tested 
drugs. Triclabendazole exhibits poor water solubility, low cell membrane permeability, and no carrier 
mediated efflux. Because unspecific adsorption to Transwell surfaces disappears if transport media is 
supplemented with small amounts of phospholipids, triclabendazole is a suitable model drug to study 
the influence of different lipid formulations on the passive permeation of poorly water soluble drugs.  
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4.3 Screening of Different Emulsions and Microemulsions for their 
Suitability as Model Formulation  
To determine the influence of lipid containing drug formulations on the permeability of lipophilic drugs, 
three structurally different formulations should be tested, which obtain ideally different microscopic 
structures. Besides of liposomes, which had been characterized already regarding cell toxicity and 
used for permeation studies through Caco-2 cell monolayer, and a microemulsion, that was 
characterized regarding cell toxicity on Caco-2 cells in previous work of our group, a third, structurally 
different lipid containing drug formulation had to be developed (115, 117). This formulation should 
consist of well characterized excipients regarding compatibility with the Caco-2 cell model. Cytotoxicity 
and influence on cell membrane of Caco-2 cell monolayer of Capmul MCM, Captex 8000, 
Cremophor EL, and ethanol had been determined in previous work. Cytotoxic effects of Capmul MCM 
had been shown exceeding concentrations of 0.02% (m/V) if used alone (117). Cremophor EL is 
known to inhibit unspecifically Pgp, the main efflux transporter in Caco-2 cells achieving carrier 
mediated efflux (94, 95, 120, 125, 139). 
It was the aim of the following section to develop an emulsion consisting of these well characterized 
components, which is well tolerated by the Caco-2 cells. Because Capmul MCM and Cremophor EL 
are known to increase paracellular transport by thight junction modulation, cell permeation 
experiments were performed observing TEER and paracellular permeability using the paracellular 
marker compound fluoresceine. 
4.3.1 Material 
Fluoresceine sodium was purchased from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland) 
and was of analytical grade. Captex 8000 was purchased from SIGMA-Aldrich (Fluka Chemie GmbH, 
Buchs, Switzerland). Capmul MCM was purchased from Abitec Corporation (Janesville, USA). 
Cremophor was ordered from Fluka (Fluka Chemie GmbH, Buchs, Switzerland). Transport media 
used for the permeation studies and the equilibrium dialysis experiments were prepared with 
Dulbecco’s Modified Eagle’s Medium (DMEM) base powder (without glucose, l-glutamine, phenol red, 
sodium pyruvate and sodium bicarbonate, purchased from SIGMA-Aldrich, Fluka Chemie GmbH, 
Buchs, Switzerland). DMEM base powder was dissolved in bi-distilled and autoclaved water and 
supplemented with glucose (4.5 g/l), HEPES (4.76 g/l), NaCl (1.987 g/l), and l-glutamine (0.876 g/l). 
The pH was adjusted to 7.4 and the final medium was filtered through a sterile filter (Supor-200, 
0.2 µm pore size, Pall Corporation, Michigan, USA) under aseptic conditions. Glucose, HEPES, NaCl, 
and l-glutamine were purchased from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). 
Dulbecco’s Phosphate Buffered Saline (D-PBS) (with Ca2+, Mg2+) was purchased from SIGMA-Aldrich 
(Fluka Chemie GmbH, Buchs, Switzerland). 
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4.3.2 Methods 
4.3.2.1 Preparation of the Formulations 
Lipid phases were prepared by melting the components at 37°C and mixing the components together. 
Lipid phase was warmed to 37°C before use and the according amount for the final formulation was 
balanced and mixed with two thirds of the final transport medium volume. The formulation was 
homogenized for 5 min at 15000 rpm with a Polytron homogenizer (Polytron PT 3000, Kinematica AG, 
Littau, Switzerland) then preheated transport medium was added to the final volume. The 
manufactured formulations were analyzed for physical stability over 24 h by examining the optical 
aspect and measuring particle size by PCS. No tendency for phase separation should be found after 
24 h. 
4.3.2.2 Particle Size Measurement 
The particle size of the formulations was determined by dynamic light scattering. The z-average 
particle size of the emulsions and the microemulsions were measured with a Zetasizer Nano ZS ZEN 
3600 (Malvern Instruments Ltd, Worcestershire, England) in disposable cuvettes (2.5 ml sample 
volume, Brand GmbH & Co, Wertheim, Germany) at 37°C. The resulting z-average diameter was the 
average out of 3 runs, consisting of 10 measurements each. 
4.3.2.3 TEER Measurements 
The integrity of the Caco-2 cell monolayer in the Transwell plates was ensured with the measurement 
of the trans-epithelial electrical resistance (TEER) before and after every transport study. 
After washing the cell monolayer with 37°C tempered D- PBS (with Ca2+, Mg2+), 1600 µl transport 
medium was added into the apical and 2800 µl transport medium was added into the basal 
compartment. The Transwell plate was equilibrated 60 min in the cell culture incubator before the pre-
experimental measurement. The TEER was measured with an EVOM-G-Meter (EVOM-G-Meter 
Modell -24, World Precision Instruments, Berlin, Germany) equipped with an EndohmTM tissue 
resistance measurement chamber containing 4.6 ml tempered transport media (World Precision 
Instruments, Berlin, Germany). The measurement chamber was tempered to 37°C with transport 
medium before the measurement. For the post-experimental TEER measurement, the withdrawn 
volume in the apical compartment was replaced with transport medium before TEER was measured. 
Caco-2 monolayer exceeding TEER values of 250 Ωcm2 were used for transport experiments. 
4.3.2.4 Determination of Transcellular Drug Permeation 
Since it is known that nonionic surfactants like Cremophor EL were interacting with tight junctions of a 
cell monolayer, physically stable formulations were tested in transport experiments, where the cell 
monolayer integrity was indirectly determined by measuring the change of fluoresceine sodium 
permeability coefficient caused by the formulations compared to the permeability coefficient of 
aqueous fluoresceine solutions as reference. Fluoresceine is a hydrophilic marker compound for 
paracellular transport (98, 140). Additionally, TEER was measured before and after the experiment. 
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Decreased integrity of the cell monolayer is expressed as increased fluoresceine permeability 
coefficient and a decreased post- experimental TEER compared to aqueous transport media. 
Cells between culture days 19-23 at passage numbers 60-65 were used for the permeation studies. 
After the pre-experimental TEER measurement, the transport medium was removed from the donor 
compartment and replaced by the tempered (37°C) drug solutions for the determination of cell 
permeation kinetics of the aqueous fluoresceine solutions. To determine the influence of the 
formulations, placebo formulations were pipetted after pre-experimental TEER measurement into 
Transwell, 1600 µl into the apical, 2800 µl to the basal compartment. Then, 30.1 µl ethanolic 
fluoresceine sodium stock solution (concentration 2 mg/ml) was added into apical compartment (apical 
to basal direction) and 52.6 µl to basal compartment (basal to apical direction). The resulting 
Fluoresceine concentration in the donor compartment was 100 µM. At least three wells were used for 
each direction. The Transwell plate was shaken at 37°C in a water saturated atmosphere under an 
incubator hood (KS15, Edmund Bühler GmbH, Tübingen& Hechingen, Germany) with a stirring rate of 
75 rpm on an orbital shaker (KS15, Edmund Bühler GmbH, Tübingen& Hechingen, Germany). 
Permeation of drug across the cell monolayer was monitored by sampling the solutions in both 
compartments at predefined points of time during 5 h, which were 15, 30, 60, 90, 120, 180, and 
300 min. The sample volume was 50 µl. The withdrawn volume was not replaced. Lipid containing 
samples were diluted 1:10 with transport medium. The samples were collected in glass vials 
(Schmidlin Labor& Service AG, Sarbach, Switzerland) and stored at 4°C until the HPLC analysis was 
performed. 
4.3.2.5 Fluoresceine Quantification  
The drug concentration of sodium fluoresceine was determined by HPLC-UV (Agilent series 1100, 
Agilent Technologies USA, equipped with a capillary pump G1376A, an auto sampler G1377AµWPS 
and a variable wavelength detector G1314a). A C-18 reversed phase column was used (CC 125/2 
Lichrospher 100 RP 18 ec, Macherey Nagel, Oensingen, Switzerland) with the following mobile phase: 
distilled water (bi-distilled and filtered through 0.45 µm)/methanol 60/40 (V/V). Ammonium acetate with 
a concentration of 0.55 g/l was added to the mobile phase. pH-value at 25°C was 6.85. An isocratic 
method was used for quantification with a flow of 0.2 ml/min, an injection volume of 40 µl and a 
runtime of 6 min. Sodium fluoresceine was detected at 475 nm in UV. Using this method, retention of 
sodium fluoresceine was approximately 4.5 min. Quantification was performed against a set of 
external standard solutions within the linear response concentration range. Samples were stored at 
4°C. 
4.3.2.6 Data Analysis 
The kinetic model describing cell permeation described by Kapitza et al. (115) was fitted to the time 
dependent concentration data with the software Easy Fit® to deduce parameters describing cell 
permeation. Easy Fit® deduced apparent permeability coefficient (P), carrier mediated efflux parameter 
(vk), initial concentration in apical compartment in apical to basal direction (c0a_AB), and initial 
concentration in basal compartment in basal to apical direction (c0b_BA). 
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4.3.3 Results and Discussion 
Table 8 shows the composition of the tested lipid phases and the results of the stability examinations 
of the tested formulations. 
 
Table 8 Lipid phase composition of screened formulations and the stability of the resulting 
formulations with transport media over 24 h. All formulations were manufactured containing 
10 mg/ml lipid phase with transport media as aqueous phase. 
Composition of the lipid phase 
Capmul MCM 
[%m/m] 
Captex 8000 
[%m/m] 
Cremophor EL 
[%m/m] 
Ethanol 
[%m/m] 
Mean 
particle 
size t=0 
[nm] Optical aspect after 24h 
5.0 49 36 10 181 opalescent, homogenous 
8.5 45.5 36.0 10 121 opalescent, homogenous 
0.0 52.63 36.84 10.53 n.d. milky, phase separation 
0.0 80.0 15.0 5.0 n.d. turbid, phase separation 
15.0 50.0 35.0 0.0 n.d opalescent, homogenous 
10.0 80.0 10.0 0.0 n.d. turbid, phase separation 
8.5 63.5 18.0 10.0 189 turbid, homogenous 
5.0 67.0 18.0 10.0 172 turbid, homogenous 
0.0 70.0 20.0 10.0 323 turbid, phase separation 
5.0 65.0 20.0 10.0 173 turbid, homogenous 
3.0 72.0 15.0 10.0 282 turbid, homogenous 
 
Since it is known that mono- and diglycerides such as Capmul MCM and nonionic surfactants such as 
Cremophor EL interact with the tight junctions of a cell monolayer, formulations that were physically 
stable for at least 24 h and contain as low Capmul MCM and Cremophor EL concentrations as 
possible were tested in transport experiments. Cell monolayer integrity was tested with the hydrophilic 
paracellular transport marker fluoresceine sodium and by monitoring the TEER. Table 9 gives an 
overview of the results. 
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Table 9 Test of physically stable formulations on their influence on Caco-2 cell monolayer 
integrity. The formulations contained 100 µM fluoresceine sodium. 
Lipid phase 
composition [%m/m] 
Lipid phase 
concentration 
[mg/ml] 
TEER before 
experiment 
[Ohm*cm-2] 
TEER after 
300 min 
[Ohm*cm-2] 
Decrease of 
TEER over 
300 min [%] 
Fluoresceine 
Papp 
[*10-6 cm/s] 
Fluoresceine in 
Transport Media 
0 644.36 535.80 16.85 2.0 
0.5 427.70 310.20 27.47 1.10 
1 436.32 223.25 48.83 2.60 
Capmul MCM 5%, 
Captex 8000 67%, 
Cremophor EL 18%, 
Ethanol 10% 5 432.40 209.93 51.45 2.80 
0.5 472.35 263.20 44.28 2.39 
1 484.10 169.20 65.05 3.25# 
Capmul MCM 8.5%, 
Captex 8000 45.5%, 
Cremophor EL 36%,  
Ethanol 10% 5 488.80 195.05 60.10 5.19# 
0.5 481.75 274.95 42.93 1.34 
1 460.60 180.95 60.71 5.05# 
Capmul MCM 5%, 
Captex 8000 49%, 
Cremophor EL 36%, 
Ethanol 10% 5 470.00 162.15 65.50 6.73# 
0.5 462.95 249.10 46.19 1.95* 
1 439.45 272.60 37.97 3.58* 
Capmul MCM 3%, 
Captex 8000 72%, 
Cremophor EL 15%, 
Ethanol 10% 5 427.70 251.45 41.21 1.31* 
# Cell monolayer detached from the filter of the Transwell insert, * Phase separation after 5 h 
 
The results of the fluoresceine permeation studies indicated the suitability of a lipid phase consisting of 
5%(m/m) Capmul, 67%(m/m) Captex, 18%(m/m) Cremophor, and 10%(m/m) ethanol to act as a model 
formulation. Different concentrations of this lipid phase were mixed with transport media resulting in an 
emulsion that was physically stable for at least 24 h and had a low influence on the integrity of the 
Caco-2 cell monolayer. The permeability coefficient of fluoresceine in this formulation was in the same 
range as for the reference fluoresceine solution. The decrease of TEER value was bigger than the 
decrease induced by the lipid phase consisting of 3%(m/m) Capmul, 72%(m/m) Captex, 15%(m/m) 
Cremophor, and 10%(m/m) ethanol, but the formulations of this lipid phase showed phase separation 
after 5 h. All other lipid phases were not compatible with the Caco-2 cell monolayer, which was 
indicated by detached cell monolayer after 300 min incubation. This progressive damage of the cell 
monolayer was additionally shown as increased fluoresceine permeation. 
4.3.4 Conclusions 
A lipid phase consisting of 5%(m/m) Capmul, 67%(m/m) Captex, 18%(m/m) Cremophor, and 10%(m/m) 
ethanol, resulting in a stable emulsion with a mean droplet size of around 170 nm in transport media, 
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does increase fluoresceine permeability only slightly. It lowers the TEER dose dependent but in all 
cases not below the limit of 200 Ohm*cm-2 over 5 h. This emulsion is the most suitable emulsion-like 
formulation for the determination of the influence of structurally different formulations on the 
permeation of lipophilic drugs. An additional validation of the influence of the emulsion and the 
microemulsion on time and lipid phase concentration dependent decrease of the monolayer integrity 
was necessary to ensure optimal experimental conditions (see next chapter). 
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4.4 Maintaining TEER over Time of the Chosen Formulations: 
Determination of Duration of Transport Experiments 
It was observed that different lipid containing drug formulations containing Captex 8000, 
Capmul MCM, Cremophor EL, and ethanol, decrease the cell monolayer integrity. An optimal 
experimental procedure had to be found to use these formulations for cell permeation experiments. 
Observations during formulation screening experiments indicated that the cells tolerated lipid phase 
concentrations up to 5 mg/ml for up to 3 h well. But after 5 h, depending on the formulation, detached 
cell monolayer were observed. To assure the cell monolayer integrity during incubation of the cell 
monolayer with the chosen formulations, TEER was observed over 5 h. This procedure was not 
necessary for the liposomes, because no effect of the liposomes on the cell monolayer integrity was 
observed up to 50 mg/ml phospholipids in previous work (115). 
4.4.1 Material and Methods 
4.4.1.1 Material  
Captex 8000 was purchased from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). Capmul 
MCM was purchased from Abitec Corporation (Janesville, USA). Cremophor was ordered from Fluka 
(Fluka Chemie GmbH, Buchs, Switzerland). Transport media used for the permeation studies and the 
equilibrium dialysis experiments were prepared with Dulbecco’s Modified Eagle’s Medium (DMEM) 
base powder (without glucose, l-glutamine, phenol red, sodium pyruvate and sodium bicarbonate, 
purchased from SIGMA-Aldrich, Fluka Chemie GmbH, Buchs, Switzerland). DMEM base powder was 
dissolved in bi-distilled and autoclaved water and supplemented with glucose (4.5 g/l), HEPES 
(4.76 g/l), NaCl (1.987 g/l), and l-glutamine (0.876 g/l). The pH was adjusted to 7.4 and the final 
medium was filtered through a sterile filter (Supor-200, 0.2 µm pore size, Pall Corporation, Michigan, 
USA) under aseptic conditions. Glucose, HEPES, NaCl, and l-glutamine were purchased from SIGMA-
Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). Dulbecco’s Phosphate Buffered Saline (D-PBS) 
(with Ca2+, Mg2+) was purchased from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). 
 
4.4.1.2 Preparation of Emulsions and Microemulsions 
Microemulsions containing 1 mg/ml and 5 mg/ml lipid phase (lipid phase consisting of 17.58%[m/m], 
Capmul, 35.05%[m/m] Captex, 36.84%[m/m] Cremophor, and 10%[m/m] ethanol) and emulsions 
containing 1 mg/ml and 5 mg/ml lipid phase (lipid phase consisting of 5%[m/m] Capmul, 67%[m/m] 
Captex, 18%[m/m] Cremophor, and 10%[m/m] ethanol) were tested. The lipid phases were prepared by 
mixing the components at 37°C. The lipid phases were stored at 4°C. Lipid phase was warmed up to 
37°C before use and the according amount was balanced and mixed with two thirds of the final 
transport medium volume. This crude formulation was homogenized for 5 min at 15000 rpm with a 
Polytron homogenizer (Polytron PT 3000, Kinematica AG, Littau, Switzerland) then preheated 
transport medium was added to the final volume. 
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4.4.1.3 TEER Measurements 
The time dependent integrity of the Caco-2 cell monolayer in the Transwell plates was ensured with 
the measurement of the trans-epithelial electrical resistance (TEER). After washing the cell monolayer 
with 37°C tempered D-PBS (with Ca2+, Mg2+), 1600 µl transport medium was added into the apical and 
2800 µl transport medium was added into the basal compartment. The Transwell plate was 
equilibrated 60 min in the cell culture incubator before the pre-experimental measurement. The TEER 
was measured with an EVOM-G-Meter (EVOM-G-Meter Modell -24, World Precision Instruments, 
Berlin, Germany) equipped with an EndohmTM tissue resistance measurement chamber (World 
Precision Instruments, Berlin, Germany) containing 4.6 ml tempered transport media. The 
measurement chamber was tempered to 37°C with transport medium before the measurement. After 
the pre experimental TEER measurement transport media was removed and the formulations were 
pipetted into the Transwell plates (3 well each). The Transwell plates were put on an orbital shaker 
(KS15, Edmund Bühler GmbH, Tübingen& Hechingen, Germany) with a stirring rate of 75 rpm under 
water saturated atmosphere at 37°C using an incubator hood (KS15, Edmund Bühler GmbH, 
Tübingen& Hechingen, Germany). TEER was monitored in intervals of 30 min during 300 min. 
4.4.2 Results 
TEER measurements during 300 min of the emulsion showed an initial decrease of the TEER. After 
60 min TEER was stabilized and remained constant, which is shown in Figure 28. No difference 
between the different lipid phase concentrations was observed. The TEER obtained after 300 min 
incubation indicates for both of the tested lipid concentrations an intact cell monolayer. 
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Figure 28 Influence of two different lipid phase concentrations of the emulsion formulation on 
TEER over 300 min. Legend: closed bars: 1 mg/ml lipid phase, open bars: 5 mg/ml lipid phase. 
 
The observed behavior of the microemulsion containing 1 mg/ml lipid phase was comparable to the 
TEER progression of the emulsions. In contrast to that, the microemulsion containing 5 mg/ml lipid 
phase causes a continuous TEER decrease over time (see Figure 29). This indicates progressive and 
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time dependent damage of the cell monolayer. In this experiment, the initial TEER was 
681.1±4.7 Ohm*cm2 and the TEER after 300 min was 306.7±46.6 Ohm*cm2, which corresponds to a 
TEER decrease of 55%. In this particular experiment, cell monolayer integrity after 300 min was still 
ensured, since a limit of 200 Ohm*cm2 is defined in literature for an intact Caco-2 cell monolayer 
(141). Taking into account that in this particular experiment initial TEER was slightly higher than the 
average initial TEER in our lab (see Appendix), cell monolayer integrity during transport experiments 
would be compromised under average or slightly lower initial TEER. A moderate TEER decrease 
down to 60% of the initial value was determined after 180 min, which would assure intact cell 
monolayer with average or slightly lower initial TEER during cell permeation experiment if cell 
permeation experiments are shortened to 180 min by the use of microemulsions containing 5 mg/ml 
lipid phase. 
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Figure 29 Influence of two different lipid phase concentrations of the microemulsion 
formulation on TEER over 300 min. Legend: closed bars: 1 mg/ml lipid phase, open bars: 
5 mg/ml lipid phase. 
 
4.4.3 Conclusions 
The cell monolayer integrity is ensured during 300 min of cell monolayer incubation with emulsions 
containing 1 mg/ml and 5 mg/ml lipid phase and a microemulsion containing 1 mg/ml lipid phase. In a 
singular experiment, it was shown that the monolayer integrity of the microemulsion containing 
5 mg/ml lipid phase was still maintained after 300 min incubation. But TEER decrease of 55% was 
indicating a strong interference of the formulation with the barrier function of the cell monolayer. To 
assure monolayer integrity during transport experiments the transport experiments of microemulsions 
with 5 mg/ml lipid phase were shortened to 180 min.  
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4.5 Development of a Method to Determine the Free Fraction of a 
Drug Formulation Containing Lipids 
It was essential to have knowledge about the free fraction of the drug in the different formulations for a 
deeper understanding of the results of the transport experiments. The development of a method to 
determine the free amount of drug in lipid containing dosage forms like liposomes, microemulsions 
and emulsions is described in this chapter. Three different approaches for the determination of 
unbound drug concentration were evaluated. Ultrafiltration using centrifugal filter devices was 
evaluated as fast technique for the separation of lipid particles and aqueous phase. As second 
method, ultracentrifugation was evaluated, which allows fast separation of constituents with different 
densities and is used for the phase separation of semisolid dosage forms. This method would allow 
direct measurement of unbound drug concentration in the aqueous phase too. The third method, 
which was evaluated, was equilibrium dialysis. This time consuming method allows indirectly 
calculation of the drug concentration in the water phase of a formulation via the determination of the 
lipid water partition coefficient. It allows the calculation of the free fraction of a drug in a formulation. 
 
4.5.1 Material and Methods 
4.5.1.1 Material 
Lipoid S 100 and Lipoid EPG were kindly provided by Lipoid GmbH (Ludwigshafen, Germany). 
Saquinavir was a kindly provided by Roche (Roche Pharmaceuticals, Basel, Switzerland). 
Progesterone, Captex 8000, and Cremophor EL were purchased from Fluka (SIGMA-Aldrich, Fluka 
Chemie GmbH, Buchs, Switzerland). Capmul MCM was purchased from Abitec (Abitec Corp., 
Janesville, WI, USA).Transport media used as buffer were made with Dulbecco’s modified Eagle’s 
medium (DMEM) base (without glucose, l-glutamine, phenol red, sodium pyruvate and sodium 
bicarbonate) (SIGMA-Aldrich, Fluka Chemie GmbH, Buchs, Switzerland). This was dissolved in bi-
distilled and autoclaved water and supplemented with glucose (4.5 g/l), HEPES (4.76 g/l), NaCl 
(1.987 g/l) and l-glutamine (0.876 g/l), the pH was adjusted to 7.40 and the final medium was 
subjected to sterile filtration and 0.5%(m/V) sodium azide was added as antimicrobial preservative. 
Glucose, Hepes, NaCl, sodium azide, and l-glutamine were all obtained from SIGMA-Aldrich (Fluka 
Chemie GmbH, Buchs, Switzerland). All other reagents were of analytical grade. 
4.5.1.2 Preparation of Liposomes 
Lipoid S100, EPG and the drug were dissolved in ethanol in a round bottomed flask. The solvent was 
evaporated to dryness and the lipid film was kept under vacuum for 30 min to eliminate solvent traces. 
The lipid film was suspended with 20 ml of tempered transport medium. The suspension was extruded 
under nitrogen pressure with a filter candle through polycarbonate filters (Nucleopore track edge 
membrane filters, Whatman plc, Kent, UK) with descending pore sizes in the following scheme: 
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2 x 0.4 µm, 5 x 0.2 µm 20 x 0.1 µm. The liposomes were analyzed with dynamic light scattering for 
particle size (see below). 
4.5.1.3 Preparation of Microemulsions 
The components of the lipid phase (Captex 8000 35.05% [m/m], Capmul MCM 17.58% [m/m], 
Cremophor EL 36.84% [m/m], and ethanol 10% [m/m]) were mixed at 37°C. The lipid phase was stored 
at 4°C. Before use, the lipid phase was warmed to 37°C and the according amount was balanced and 
mixed with transport medium. The formulation was homogenized for 5 min at 15000 rpm with a 
Polytron homogenizer (Polytron PT 3000, Kinematica AG, Littau, Switzerland). The formulations were 
analyzed with dynamic light scattering for particle size. 
4.5.1.4 Particle Size 
The particle size of the formulations was measured by dynamic light scattering. The z-average 
diameter of the formulations were determined with a Zetasizer 1000HSA (Malvern Instruments Ltd, 
Worcestershire, England) equipped with a 100 nm lens in disposable cuvettes (2 ml size, Greiner 
Labortechnik, Kremsmünster, Austria) at 25°C. Samples were diluted with sterile filtered transport 
media (0.2 µm) until counting rates between 100 and 300 KCts/s were reached. The resulting z-
average diameter was the average out of 5 runs, consisting of 10 measurements each. 
4.5.1.5 Ultrafiltration 
Centrifugal filter devices with a molecular weight cut off of 3000 D, 100000 D (Microcon YM3, 
Millipore, Bedford, MA, USA), and 30000 D (Ultrafree- 0.5 centrifugal filter NMWL Membrane, Tube 
Biomax, Millipore, Bedford, MA, USA) were used. After pippetting 1 ml of the formulation, the filter 
devices were spun for 30 min at 14000 rpm with an Eppendorf centrifuge (5415C, Eppendorf / Dr. 
Vaudaux AG, Schönenbuch, Switzerland). This method allows a direct measurement of the free drug. 
Therefore, the filtrate was injected into the HPLC for determination of drug content.  
4.5.1.6 Ultracentrifugation 
The formulations were fractionated by ultracentrifugation using an ultracentrifuge type Centricon T-
1075 and a rotor TFT 7013 (Kontron Instruments, Mailand, Italy). Quick-Seal centrifuge tubes, 5/8X3 
(Beckman Instruments, Palo Alto, USA) were used. The formulations were centrifuged at 37°C for 2 
and 4 h at 450000 g. The clear water phase was carefully removed by a syringe and analyzed with 
HPLC for determination of drug concentration. This drug concentration represents the free drug 
concentration. 
4.5.1.7 Equilibrium Dialysis 
The formulations were dialyzed with horizontal diffusion cells consisting of glass with a chamber 
volume of 10 ml and a membrane surface of approximately 2 cm2. The chambers were separated by 
the following membranes: SpectraPor® 7 regenerated cellulose membranes with a molecular weight 
cut off of 50000 D, 2000 D (Spectrum Labs, DG Breda, Netherlands), and Membracell MD 34-14 
(Amersham, Uppsala, Sweden) with a molecular weight cut off of 34000 D. To maintain a temperature 
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of 37°C, a water bath was used. The solutions in the cells were stirred at 1000 rpm with Teflon-
paddles driven by a stirring device (Janke & Kunkel RE162, IKA Labortechnik, Staufen, Germany). 
The formulations were dialyzed for at least 34-48 h until equilibrium was reached. The samples were 
analyzed with HPLC. To avoid microbial contamination, resulting in a potential degradation of the drug 
or the formulation, 0.5% (m/V) sodium azide was added to the transport media and the formulations. 
The method does not allow measuring directly the unbound amount of drug, because the total volume 
of the water phase changes. The partition between the lipid particles and the water phase was 
calculated using Equation 49. 
tot
w
c
c
z =  
Equation 49 
 
Free fraction of drug is denoted by z, cw indicates equilibrium concentration of drug in water phase 
(acceptor concentration) [mg/ml], and ctot indicates total equilibrium concentration of drug (donor 
concentration) [mg/ml] 
4.5.1.8 Drug Quantification 
The drug concentration of progesterone and saquinavir was determined by HPLC-UV (Agilent series 
1100, Agilent Technologies USA, equipped with a G1312A binary pump, an auto sampler G1367B and 
a variable wavelength detector G1314B). A C-18 reversed phase column was used (CC 125/2 
Lichrospher 100 RP 18 ec, Macherey Nagel, Oensingen, Switzerland) with the following mobile phase 
for progesterone: distilled water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 
40/45/15 (V/V). Ammonium acetate with a concentration of 0.55 g/l was added to the mobile phase. 
The pH-value at 25°C was 6.9. For saquinavir the following mobile phase was used: distilled water 
(bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 35/50/15 (V/V). Ammonium acetate 
with a concentration of 0.55 g/l was added to the mobile phase. The pH-value at 25°C was 7.0. An 
isocratic method was used for quantification with a flow of 0.25 ml/min, an injection volume of 100 µl 
and a runtime of 8 min. Progesterone and saquinavir were detected at 239 nm in UV. Using this 
methods, retention of progesterone was approximately 5 min, retention of saquinavir was 
approximately 7 min. Quantification was performed against a set of external standard solutions within 
the linear response concentration range. Lipid containing samples were diluted 1:10 with transport 
media before injection. 
4.5.2 Results and Discussion 
4.5.2.1 Ultrafiltration 
After the centrifugation of liposomes, containing saquinavir (2.2 mg/ml), Lipoid S100 (50 mg/ml), and 
Lipoid EPG (0.22 mg/ml), the centrifugate was clear and no particles were detected with dynamic light 
scattering, whereas liposomes had a particle size of approximately 140 nm. As control, a solution 
containing saquinavir (10 µg/ml) was ultrafiltrated. The drug concentration of the clear filtrates and the 
control solution was determined by HPLC (Table 10).  
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Table 10 Saquinavir concentrations after ultrafiltration of liposomes (containing saquinavir 
[2.2 mg/ml], Lipoid S100 [50 mg/ml], and Lipoid EPG [0.22 mg/ml]) and a control solution 
(containing 10 µg/ml saquinavir). Supernatant is denoted by s, filtrate by f, and recovery by rec. 
 Saquinavir 
concentration 
[mg/ml] before 
ultrafiltration 
Saquinavir 
concentration 
[mg/ml] after ultra-
filtration with 
Microcon YM3, Cut 
off 3000 
Saquinavir 
concentration after 
ultrafiltration with 
Microcon YM3, Cut 
off 100000 [mg/ml] 
Saquinavir 
concentration after 
ultrafiltration with 
Ultrafree Membrane, 
Cut off 30000 
[mg/ml] 
  s f rec s f rec s f rec 
Liposomes 2.2 1.44 # 65% 1.44 # 65% 1.8 # 85% 
Solution 0.01 n.d. # - n.d. # - n.d. # - 
#: below detection limit, n.d. not determined 
 
None of the filtrates contained a measurable amount of saquinavir. While the cut off of the membranes 
was 50 to 500 times higher than the molecular weight, saquinavir was not able to pass the 
membranes. Due to the low recovery of the formulations, we assume that the lipophilic saquinavir 
adsorbed to the filter membranes or the filtration devices. For the determination of free drug 
concentration of highly lipophilic molecules, ultrafiltration is not suitable. 
4.5.2.2 Ultracentrifugation 
After 2 h of centrifugation of saquinavir liposomes, a gradient over the whole tube was visible but there 
was no clear phase separation. Centrifugation for 4 h resulted in two separated phases containing of a 
clear water phase on the top and a liposome pellet on the bottom of the centrifugation tube. No 
particles were detected with PCS in the clear water phase. The results of the saquinavir quantification 
of the clear water phase by HPLC are displayed in Table 11. 
 
Table 11 Saquinavir quantification in the clear water phase after ultracentrifugation of 
liposomes (containing saquinavir [concentrations listed in table], Lipoid S100 [50 mg/ml], and 
Lipoid EPG [0.22 mg/ml]) for 4 h at 450000 g. 
Total saquinavir concentration 
[mg/ml] 
Saquinavir concentration in the 
water phase [µg/ml] 
Number of measurements 
2.2 19.3 ± 13.1 5 
4.5 23.7 ± 20.7 7 
7.5 12.8 ± 8.8 5 
 
The results were in the expected order of magnitude but the expected correlation of the lowest to the 
highest saquinavir concentration was not found. Together with the poor reproducibility, expressed in 
the high standard deviation, it was concluded that the used ultracentrifugation method is not a suitable 
method to determine the amount of a highly lipophilic drug in the water phase. 
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4.5.2.3 Equilibrium Dialysis 
We evaluated three different membranes on the permeation of saquinavir dissolved in transport 
media. Saquinavir was taken for this evaluation because it achieves the highest molecular mass out of 
the model compounds, which was expected to be responsible for slowest permeation through dialysis 
membrane. Three different dialysis membranes were compared, all of them consisting of hydrophilic 
material (regenerated cellulose in the case of 34000 D and 50000 D and of cellulose ester in the case 
of 2000 D) to avoid adsorption of lipophilic drug molecules. Dialysis was performed during 30-50 h. 
Figure 30 shows the resulting concentration versus time profiles. It indicates that the 2000 D 
membrane is not applicable for the chosen conditions. For further experiments, the Spectra/por 
50000 D membrane was preferred because it showed a higher drug permeation resulting in shorter 
time for equilibration. 
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Figure 30 Dialysis of a saquinavir solution containing saquinavir (7.5 µg/ml) in transport media 
at 37°C. Comparison of three different dialysis membranes. Legend: donor compartment with 
the MembraCell membrane (○), acceptor compartment with the MembraCell membrane (•), 
donor compartment with the 50000 D membrane (□), acceptor compartment with the 50000 D 
membrane (■), donor compartment with the 2000 D membrane (x), acceptor compartment with 
the 2000 D membrane (+). 
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Figure 31 Concentration curve of the acceptor compartment of an equilibrium dialysis of 
liposomes, containing saquinavir (7.5 mg/ml), Lipoid S100 (50 mg/ml), and Lipoid EPG 
(0.22 mg/ml). A SpectraPor® 7 regenerated cellulose membrane with a cutoff of 50000 D was 
used. 
 
The method was tested with saquinavir liposomes, containing saquinavir (7.5 mg/ml), Lipoid S100 
(50 mg/ml), and Lipoid EPG (0.22 mg/ml) and proven with progesterone liposomes, containing 
progesterone (0.5 mg/ml), Lipoid S100 (50 mg/ml), and Lipoid EPG (0.05 mg/ml). After 48 h the 
saquinavir formulation was nearly in equilibrium. The resulting time concentration curve of the 
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Figure 32 Concentration curve of the acceptor compartment of an equilibrium dialysis of 
liposomes, containing progesterone (0.5 mg/ml), Lipoid S100 (50 mg/ml), and Lipoid EPG 
(0.05 mg/ml). A SpectraPor® 7 regenerated cellulose membrane with a cutoff of 50000 D was 
used. 
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acceptor compartment is shown in Figure 31. The resulting time concentration curve of the acceptor 
compartment of the progesterone formulation dialysis is displayed in Figure 32. Equilibrium conditions 
of the progesterone formulation dialysis were reached faster than of the saquinavir formulation. 
Because of the smaller molecular weight of progesterone, faster membrane permeation was expected. 
The equilibrium dialysis of lipophilic drugs in liposomes is a suitable method to characterize these drug 
delivery systems. 
Phospholipids are insoluble in aqueous media, no unbound phospholipids are available to pass the 
dialysis membrane. Compared to liposomes, in emulsions and microemulsions free surfactant 
molecules were expected in solution and therefore able to cross the dialysis membrane. 
Cremophor EL (Molecular weight 2515 D, from ref. (120)) is able to cross a 50000 D dialysis 
membrane, but not a dialysis membrane with a cut off of 2000 D. Therefore, we dialyzed a 
progesterone microemulsion containing progesterone (0.01 mg/ml) and 5 mg/ml lipidphase with a 
2000 D and a 50000 D membrane. Progesterone was chosen because of its small molecular weight 
and because saquinavir showed no reproducible data when a saquinavir solution was dialyzed with 
the 2000 D membrane (see Figure 30). 
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Figure 33 Comparison of two different dialysis membranes on the dialysis of progesterone 
microemulsion containing progesterone (0.01 mg/ml) and 5 mg/ml lipid phase (Captex 8000 
35.05% [m/m], Capmul MCM 17.58% [m/m] Cremophor EL 36.84% [m/m], and ethanol 10% [m/m]) at 
37°C. Legend: donor compartment with the 50000 D membrane (□), acceptor compartment with 
the 50000 D membrane (■), donor compartment with the 2000 D membrane (x), acceptor 
compartment with the 2000 D membrane (+). 
 
The overlay of the resulting concentration versus time profiles is displayed in Figure 33. Time needed 
for the system to equilibrate was different, 30 h with the 50000 D membrane and 50 h with the 2000 D 
membrane. The measured unbound drug concentration in equilibrium was the same, which indicates 
that there were no Cremophor EL molecules present in the acceptor or at least that the amount was 
too small to have a measurable effect on the solubility of the drug in the water phase. This suggestion 
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is supported by recently published findings of Mahler et al. where a polysorbate 20 containing protein 
formulation was dialyzed. It was concluded that polysorbate 20, that has similar properties as 
Cremophor EL, could not be significantly reduced by dialysis (142).  
Table 12 displays the calculated free fractions of progesterone and saquinavir formulations. The 
resulting free fractions were consistent with the theory, where one expects a lower free fraction for a 
higher amount of lipid phase and for a higher lipophilicity of a drug. Saquinavir, representing the more 
lipophilic drug, has the lower free fraction than progesterone. 
 
Table 12 Calculated free fractions of different drugs and formulations 
Formulation Drug Lipid phase [mg/ml] Free fraction (*104) 
Liposomes saquinavir 50 6.73 
 progesterone 50 47.9 
Microemulsion progesterone 5 696.4 
4.5.3 Conclusions 
Equilibrium dialysis was found to be a reliable method to determine the free fraction of a lipophilic drug 
in liposomes and microemulsions. It was shown that the surfactant Cremophor EL had no influence on 
the free fraction of progesterone in a microemulsion.  
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4.6 Calculation of the Free Fraction of Progesterone Liposome 
Formulations  
For the progesterone liposomes containing 0.1 mg/ml and 1 mg/ml lipids, no equilibrium dialysis to 
determine the free fraction was performed. Therefore, two different approaches for the calculation of 
free fraction of a drug between lipid phase and transport media were developed and compared to 
each other, which were a graphical approach to estimate directly the free fraction and a mathematical 
approach to calculate the free fraction out of a partition coefficient K. 
4.6.1 Derivation of an Equation for the Calculation of a Partition 
Coefficient of a Drug Between Lipid Phase and Water Phase out of 
Equilibrium Dialysis Experiments 
This chapter describes the derivation of an equation for the calculation of a partition coefficient of a 
drug between lipid phase and water phase out of equilibrium dialysis experiments that can applied for 
the calculation of free fractions of formulations if no equilibrium dialysis data are available for singular 
lipid phase concentrations. Figure 34 shows the equilibrium situation in dialysis cells. 
 
 
Figure 34 The equilibrium situation in dialysis cells. 
 
Definition of lipid/water partition coefficient (K) referring to the total molar mass (“mole Fraction”) is 
shown in Equation 50, where ndL are the moles of drug associated with lipid phase, ndw are the moles 
of unbound drug in water phase, nL moles of lipids in the system, and nw the moles of water in the 
system. 
dww
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Equation 50 
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Mass balance considerations: 
dwwwtot nnn +=,  
Equation 51 
 
The water phase, expressed as ntot, w is composed of the moles of water in the system and the moles 
of free drug in the water phase. The total amount of drug is the sum of drug in the lipid phase (ndL) and 
the free drug in the water phase and is equal to the total drug concentration in equilibrium (
∞,totc ) in 
the formulation, expressed as total mass (mtot) divided by density of the formulation (ρtot): 
tot
tot
tot
dwdL m
c
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ρ
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Equation 52 
 
wwddwLLddLtot MWnMWnMWnMWnm ⋅+⋅+⋅+⋅=  
Equation 53 
 
There is MWd the molecular weight of drug, MWL molecular weight of Lipid, MWw the molecular weight 
of water assumed to be 18 g/mol. Equation 53 was inserted into Equation 52: 
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Replacement of unknown parameters ndL and ndw in Equation 56 by Equation 50 solved after ndL  
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where cw,∞ delineates the concentration of unbound drug in water in equilibrium and ρw the density of 
water phase.  
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Insertion of Equation 58 in Equation 56: 
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Equation 59 
 
In Equation 59 all parameters except K were known. Parameters were inserted and the equation was 
solved after K.  
To calculate the free fraction z out of lipid/water partition coefficient K, the following mathematical 
coherence was used, where K’ indicates a lipid/water partition referring the drug concentration in the 
lipid particles (c’L) to the concentration of the drug in the water phase (cw): 
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It follows out of mass balance considerations: 
)('' wtotwwwLLwwtottot VVcKcVcVcVcV −+=+=  
Equation 61 
 
If Equation 61 is divided by Vtot*cw and is transformed, Equation 62 results. 
)1('1 VFzKzVF −+=  
Equation 62 
 
where VF denotes the volume fraction, which is the ratio of Vw to Vtot. When Equation 62 is solved 
after z, the following mathematical relation results:  
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Equation 63 
 
Equation 63 was used to calculate the free fraction if no experimental data was available. 
4.6.1.1 Results of the Calculated Partition Coefficients 
Lipid/water partitions referring to the total molar mass (K) of dialyzed progesterone liposomes were 
calculated using Equation 59. Table 13 gives an overview of the results. 
 
Table 13 Lipid/water partition coefficients referring to the total molar mass (K) of dialyzed 
progesterone liposomes. The density of transport media (1.0 g/ml) and lipid particles (1.0 g/ml) 
was inserted into Equation 59. For the molar amount of lipids, the molecular weight of the 
phospholipid phosphatidylcholine of 761 g/mol was used. 
lipid concentration 
[mg/ml] 
ctot (*106) 
[mol/ml] 
cw (*108) 
[mol/ml] 
nL (*105) 
[mol] 
nw 
[mol] K K' 
50 9.44 4.52 6.57 0.56 9.71*105  2.18*103 
50 3.42 1.29 6.57 0.56 2.49*106 5.59*103 
50 0.33 0.15 6.57 0.56 4.30*106 9.67*103 
25 1.53 1.14 3.29 0.56 2.23*106 5.16*103 
25 0.74 0.52 3.29 0.56 3.09*106 7.13*103 
25 0.12 0.10 3.29 0.56 3.38*106 7.80*103 
10 3.03 6.26 1.31 0.56 6.66*105 1.56*103 
10 0.79 1.49 1.31 0.56 1.64*106 3.84*103 
10 0.13 0.25 1.31 0.56 2.50*106 5.87*103 
5 1.98 4.56 0.66 0.56 9.43*105 2.22*103 
5 0.65 2.36 0.66 0.56 1.24*106 2.92*103 
5 0.33 1.16 0.66 0.56 1.72*106 4.04*103 
0.5 0.15 4.06 0.066 0.56 8.60*105 2.04*103 
0.5 0.09 2.89 0.066 0.56 9.73*105 2.30*103 
0.5 0.04 1.30 0.066 0.56 1.38*106 3.27*103 
Average K     1.89*106  
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The average K of 1.89*106, representing the lipid/water partition referring to the total molar mass of the 
used formulation, was used to calculate the free fraction of the progesterone liposomes, where no 
experimental data was available. Table 14 displays the results. The obtained free fractions of 
progesterone liposomes containing 0.1 and 1 mg/ml phospholipids were in the expected order of 
magnitude. 
 
Table 14 Calculated free fractions for the progesterone liposomes containing 0.1 mg/ml and 
1 mg/ml phospholipids. For the calculation of the lipid/water partition referring the drug 
concentration in the lipid particles to the concentration of the drug in the water phase K’, the 
displayed volume fraction VF was used and inserted into Equation 63 for the calculation of the 
free fraction. Molar mass of the lipids is denoted by nL, molar mass of the water phase is 
denoted by nw. 
Lipid concentration 
[mg/ml] 
nL 
[mol] 
nw 
[mol] K K' VF 
Calculated free 
fraction z 
1 1.31*10-6 0.555 1.89*106 4474.25 0.999 0.18 
0.1 1.31*10-7 0.555 1.89*106 4478.29 0.9999 0.69 
 
4.6.2 Graphical Approach to Assess the Free Fraction of Liposome 
Formulations  
If the lipid phase concentration is plotted against 1/z, a linear relationship results for all drugs and all 
formulations. Figure 35 displays the resulting plot of the progesterone liposomes. 
 
 
Figure 35 Plot of lipid concentration versus 1/z for progesterone liposomes. Linear regression 
analysis resulted in the following equation: y=4.7059x+1 (r2=0.9921).  
 
The equation resulting out of linear regression analysis of the plot, y=4.7059x+1 (r2=0.9921), was used 
to calculate the free fraction of progesterone liposomes containing 0.1 mg/ml (z= 0.18) and 1 mg/ml 
(z=0.68) lipid phase.  
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4.6.3 Conclusions 
The two methods to calculate the free fractions of lipid containing drug formulations were equal for the 
two free fractions where no equilibrium dialysis data was available. The mathematical approach is a 
general solution to calculate free fractions of lipid containing dosage forms, if lipid/water partition is 
known or can be calculated as shown in this section. For the calculation of the free fraction of 
progesterone liposomes in this work, the easier and less error-prone approach to assess the missing 
free fractions without experimental data was used. A free fraction of 0.18 for 1 mg/ml lipids and of 0.68 
for 0.1 mg/ml lipids was used for further calculations. 
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4.7 Measurements of Cellular Drug Uptake  
The filter of the Transwell insert is a possible additional diffusion barrier for both, the drug and the lipid 
particles. This additional barrier may hinder the drug permeation across the cell monolayer on the 
basolateral side of the Caco-2 cell monolayer. If this arrives, different apparent permeability 
coefficients from the apical to cellular compartment compared to basal to cellular compartment result. 
Additionally, if the lipid particles are not able to diffuse through the filter pores, drug permeation 
because of direct transfer from lipid particle to cell membrane will not take place on the basolateral 
membrane.  
Usually, drug uptake experiments were performed using a cell monolayer grown on a Petri dish after 
adding a drug containing solution into the Petri dish by determination of the disappearance of drug 
from this solution. Correlating this method with cell permeation experiments in Transwell plates may 
lead to inconclusive data, because of different hydrodynamics, different monolayer density, different 
cell differentiation, and a different surface area. Taking into consideration that the cell uptake of highly 
permeable compounds may be diffusion boundary layer controlled, it is of importance to use Transwell 
inserts for the evaluation of the uptake to ensure hydrodynamics. A procedure to estimate the 
permeation of a compound between basal and cellular compartment using Transwell plates was 
described by Ho et. al already for drug efflux (59). For the determination of the drug permeation from 
apical to basal compartment, sealed Transwell inserts instead of Petri dishes were used (see method 
section below). 
Using this method, an experimental evaluation of uptake of lipophilic drugs is difficult, because the 
intracellular concentration is calculated indirectly by the decrease of the donor concentration. 
Permeation of a lipophilic drug could be overestimated easily because of possible unspecific drug 
adsorption to the plastic made surface of the Transwell plates which could be wrongly interpreted as 
drug permeation into the cell. For this reason drug uptake was performed for progesterone only, 
because propranolol showed low interaction with the formulations and unspecific adsorption was 
observed for saquinavir and triclabendazole. Assuming that the particle size of the formulation affects 
drug permeation through the Transwell filter, the emulsion was taken as model formulation expecting 
the highest influence on drug permeation because of its particle size that was bigger than particle 
sizes of the other formulations.  
4.7.1 Material and Methods 
4.7.1.1 Material 
Transport media used for the permeation studies and the equilibrium dialysis experiments were 
prepared with Dulbecco’s Modified Eagle’s Medium (DMEM) base powder (without glucose, 
l-glutamine, phenol red, sodium pyruvate and sodium bicarbonate, purchased from SIGMA-Aldrich, 
Fluka Chemie GmbH, Buchs, Switzerland). DMEM base powder was dissolved in bi-distilled and 
autoclaved water and supplemented with glucose (4.5 g/l), HEPES (4.76 g/l), NaCl (1.987 g/l), and 
l-glutamine (0.876 g/l). The pH was adjusted to 7.4 and the final medium was filtered through a sterile 
filter (Supor-200, 0.2 µm pore size, Pall Corporation, Michigan, USA) under aseptic conditions. 
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Glucose, HEPES, NaCl, and l-glutamine were purchased from SIGMA-Aldrich (Fluka Chemie GmbH, 
Buchs, Switzerland). Dulbecco’s Phosphate Buffered Saline (D-PBS) (with Ca2+, Mg2+) was purchased 
from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). 6-well Polycarbonate Membrane 
Transwell Plates with an insert area of 4.7 cm2 and 0.4 µm pore size were ordered from Costar 
(Corning Incorporated, Corning, NY, USA). Captex 8000 was purchased from SIGMA-Aldrich (Fluka 
Chemie GmbH, Buchs, Switzerland), Capmul MCM was purchased from Abitec Corporation 
(Janesville, USA). Cremophor EL was ordered from Fluka (Fluka Chemie GmbH, Buchs, Switzerland). 
Progesterone was purchased from Fluka (SIGMA-Aldrich, Fluka Chemie GmbH, Buchs, Switzerland).  
4.7.1.2 Preparation of the Emulsions 
Emulsions containing 14.5 µM progesterone and 0.5 mg/ml or 5 mg/ml of the emulsion lipid phase 
(lipid phase consisting of 5%[m/m] Capmul MCM, 67%[m/m] Captex 8000, 18%[m/m] Cremophor EL, and 
10%[m/m] ethanol) were tested. The lipid phase was prepared by mixing the components at 37°C. The 
lipid phase was warmed up to 37°C before use and the according amount was balanced and mixed 
with two thirds of the final transport medium volume. The formulation was homogenized for 5 min at 
15000 rpm with a Polytron homogenizer (Polytron PT 3000, Kinematica AG, Littau, Switzerland) and 
preheated transport medium was added to the final volume. 
4.7.1.3 Measuring the Cellular Uptake to the Cellular Compartment 
Caco-2 cells cultured during 21 days were used. Both compartments of the wells were rinsed with 
tempered D-PBS (with magnesium and calcium). For determination of drug uptake from apical 
compartment to cellular compartment, the Transwell inserts were sealed on the basal side using 
aluminum foil, cut to the size of the filter insert. PTFE Thread seal tape was wrapped three times 
around the insert to seal it completely. Then 1600 µl of the drug formulation was added into the apical 
compartment.  
For the drug uptake from the basal to the cellular compartment, 200 µl transport media was added to 
the apical compartment to avoid desiccation of the cells and then 2800 µl of the drug formulation was 
added into the basal compartment. The plate was shaken on an orbital shaker (KS15, Edmund Bühler 
GmbH, Tübingen& Hechingen, Germany) with 75 rpm under water saturated atmosphere with 75 rpm 
at 37°C. Samples of 100 µl were taken after 0, 2.5, 5, 7.5, 10, 15, 20, and 30 min. Drug quantification 
was performed by HPLC. 
4.7.1.4 Drug Quantification 
Drug quantification of progesterone was performed by HPLC-UV (Agilent series 1100, Agilent 
Technologies USA, equipped with a G1312A binary pump, an auto sampler G1367B and a variable 
wavelength detector G1314B) using a C-18 reversed phase column (CC 125/2 Lichrospher 100 RP 18 
ec, Macherey Nagel, Oensingen, Switzerland). An Isocratic method with a flow rate of 0.25 ml/min was 
used with the following mobile phase: distilled water (bi-distilled and filtered through 
0.45 µm)/methanol/tetrahydrofuran 40/45/15 (V/V). Ammonium acetate with a concentration of 0.55 g/l 
was added to the mobile phase. The pH-value at 25°C was 6.9. An injection volume of 40 µl and a 
runtime of 7.5 min were used to detect progesterone at 239 nm in UV. Using this method, retention 
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time of progesterone was approximately 5 min. The samples were stored at 4°C. Quantification was 
performed against a set of external standard solutions within the linear response concentration range. 
4.7.1.5 Calculation of the Permeability Coefficients 
The time dependent change of mass in apical to basal direction of the cellular compartment (mcAB) is 
described for progesterone by the following equation 
mcABaABa
cAB ScKcP
dt
dm
C
a *)(* ⋅−=  
Equation 64 
 
where Pa denotes apparent permeability coefficient, caAB concentration in apical compartment, Ka/c 
formulation-to-cell partition coefficient, ccAB drug concentration in cellular compartment and Sm cell 
monolayer surface area. If sink conditions are assumed, ccAB is assumed to be 0 and the apparent 
permeability coefficients were calculated after Equation 2 (as described in the theoretical section) for 
the time interval 0 to 2.5 min. For that reason the intracellular concentrations were calculated 
assuming that the disappeared drug amount permeated into the cell. This amount was divided by the 
cell monolayer volume resulting in the intracellular concentration which was inserted into the equation. 
The volume of the cell monolayer as receiver volume was inserted as 0.0094 cm3. 
4.7.2 Results and Discussion 
It was possible to measure drug uptake from basal compartment to cellular compartment and from 
apical compartment to cellular compartment using Transwell plates for both directions. The sealing 
with aluminum foil and PTFE seal tape worked well, no leakage was observed. The results clearly 
indicate an influence of the lipid concentration on drug uptake by the cells. Initially, the drug uptake is 
higher from the 0.5 mg/ml lipid phase than from the 5 mg/ml lipid phase formulation, expressed in a 
higher apparent permeability for the time interval from 0 to 2.5 min as displayed in  
Table 15. The results of these uptake experiments show a decrease of drug uptake with increasing 
lipid concentration, which is the same tendency as observed in cell permeation experiments. 
 
Table 15: Quantitative results of progesterone uptake from an emulsion containing 0.5 mg/ml 
and 5 mg/ml lipid phase, respectively. The apparent permeability coefficients were calculated 
for the time interval from 0 to 2.5 min.  
Lipid phase 
concentration 
[mg/ml] 
Apical-cell uptake 
permeability 
coefficient [cm/s] 
Basal-cell uptake 
permeability 
coefficient [cm/s] 
Drug fraction 
remaining in 
donor after apical 
to cell uptake 
Drug fraction 
remaining in 
donor after basal 
to cell uptake 
0.5 3.45±0.23*10-4 5.31±0.18*10-4 0.72±0.014 0.76±0.015 
5 1.76±0.16*10-4 1.42±0.06*10-4 0.91±0.0079 0.91±0.0069 
 
Over time, a higher fraction of the 0.5 mg/ml formulation is taken up, which is consistent with the 
estimated formulation-to-cell partition coefficient of the transport experiments. Ka/C was smaller for the 
Marcel Schneider Page 116 of 172 University of Basel, 2008 
0.5 mg/ml formulation and indicates a higher drug concentration in the cell after the equilibrium was 
reached. The normalized uptake profiles are shown in Figure 36 and Figure 37. 
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Figure 36 Transport of progesterone from apical to cellular compartment is influenced by the 
lipid concentration. The y-axis describes the amount of drug divided by the initial amount. 
 
 
Influence of Emulsion Lipidphase on Progesterone Uptake from Basal to Cellular 
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Figure 37 Transport of progesterone from basal to cellular compartment is influenced by the 
lipid concentration. The y-axis describes the amount of drug divided by the initial amount. 
 
No difference between apical to cell and basal to cell uptake was observed. The result of the drug 
uptake experiments implicates that the drug uptake of the chosen formulation and drug is direction 
independent. This indicates a negligible influence of the filter insert on the permeation of progesterone 
out of emulsions. Taking into account that no systematic influence on cellular uptake was measured 
with the chosen experimental setting, no influence of the filter insert is expected on other formulations 
and drug uptake of the other model drugs. 
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4.7.3 Conclusions 
The drug uptake of progesterone out of emulsions is influenced by the lipid concentration. Increased 
lipid concentrations decrease the apparent permeability delineating drug uptake. The analogy of the 
effects of the lipid phase to the cell permeation experiments is obvious. The filter insert did not 
influence drug uptake with the chosen experimental setting. No influence of the filter insert is expected 
on other formulations and drug uptake of the other model drugs either. 
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4.8 Measurements of Passive Cellular Efflux 
Similar to cell uptake experiments, drug permeation from cell monolayer to the apical or basal 
compartment can be determined (59). Fundamental understanding of drug uptake and drug efflux by 
the cells may help to understand the transcellular drug permeation. Passive drug efflux may be 
influenced by lipophilicity of the drug, type and concentration of lipid particles, presence of carrier 
mediated efflux, and presence of a filter on basolateral side. If the process is diffusion boundary layer 
controlled, hydrodynamics may have a contribution to the permeation. Therefore all experiments were 
performed into Transwell plates. 
The aim of these experiments was the determination of the passive drug efflux from the cell monolayer 
to the basal compartment. Progesterone and triclabendazole were used as model drugs to estimate 
the influence of passive drug efflux from cellular to basal compartment. Using these drugs, drug 
permeation on the basolateral side is not interfered by carrier mediated apical efflux. The different 
lipophilicity of these two compounds may allow a conclusion on a possible influence of lipophilicity on 
drug permeation from cell monolayer to basal compartment. We compared microemulsions and 
emulsions of both drugs representing the formulations with the most different particle sizes. This may 
allow conclusion on a possible effect of the particle size on drug permeation from cell monolayer to 
basal compartment.  
4.8.1 Material and Methods 
4.8.1.1 Material 
Transport media used for the permeation studies and the equilibrium dialysis experiments were 
prepared with Dulbecco’s Modified Eagle’s Medium (DMEM) base powder (without glucose, 
l-glutamine, phenol red, sodium pyruvate and sodium bicarbonate, purchased from SIGMA-Aldrich, 
Fluka Chemie GmbH, Buchs, Switzerland). DMEM base powder was dissolved in bi-distilled and 
autoclaved water and supplemented with glucose (4.5 g/l), HEPES (4.76 g/l), NaCl (1.987 g/l), and 
l-glutamine (0.876 g/l). The pH was adjusted to 7.4 and the final medium was filtered through a sterile 
filter (Supor-200, 0.2 µm pore size, Pall Corporation, Michigan, USA) under aseptic conditions. 
Glucose, HEPES, NaCl, and l-glutamine were purchased from SIGMA-Aldrich (Fluka Chemie GmbH, 
Buchs, Switzerland). Dulbecco’s Phosphate Buffered Saline (D-PBS) (with Ca2+, Mg2+) was purchased 
from SIGMA-Aldrich (Fluka Chemie GmbH, Buchs, Switzerland). 6-well Polycarbonate Membrane 
Transwell Plates with an insert area of 4.7 cm2 and 0.4 µm pore size were ordered from Costar 
(Corning Incorporated, Corning, NY, USA). Captex 8000 was purchased from SIGMA-Aldrich (Fluka 
Chemie GmbH, Buchs, Switzerland), Capmul MCM was purchased from Abitec Corporation 
(Janesville, USA). Cremophor EL was ordered from Fluka (Fluka Chemie GmbH, Buchs, Switzerland). 
Triclabendazole was provided by Phares Drug Delivery (Muttenz, Switzerland). Progesterone was 
purchased from Fluka (SIGMA-Aldrich, Fluka Chemie GmbH, Buchs, Switzerland).  
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4.8.1.2 Preparation of the Formulations 
Emulsions containing 63 µM progesterone or 63 µM triclabendazole combined with 0.5 mg/ml or 
5 mg/ml of the emulsion lipid phase (lipid phase consisting of 5%[m/m] Capmul MCM, 67%[m/m] 
Captex 8000, 18%[m/m] Cremophor EL, and 10%[m/m] ethanol) and microemulsions containing 63 µM 
progesterone or 63 µM triclabendazole and 0.5 mg/ml or 5 mg/ml of the microemulsion lipid phase 
(lipid phase consisting of Captex 8000 35.05% [m/m], Capmul MCM 17.58% [m/m], Cremophor EL 
36.84% [m/m], and ethanol 10% [m/m]) were tested. The lipid phase was prepared by mixing the 
components at 37°C. The lipid phase was warmed to 37°C before use and the according amount was 
balanced and mixed with two thirds of the final transport medium volume. The formulation was 
homogenized for 5 min at 15000 rpm with a Polytron homogenizer (Polytron PT 3000, Kinematica AG, 
Littau, Switzerland) and preheated transport medium was added to the final volume. 
4.8.1.3 Determination of Passive Drug Efflux 
The Transwell plates, cultured for 19-21 days, were rinsed with D-PBS (with magnesium and calcium). 
The drug formulation was added to the apical compartment. Placebo formulation, containing the same 
lipid concentration, was added to the basal compartment and the plates were incubated at 37°C under 
water saturated atmosphere at a stirring rate of 75 rpm for 180 min on an orbital shaker (KS15, 
Edmund Bühler GmbH, Tübingen& Hechingen, Germany). Before the formulations were removed and 
the plates rinsed twice with transport media, samples were taken in apical and basal compartment. 
Fresh placebo formulation was added to the basal compartment and to avoid dryness, 200 µl transport 
media was added to the apical compartment. Samples of 100 µl were taken and quantified with HPLC 
at predefined points of time after 0, 15, 30, 45, 60, 90, and 120 min. 
4.8.1.4 Drug Quantification 
Drug quantification of all drugs was performed by HPLC-UV (Agilent series 1100, Agilent 
Technologies USA, equipped with a G1312A binary pump, an auto sampler G1367B and a variable 
wavelength detector G1314B) using a C-18 reversed phase column (CC 125/2 Lichrospher 100 RP 18 
ec, Macherey Nagel, Oensingen, Switzerland). Isocratic methods with a flow rate of 0.25 ml/min were 
used. The drug concentration of progesterone was determined with the following mobile phase: 
distilled water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 40/45/15 (V/V). 
Ammonium acetate with a concentration of 0.55 g/l was added to the mobile phase. The pH-value at 
25°C was 6.9. An injection volume of 40 µl and a runtime of 7.5 min were used to detect progesterone 
at 239 nm in UV. Using this method, retention time of progesterone was approximately 5 min. The 
samples were stored at 4°C. Quantification was performed against a set of external standard solutions 
within the linear response concentration range.  
The drug concentration of triclabendazole was determined with the following mobile phase: distilled 
water (bi-distilled and filtered through 0.45 µm)/methanol/tetrahydrofuran 35/40/25 (V/V). Ammonium 
acetate with a concentration of 0.55 g/l was added to the mobile phase. The pH- value at 25°C was 
6.7. An injection volume of 40 µl and a runtime of 8 min were used to detect triclabendazole at 305 nm 
in UV. Using this method retention time of triclabendazole was approximately 5.6 min. Quantification 
of triclabendazole was performed against a set of external standard solutions within the linear 
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response concentration range. To maintain the sample stability and reproducibility, the standard 
solutions of triclabendazole contained the same amount of lipids as the samples. Samples were stored 
at 4°C. 
4.8.1.5 Calculation of Permeability Coefficient Delineating Drug Efflux 
The time dependent change of concentration in apical to basal direction of the basal compartment 
(cbAB) is described for drugs, which were no subject to carrier mediated apical efflux, by the following 
equation 
b
m
bABcABb
bAB
V
S
ccKP
dt
dc
C
a *)(* −⋅=  
Equation 65 
 
where Pb denotes apparent permeability coefficient, cbAB concentration in basal compartment, Ka/c 
formulation-to-cell partition coefficient, ccAB drug concentration in cellular compartment and Sm cell 
monolayer surface area and Vb volume of basal compartment. If sink conditions are assumed cbAB is 0. 
Consequently, apparent permeability coefficient delineating passive drug efflux from cellular to basal 
compartment was calculated after Equation 66 for the time interval 0 to 15 min. 
0cABm
bbAB
b
cKS
V
dt
dcP
C
a ⋅⋅
⋅=  
Equation 66 
 
For that reason the initial intracellular concentration (ccAB0) was calculated out of pre-experimental 
mass balance, assuming that the disappeared drug amount had permeated into the cell. The 
disappeared amount was calculated by comparing the initial drug amount of the formulation with the 
sum of drug amounts of basal and apical compartment after 180 min of incubation. This amount was 
divided by the cell monolayer volume resulting in the initial intracellular concentration which was used 
for the calculation. The cell monolayer volume was assumed to be 0.0094 cm3. 
4.8.2 Results and Discussion 
It was possible to measure passive drug efflux from cell compartment to basal compartment for both 
drugs with the described method. The results displayed in Table 16 indicate decreasing apparent 
permeability coefficient with increased lipid concentration for both drugs. The obtained apparent 
permeability coefficients of the passive efflux experiments were one order of magnitude lower than the 
apparent permeability coefficients deduced by data fitting of cell permeation experiments. 
Because of the initially small amount of drug inside of the cell monolayer and the high permeability 
coefficient of progesterone, an initial time interval of 15 min was obviously too long to maintain sink 
conditions which is a limitation of the used equation. This may explain the lower apparent permeability 
coefficients compared to apparent permeability coefficients deduced from cell permeation 
experiments.  
The passive efflux of triclabendazole from the cellular to the basal compartment delineated by the 
apparent permeability coefficient was lower than the passive efflux of progesterone. The permeation of 
Marcel Schneider Page 121 of 172 University of Basel, 2008 
triclabendazole from cell monolayer to the emulsions and to the microemulsion containing 0.5 mg/ml 
lipid was not finished after 120 min (see Figure 38). 
Qualitatively, these results correspond to the deduced apparent permeability coefficients of the cell 
permeation experiments, where a decrease of the permeability coefficients was observed if the lipid 
concentration was increased.  
 
Table 16 Quantification of passive drug efflux from cellular to basal compartment. All 
formulations used for incubation contained a drug concentration of 63 µM. The apparent 
permeability coefficient delineating passive drug efflux from cellular to basal compartment was 
calculated for the time interval 0-15 min.  
Formulation Lipid phase 
concentration 
[mg/ml] 
Apparent permeability 
coefficient cell-basal 
efflux [cm/s] 
Drug fraction effluxed 
to acceptor after cell to 
basal efflux after 
120 min 
Progesterone emulsion 0.5 9.25±0.7*10-6 0.25 
 5 7.62±1.0*10-7 0.32 
Progesterone microemulsion 0.5 2.57±0.66*10-5 0.47 
 5 4.71±0.83*10-6 0.49 
Triclabendazole emulsion 0.5 6.19±0.37*10-6 0.20 
 5 9.83±0.33*10-7 0.21 
Triclabendazole 
microemulsion 
0.5 3.11±0.22*10-6 0.52 
 5 2.13±0.09*10-6 0.67 
 
 
 
 
Figure 38 Transport of triclabendazole from the cellular to the basal compartment (containing 
a microemulsion with 0.5 mg/ml (▲) and 5 mg/ml (○) lipid phase) is influenced by the lipid 
concentration.  
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4.8.3 Conclusions 
Apparent permeability coefficients delineating passive drug efflux from cell monolayer to basal 
compartment show that the lipid concentration of a lipid containing formulation influences drug 
permeation from cellular compartment to the acceptor. The observed decrease of apparent 
permeability coefficients corresponds to observations made by cell permeation experiments. The 
obtained permeabilities were much lower than the apparent trans-monolayer permeabilities caused by 
violation of sink conditions. Therefore no quantitatively relevant statement can be made.  
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5 CONCLUSIONS AND OUTLOOK 
5.1 Conclusions 
It was shown in this work, that it is possible to test the effect of lipid containing drug formulations on 
drug permeation using the Caco-2 model, if the formulations are tolerated by the cell monolayer. 
Therefore, much attention had to be paid on the maintenance of the cell monolayer integrity during the 
cell permeation experiments which resulted in determination of the maximal applicable lipid phase 
concentrations and additionally a limitation of duration of cell permeation experiment.  
A methodology to determine unbiased parameters describing the in vitro absorption of lipid containing 
formulations of poorly water soluble drugs was developed and evaluated in this work. This 
methodology comprises the description of transcellular drug permeation through Caco-2 cell 
monolayers and the analysis of the obtained data with a biophysical model for a mechanistic 
understanding of the influence of lipid containing drug formulations on drug absorption.  
For the determination of drug absorption parameters in Caco-2 cell monolayer, a refined mathematical 
model based on previous work of our group was used. In earlier work, this model was derived for a 
mechanistic description of transcellular drug permeation including passive permeation and carrier 
mediated efflux. This model showed difficulties in prediction of intracellular drug concentration during 
cell permeation experiment of highly lipophilic compounds. To improve prediction of intracellular drug 
concentrations during cell permeation experiments, experimental cell monolayer extractions were 
taken into account for data fitting. A formulation-to-cell partition coefficient and independent 
permeability coefficients for the apical and the basal cell membrane were introduced into the model. 
This refined mathematical model, which is proposed in this study for the determination of drug 
absorption parameters in Caco-2 cell monolayers, is still able to detect carrier mediated transport. It 
further divides trans-monolayer permeability into independent permeability coefficients of the apical 
membrane and the basal membrane and allows deducing formulation-to-cell partition coefficient, 
intracellular time dependent concentration, and quantification of carrier mediated efflux directly out of 
time dependent experimental concentration data. If a compound undergoes carrier mediated efflux, 
the differentiation of Pa and Pb is limited because of mathematical correlation of these parameters.  
The analysis of the transcellular permeation experiments with this model indicates a decrease of 
apparent permeability coefficient with increasing lipid concentration, if an interaction of a drug with a 
lipid containing formulation is given. For a better understanding of this formulation effect, a reliable 
method for the determination of the free fraction of drug was developed, based on equilibrium dialysis 
that allows precise measurement of the free fraction. It was shown in this thesis, that this method is 
applicable to the used lipid containing drug formulations. 
A biophysical model for delineating contribution of different transport steps to the apparent 
permeability coefficient was developed taking into account transport of lipid particles and free 
molecules through diffusion boundary layer, permeation of free drug molecules through the cell 
membrane, and the drug permeation caused by direct drug transfer from lipid particles to the cell 
membrane. It was shown that the permeability coefficient that delineates the contribution of drug 
transport in the diffusion boundary layer is in the same order of magnitude for all tested drugs and 
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formulations and is the rate limiting step for an aqueous solution of the lipophilic model drugs. The 
permeability coefficient of the free drug through the cell membrane was independent of the formulation 
and dependent on the drug. This evaluation of the apparent permeability coefficient has confirmed that 
the free fraction of a drug is the major determinant of intestinal cell permeation. High free fraction 
indicates apparent permeability coefficients similar to aqueous solution; low free fraction indicates 
lower apparent permeability coefficients. Additionally, the direct transfer of lipophilic drugs from lipid 
phase of the formulation to cell membrane can also make an essential contribution to drug 
permeation. The relative significance of these two processes depends on the drug and the 
formulation. In this work drug transfer from the lipid particles to the membrane upon collision was 
relevant for progesterone only. These observations apply to structurally different lipid containing drug 
formulations.  
It was shown that permeability coefficient that delineates drug uptake of progesterone formulations 
and permeability coefficient that delineates passive drug efflux of progesterone and triclabendazole 
formulations are influenced by the lipid concentration similar as observed in cell permeation 
experiments. It was shown further that drug uptake of progesterone was independent of transport 
direction. Based on these results we assume that the microporous Transwell filter support was not rate 
limiting.  
Summarized, the effects of lipid containing drug formulations on the absorption of lipophilic drugs are: 
 
1) The use of lipid containing drug formulations lowers apparent permeability coefficient by 
lowering the drug uptake from donor compartment to cellular compartment. The extent is 
dependent on free fraction. Increased lipid phase concentration increases formulation-to-cell 
partition coefficient.  
2) The qualitative effect on apparent permeability coefficient is independent of the formulation if 
the used drug interacts with the formulation. 
3) Depending on formulation and drug, direct mass transfer from lipid particle to cellular 
membrane may contribute to transcellular permeation. 
 
Apparent drug permeability coefficient depends on free fraction, whereas drug flux depends on 
absolute amount of free drug in water phase. Therefore simultaneous increase of drug and lipid 
concentration provides an undiminished drug flux, which may improve bioavailability by prolonged 
intestinal absorption at a sustained rate. These findings are independent of the composition and the 
structure of the lipid formulation. In addition flux can be further increased by direct drug transfer from 
lipid particle to cellular membrane. This was observed for only one drug in the present work. Possible 
necessary structure activity relationship of drugs for this to take place should be investigated in the 
future. The results of this work shed light into the mechanism of drug absorption from lipid formulations 
and demonstrate potential beneficial effects of these formulations on absorption of lipophilic drugs in 
vivo. They may be used for the development of efficient oral dosage forms to improve bioavailability 
for these drugs. 
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5.2 Outlook 
The proposed mathematical model for the determination of drug absorption parameters in Caco-2 cell 
monolayer is a useful tool for a better understanding of the mechanisms taking place during cell 
monolayer permeation. To increase the knowledge about rate determining processes and partial steps 
of the absorption process it may be of great interest to implement measurements of partial processes 
into the model such as cellular uptake and cellular efflux from apical and basal side systematically, 
since few uptake and passive efflux data have been used in this work. 
 
The proposed biophysical model for the subdivision of the apparent permeability coefficient showed 
that besides of the free fraction, a mass transfer caused by direct drug transport from lipid particles to 
the cell membrane may take place. The data of this work are based on few model drugs and three 
structurally different lipid containing drug formulations. To proof the proposed concept, one should 
take into consideration additional drugs and formulations. Since we did not observe for all tested drugs 
a mass transfer caused by direct drug transport from lipid particles to the cell membrane, it would be 
essential to have a more profoundly understanding about possible systematical relationship between 
drug molecular structure or physicochemical properties responsible for the ability of drugs to undergo 
mass transfer caused by direct drug transfer. Ideally, the outcome may be used predictively for the 
improvement of oral drug absorption of poorly water soluble compounds.  
 
It is considered to be difficult to proof the observed mass transfer caused by direct drug transport from 
lipid particles to the cell membrane by additional measurements and alternative methods. It is 
considered to be easier to exclude the effects of direct mass transfer by comparing the results of this 
thesis with a different experimental setting that does not allow any interaction of lipid vesicles with the 
cellular membrane. This could be done by the introduction of an additional physical barrier, which is on 
one hand not rate determining for the used drugs but does not allow permeation of any lipid particles 
on the other hand. The use of particles with much larger particle sizes may help to separate the 
particles from the cell surfaces without affecting drug permeation, if these large particles show similar 
effects on drug permeation with the experimental setup used in this thesis. For the investigation of this 
particular case, liposomes may be a useful model, because it is possible to produce large and 
homogenous particles. 
 
Another open question is the relevance of the described mechanism in vivo, because the situation in 
the small intestine is different from the experimental setting used in this study. Most important 
difference and possibly affecting mass transfer from lipid particle to cellular membrane is the presence 
of a mucus layer in the intestine, which is described as an additional barrier for drug transport. The 
mucus layer may allow particles to diffuse, but will surely influence the velocity of diffusion of these 
particles because of an increased viscosity compared to buffer media. The investigation of permeation 
of lipid particles through mucus, use of an artificial mucus layer on the Caco-2 cells, use of a cell 
model producing a mucus layer, or use of animal intestinal tissue may be valuable tools for the 
investigation of this interesting question. 
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Oral administered drug formulations undergo dilution, degradation, and lipid digestion in vivo. The 
products of this mechanisms and the presence of bile salts results in physically different formulations, 
such as mixed micelles. Since methods for in vitro lipid digestion have been developed in recent years 
it may be interesting to study the influence of digested products on drug absorption with a suitable 
model. Because of the known sensitivity of the Caco-2 cell monolayers to surfactants, bile salts, 
mono-, and di-glycerides one would have to proof the model suitability for this kind of investigation or 
maybe to use a different model, e.g. excised tissue. 
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6 APPENDIX  
6.1 Determined TEER Values 
6.1.1 Screening Experiments 
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Figure 39 TEER values of Caco-2 cell monolayer used in drug screening experiments. The 
columns display the absolute values measured before the experiments and the connected 
points the TEER values after the experiment in % of the initial values. At least 3 wells were 
used per group. Meaning of the x-axis labels: ab apical to basal transport, ba basal to apical 
transport; numbers in the middle row: used drug concentration [µM]. 
 
 
6.1.2 Microemulsions 
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Figure 40 TEER values of Caco-2 cell monolayer used in the experiments with saquinavir 
microemulsions. The columns display the absolute values measured before the experiments 
and the connected points the TEER values after the experiment in % of the initial values. At 
least 3 wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba 
basal to apical transport; numbers in the middle row: used drug concentration [µM]; numbers 
in the bottom row: used lipid concentrations [mg/ml]. 
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Figure 41 TEER values of Caco-2 cell monolayer used in the experiments with progesterone 
microemulsions. The columns display the absolute values measured before the experiments 
and the connected points the TEER values after the experiment in % of the initial values. At 
least 3 wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba 
basal to apical transport; numbers in the middle row: used drug concentration [µM]; numbers 
in the bottom row: used lipid concentrations [mg/ml]. 
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Figure 42 TEER values of Caco-2 cell monolayer used in the experiments with triclabendazole 
microemulsions. The columns display the absolute values measured before the experiments 
and the connected points the TEER values after the experiment in % of the initial values. At 
least 3 wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba 
basal to apical transport; numbers in the middle row: used drug concentration [µM]; numbers 
in the bottom row: used lipid concentrations [mg/ml]. 
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Figure 43 TEER values of Caco-2 cell monolayer used in the experiments with propranolol 
microemulsions. The columns display the absolute values measured before the experiments 
and the connected points the TEER values after the experiment in % of the initial values. At 
least 3 wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba 
basal to apical transport; numbers in the middle row: used drug concentration [µM]; numbers 
in the bottom row: used lipid concentrations [mg/ml]. 
 
 
6.1.3 Emulsions 
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Figure 44 TEER values of Caco-2 cell monolayer used in the experiments with saquinavir 
emulsions. The columns display the absolute values measured before the experiments and the 
connected points the TEER values after the experiment in % of the initial values. At least 3 
wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba basal 
to apical transport; numbers in the middle row: used drug concentration [µM]; numbers in the 
bottom row: used lipid concentrations [mg/ml]. 
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Figure 45 TEER values of Caco-2 cell monolayer used in the experiments with progesterone 
emulsions. The columns display the absolute values measured before the experiments and the 
connected points the TEER values after the experiment in % of the initial values. At least 3 
wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba basal 
to apical transport; numbers in the middle row: used drug concentration [µM]; numbers in the 
bottom row: used lipid concentrations [mg/ml]. 
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Figure 46 TEER values of Caco-2 cell monolayer used in the experiments with triclabendazole 
emulsions. The columns display the absolute values measured before the experiments and the 
connected points the TEER values after the experiment in % of the initial values. At least 3 
wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba basal 
to apical transport; numbers in the middle row: used drug concentration [µM]; numbers in the 
bottom row: used lipid concentrations [mg/ml]. 
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Figure 47 TEER values of Caco-2 cell monolayer used in the experiments with propranolol 
emulsions. The columns display the absolute values measured before the experiments and the 
connected points the TEER values after the experiment in % of the initial values. At least 3 
wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba basal 
to apical transport; numbers in the middle row: used drug concentration [µM]; numbers in the 
bottom row: used lipid concentrations [mg/ml]. 
 
 
6.1.4 Liposomes 
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Figure 48 TEER values of Caco-2 cell monolayer used in the experiments with progesterone 
liposomes (lipid concentrations from 0-5 mg/ml). The columns display the absolute values 
measured before the experiments and the connected points the TEER values after the 
experiment in % of the initial values. At least 3 wells were used per group. Meaning of the x-
axis labels: ab apical to basal transport, ba basal to apical transport; numbers in the middle 
row: used drug concentration [µM]; numbers in the bottom row: used lipid concentrations 
[mg/ml]. 
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Figure 49 TEER values of Caco-2 cell monolayer used in the experiments with progesterone 
liposomes (lipid concentrations from 10-50 mg/ml). The columns display the absolute values 
measured before the experiments and the connected points the TEER values after the 
experiment in % of the initial values. At least 3 wells were used per group. Meaning of the x-
axis labels: ab apical to basal transport, ba basal to apical transport; numbers in the middle 
row: used drug concentration [µM]; numbers in the bottom row: used lipid concentrations 
[mg/ml]. 
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Figure 50 TEER values of Caco-2 cell monolayer used in the experiments with propranolol 
liposomes. The columns display the absolute values measured before the experiments and the 
connected points the TEER values after the experiment in % of the initial values. At least 3 
wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba basal 
to apical transport; numbers in the middle row: used drug concentration [µM]; numbers in the 
bottom row: used lipid concentrations [mg/ml]. 
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Figure 51 TEER values of Caco-2 cell monolayer used in the experiments with triclabendazole 
liposomes. The columns display the absolute values measured before the experiments and the 
connected points the TEER values after the experiment in % of the initial values. At least 3 
wells were used per group. Meaning of the x-axis labels: ab apical to basal transport, ba basal 
to apical transport; numbers in the middle row: used drug concentration [µM]; numbers in the 
bottom row: used lipid concentrations [mg/ml]. 
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6.2 Drug Extraction from Caco-2 Cell Monolayer at the Endpoint of 
the Transport Experiments 
Table 17 to Table 20 show the obtained intracellular concentrations obtained of cell monolayer 
extraction at the endpoint of the transport studies. Formulation-to-cell partition coefficients were 
calculated out of the different concentrations in the compartments at the endpoint of the experiments. 
These are in apical to basal direction the apical to cell and the basal to cell partition coefficient, in 
basal to apical direction the basal to cell and the apical to cell partition coefficient, respectively. The 
average of these four partition coefficients are shown in the tables as Ka/C and were very similar to the 
Ka/C obtained by data fitting. 
 
Table 17 Cell extractions and calculated Ka/C values of liposome permeation experiments of 
progesterone (PG) formulations. 
Drug Lipid 
content 
[mg/ml] 
Drug 
Conc. 
[µM] 
Cellular 
Drug Conc 
a_b [µM] 
Cellular 
Drug Conc 
b_a [µM] 
Ca end a-b 
[µM] 
Cb end ab 
[µM] 
Ca end b-a 
[µM] 
Cb end b-a 
[µM] 
Average 
Ka/C 
PG 0 4.45 0.00 28.40 0.73 0.77 1.53 1.56 0.0545 
 0 14.63 34.89 40.14 2.93 5.94 3.07 6.09 0.1206 
 0 31.80 154.63 171.13 7.17 7.30 13.08 13.73 0.0626 
 0 63.60 659.14 1202.80 16.19 16.30 31.56 31.53 0.0254 
 0.1 31.80 120.48 210.75 8.25 7.62 14.84 14.89 0.0682 
 0.1 63.60 655.13 1401.48 18.51 19.00 36.00 34.46 0.0269 
 0.1 159.00 1265.95 1595.05 43.07 44.69 71.01 69.51 0.0394 
 0.5 31.80 137.29 220.20 9.74 5.24 13.85 17.07 0.0624 
 0.5 63.60 230.18 368.87 17.04 15.74 26.69 29.41 0.0736 
 0.5 159.00 538.60 800.13 47.36 42.50 73.22 85.49 0.0913 
 1 31.80 95.92 140.50 10.02 10.46 17.05 17.80 0.1154 
 1 63.60 120.34 267.28 19.09 21.14 36.47 34.24 0.1497 
 1 159.00 695.45 1049.61 51.52 46.67 80.61 83.16 0.0743 
 5 159.00 465.23 775.51 61.64 46.78 86.23 102.01 0.1189 
 5 318.00 766.21 1130.61 135.32 113.63 196.75 217.46 0.1728 
 5 794.99 1234.39 2077.54 311.00 223.86 428.03 511.03 0.2213 
 10 63.60 20.22 11.38 28.98 19.26 28.67 43.95 2.1919 
 10 159.00 61.49 87.79 65.10 41.32 77.25 104.04 0.9489 
 10 318.00 158.53 223.20 148.86 90.46 144.80 205.20 0.7694 
 10 794.99 548.91 704.78 372.37 242.50 437.40 583.10 0.6420 
 10 1589.98 666.88 899.45 734.56 412.87 801.05 1133.16 0.9678 
 25 63.60 1.61 4.63 38.16 14.63 23.22 48.90 12.1086 
 25 159.00 86.48 82.82 93.64 35.25 62.63 115.00 0.9088 
 25 318.00 35.22 38.87 192.49 62.34 108.33 242.79 4.0674 
 25 794.99 185.05 178.08 507.55 152.88 276.51 632.48 2.1684 
 25 1589.98 304.93 333.71 1033.54 271.25 528.66 1292.86 2.4343 
 25 3307.15 1241.57 1106.94 2044.42 608.99 1042.78 2538.78 1.3432 
 50 63.60 62.65 60.29 47.30 12.28 17.22 61.62 0.5647 
 50 159.00 23.55 19.89 110.45 24.32 42.83 129.46 3.5962 
 50 318.00 46.72 32.68 215.48 37.30 66.91 252.34 3.7949 
 50 794.99 63.97 114.37 596.49 102.28 183.26 679.98 4.6177 
 50 1589.98 495.75 363.80 1101.94 240.24 359.43 1262.80 1.7916 
 50 3307.15 1506.21 910.71 3427.77 512.65 931.84 3953.98 1.9952 
 50 6709.70 1954.92 1505.31 3603.25 736.25 1319.70 5410.18 1.6726 
 50 11193.44 8069.20 2107.93 9923.23 1315.14 2179.33 8534.93 1.6189 
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Table 18 Cell extractions and calculated Ka/C values of liposome permeation experiments of 
triclabendazole (TBZ) and propranolol (PPL) formulations. 
Drug Lipid 
content 
[mg/ml] 
Drug 
Conc. 
[µM] 
Cellular 
Drug Conc 
a_b [µM] 
Cellular 
Drug Conc 
b_a [µM] 
Ca end a-b 
[µM] 
Cb end ab 
[µM] 
Ca end b-a 
[µM] 
Cb end b-a 
[µM] 
Average 
Ka/C 
PPL 0 60.71 252.33 376.64 19.44 15.83 36.22 29.48 0.0786 
 0 30.63 n.d. n.d. 10.13 7.90 18.82 14.60 n.d. 
 0 13.75 n.d. 88.30 5.04 3.13 8.26 6.10 0.0813 
 0 4.10 n.d. n.d. 1.56 1.29 2.59 1.93 n.d. 
 0.1 31.8 141.94 246.37 10.16 10.29 15.15 15.37 0.0670 
 0.1 63.6 294.14 472.63 17.56 14.64 30.65 25.55 0.0571 
 0.1 159 299.52 394.31 46.24 47.23 81.71 87.93 0.1856 
 1 31.8 53.37 85.52 7.16 6.88 15.06 13.88 0.1504 
 1 63.6 283.91 402.54 16.52 14.06 25.84 26.22 0.0593 
 1 159 382.88 528.89 43.94 42.01 73.95 75.33 0.1267 
 10 63.6 63.35 77.70 17.81 14.78 25.76 28.83 0.3043 
 10 159 99.29 146.16 38.76 31.23 62.22 60.55 0.3862 
 10 794 741.33 1388.24 271.28 214.28 399.55 452.47 0.3172 
TBZ 0.1 14.5 311.67 303.71 2.59 1.36 2.34 4.19 0.0085 
 0.1 31.8 421.76 384.65 8.25 3.48 6.62 12.21 0.0192 
 0.1 63.6 1042.52 978.04 23.60 12.47 17.61 36.11 0.0224 
 0.5 31.8 279.46 132.46 22.78 3.99 7.90 28.72 0.0931 
 0.5 63.6 522.38 246.24 29.53 4.89 9.91 34.97 0.0620 
 0.5 159 960.73 494.59 80.36 13.39 27.84 98.51 0.0883 
 1 31.8 114.23 48.75 23.60 3.04 5.75 27.79 0.2303 
 1 63.6 217.46 120.93 41.01 4.22 9.46 40.63 0.1555 
 1 159 309.45 255.17 104.03 12.18 22.50 111.84 0.2255 
 10 63.6 34.94 8.27 49.83 1.66 2.89 50.58 1.9857 
 10 159 74.18 43.20 143.92 5.93 11.24 140.37 1.3824 
 10 794 669.20 212.06 642.85 24.02 51.60 572.38 0.9847 
n.d.: not determined 
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Table 19 Cell extractions and calculated Ka/C values of all microemulsion permeation 
experiments. Abbreviations: Progesterone (PG), triclabendazole (TBZ), propranolol (PPL), 
saquinavir (SQV) 
Drug Lipid 
Content 
[mg/ml] 
Drug 
Conc. [uM] 
Cellular 
Drug Conc 
a_b [µM] 
Cellular 
Drug Conc 
b_a [µM] 
Ca end a-b 
[µM] 
Cb end ab 
[µM] 
Ca end b-a 
[µM] 
Cb end b-a 
[µM] 
Average 
Ka/C 
PG 0 4.45 0.00 28.40 0.73 0.77 1.53 1.56 0.0545 
 0 14.63 34.89 40.14 2.93 5.94 3.07 6.09 0.1206 
 0 31.80 154.63 171.13 7.17 7.30 13.08 13.73 0.0626 
 0 63.60 659.14 1202.80 16.19 16.30 31.56 31.53 0.0254 
 0.5 14.5 26.27 58.46 1.81 1.68 5.05 3.83 0.0712 
 0.5 31.8 782.33 938.45 9.11 9.32 14.91 13.84 0.0135 
 0.5 63.6 139.94 163.04 10.06 11.44 16.96 16.43 0.0896 
 1 14.5 57.01 77.42 3.27 2.82 6.18 6.81 0.0686 
 1 31.8 267.29 821.54 8.58 9.58 15.97 18.26 0.0274 
 1 63.6 61.68 136.74 10.64 12.69 19.66 13.94 0.1560 
 5 14.5 16.94 24.21 6.50 2.91 5.26 9.02 0.2864 
 5 31.8 n.d. n.d. 20.89 12.54 20.25 29.16 n.d. 
 5 63.6 79.71 144.59 30.37 14.36 26.07 42.70 0.2592 
PPL 0 60.71 252.33 376.64 19.44 15.83 36.22 29.48 0.0786 
 0 30.63 n.d. n.d. 10.13 7.90 18.82 14.60 n.d. 
 0 13.75 n.d. 88.30 5.04 3.13 8.26 6.10 0.0813 
 0 4.10 n.d. n.d. 1.56 1.29 2.59 1.93 n.d. 
 0.5 14.5 81.47 120.70 5.63 5.08 8.19 6.76 0.0639 
 0.5 31.8 n.d. n.d. 14.11 12.16 27.82 24.14 n.d. 
 0.5 63.6 359.70 607.11 22.92 20.53 39.36 35.03 0.0608 
 1 14.5 90.63 147.65 5.74 4.96 9.87 8.15 0.0600 
 1 31.8 n.d. n.d. 23.65 15.28 44.50 35.28 n.d. 
 1 63.6 393.03 455.59 23.25 21.38 40.46 36.17 0.0704 
 5 14.5 68.62 82.17 7.01 6.16 11.47 9.64 0.1122 
 5 31.8 n.d. n.d. 10.34 9.17 19.12 15.18 n.d. 
 5 63.6 149.51 280.15 27.13 22.62 46.51 38.67 0.1592 
TBZ 0.5 14.5 102.97 77.80 8.02 1.90 4.26 9.92 0.0697 
 0.5 31.8 n.d. n.d. 16.24 4.76 9.87 32.86 n.d. 
 0.5 63.6 476.17 316.87 30.55 6.90 14.93 33.31 0.0577 
 1 14.5 5.88 4.93 9.05 2.43 4.65 11.99 1.3319 
 1 31.8 n.d. n.d. 28.56 8.58 15.96 43.90 n.d. 
 1 63.6 26.67 19.39 38.91 9.39 18.68 48.54 1.3196 
 5 14.5 33.79 20.05 18.57 1.48 2.84 19.26 0.4239 
 5 31.8 34.87 22.41 31.49 2.30 4.36 31.80 0.6457 
 5 63.6 125.91 68.68 57.86 4.50 8.58 65.12 0.3921 
SQV 0 14 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0 5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0 4.5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0 10.4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0.5 3 1.00 1.62 1.08 0.02 1.24 0.41 0.5314 
 0.5 7 1.70 2.53 2.58 0.08 2.76 1.07 0.7701 
 0.5 14.5 n.d. n.d. 18.62 0.09 23.12 5.50 n.d. 
 1 3 1.98 1.31 2.19 0.02 1.88 1.13 0.8525 
 1 7 1.74 1.46 5.68 0.08 5.29 3.18 2.2763 
 1 14.5 n.d. n.d. 22.12 0.10 16.47 11.32 n.d. 
 5 3 2.08 1.71 3.23 0.18 1.02 2.87 0.9800 
 5 7 1.63 1.41 5.66 0.18 1.56 5.08 2.0707 
 5 14.5 n.d. n.d. 19.40 0.65 5.53 18.04 n.d. 
n.d.: not determined 
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Table 20 Cell extractions and calculated Ka/C values of all emulsion permeation experiments. 
Abbreviations: Progesterone (PG), triclabendazole (TBZ), propranolol (PPL), saquinavir (SQV) 
Drug 
Lipid 
content 
[mg/ml] 
Drug conc. 
[uM] 
Cellular 
drug conc 
a_b [µM] 
Cellular 
drug conc 
b_a [µM] 
Ca end a-b 
[µM] 
Cb end ab 
[µM] 
Ca end b-a 
[µM] 
Cb end b-a 
[µM] 
Average 
Ka/C 
PG 0 4.45 0.00 28.40 0.73 0.77 1.53 1.56 0.0545 
 0 14.63 34.89 40.14 2.93 5.94 3.07 6.09 0.1206 
 0 31.80 154.63 171.13 7.17 7.30 13.08 13.73 0.0626 
 0 63.60 659.14 1202.80 16.19 16.30 31.56 31.53 0.0254 
 0.5 3 0.79 2.67 0.68 0.72 1.24 1.08 0.6625 
 0.5 14.5 31.96 57.26 3.70 3.31 6.30 5.95 0.1084 
 0.5 31.8 84.57 128.56 8.43 8.14 15.85 14.36 0.1077 
 1 3 0.64 1.70 0.49 0.70 1.27 1.14 0.8167 
 1 14.5 9.70 35.80 4.94 4.82 9.34 8.43 0.3757 
 1 31.8 19.66 30.62 7.80 7.20 13.78 12.87 0.4083 
 5 14.5 2.51 2.08 5.39 4.05 6.59 9.27 2.8439 
 5 31.8 5.12 12.55 14.67 11.56 21.99 23.84 2.1936 
 5 63.6 151.77 241.63 20.90 14.45 27.07 36.36 0.1239 
PPL 0 60.71 252.33 376.64 19.44 15.83 36.22 29.48 0.0786 
 0 30.63 n.d. n.d. 10.13 7.90 18.82 14.60 n.d. 
 0 13.75 n.d. 88.30 5.04 3.13 8.26 6.10 0.0813 
 0 4.10 n.d. n.d. 1.56 1.29 2.59 1.93 n.d. 
 0.5 14.5 151.50 272.31 7.78 7.00 11.76 9.81 0.0442 
 0.5 31.8 313.11 434.55 14.67 12.91 23.37 18.59 0.0462 
 0.5 63.6 350.24 640.52 25.71 22.34 44.80 38.04 0.0666 
 1 14.5 374.60 504.37 5.25 4.23 8.86 6.98 0.0142 
 1 31.8 403.35 482.99 11.42 10.11 19.69 16.60 0.0321 
 1 63.6 133.04 219.57 22.84 19.84 39.06 32.72 0.1619 
 5 14.5 63.71 96.93 7.83 7.32 11.21 10.38 0.1151 
 5 31.8 161.34 256.88 12.75 11.06 20.94 19.63 0.0764 
 5 63.6 187.65 276.19 24.31 23.77 40.55 38.47 0.1356 
TBZ 0.5 14.5 81.13 59.74 9.52 2.02 5.84 12.58 0.1126 
 0.5 31.8 139.62 125.60 15.69 2.78 6.89 17.16 0.0809 
 0.5 63.6 326.65 196.38 24.74 4.69 11.20 27.19 0.0714 
 1 14.5 51.75 40.62 8.46 1.70 3.27 10.92 0.1364 
 1 31.8 122.66 85.44 19.63 2.54 9.33 20.77 0.1333 
 1 63.6 179.51 128.57 40.76 6.23 14.09 44.39 0.1792 
 5 14.5 26.18 22.66 14.92 0.70 2.34 16.32 0.3550 
 5 31.8 40.36 30.47 27.85 2.19 4.89 30.24 0.4743 
 5 63.6 70.51 49.40 59.14 6.42 12.34 59.87 0.5978 
SQV 0 14 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0 5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0 4.5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0 10.4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 0.5 3 0.36 1.65 1.75 0.07 2.65 0.41 1.7413 
 0.5 7 0.12 1.94 2.89 0.07 3.32 1.02 6.8533 
 0.5 14.5 2.11 6.90 7.89 0.21 10.92 1.85 1.4228 
 1 3 0.09 1.04 2.77 0.07 3.14 1.11 8.7227 
 1 7 0.21 2.75 3.55 0.07 4.29 1.22 4.8349 
 1 14.5 2.37 5.97 11.80 0.19 11.40 5.07 1.9555 
 5 3 0.18 0.33 2.68 0.09 1.67 1.89 6.5866 
 5 7 0.26 0.56 5.08 0.21 2.72 3.90 8.0184 
 5 14.5 0.38 1.52 13.56 0.20 6.08 10.38 11.6663 
n.d.: not determined 
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6.3 Additional Figures of Qualitative Influence of Lipid Phase 
Concentration on Apparent Permeability Coefficient 
A Saquinavir Emulsion 
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Figure 52 Qualitative influence of the lipid concentration on apparent permeability coefficient 
of the tested saquinavir formulations: Panel A shows the influence of lipid phase 
concentrations of the emulsion, and panel B shows the influence of the lipid phase of the 
microemulsion on the apparent permeability coefficient. Same pattern or color indicates same 
drug concentration. Each column represents the deduced apparent permeability coefficient 
out of one transport experiment (n=3). 
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Figure 53 Qualitative influence of the lipid concentration on apparent permeability coefficient 
of the tested triclabendazole formulations: Panel A shows the influence of the liposomes, 
panel B shows the influence of lipid phase concentrations of the emulsion, and panel C shows 
the influence of the lipid phase of the microemulsion on the apparent permeability coefficient. 
Same pattern or color indicates same drug concentration. Each column represents the 
deduced apparent permeability coefficient out of one transport experiment (n=3). 
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A Propranolol Liposomes 
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Figure 54 Qualitative influence of the lipid concentration on apparent permeability coefficient 
of the tested propranolol formulations: Panel A shows the influence of the liposomes, panel B 
shows the influence of lipid phase concentrations of the emulsion, and panel C shows the 
influence of the lipid phase of the microemulsion on the apparent permeability coefficient. 
Same pattern or color indicates same drug concentration. Each column represents the 
deduced apparent permeability coefficient out of one transport experiment (n=3). 
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6.4 Determination of Maximal Drug Solubility in Formulation Lipid 
Phases and Calculation of Theoretical Maximal Fluxes 
For a prediction of the maximal drug load in transport experiments and to avoid oversaturated 
conditions using emulsions and microemulsions, the maximal drug solubility in the lipid phase was 
determined for each drug.  
6.4.1 Methods 
To determine the saturation solubility of the used drugs in transport media and the lipid phases of the 
microemulsion and the emulsion, 0.5 ml of transport media or lipid phase, all tempered to 37°C, were 
pipetted into a microtube. The drug was added to the samples in exceeding the solubility. The 
microtubes were sealed with two layers of Parafilm additionally and shaken at 37°C and 1000 rpm. 
After 12 h the tubes were checked and if all drug was dissolved, more drug was added. After 
equilibration for at least 48 h, the microtubes were spun for 3 min at 14000 rpm on an Eppendorf 
centrifuge. Samples of 50 µl of clear supernatant were taken and diluted 1:10’000 with transport media 
before analyzing them by HPLC. 
6.4.2 Results 
The results of the maximal solubility in the lipid phases (css) are shown in Table 21. Besides of the 
maximal solubility, this table contains additional information. It displays the theoretical maximal 
possible drug load of a formulation containing the maximal lipid concentration. Out of permeability 
coefficient within the maximal lipid concentration, a theoretical maximal flux was calculated. 
 
Table 21 Maximal drug solubility in the lipid phase (css) and theoretical maximal flux 
Formulation lipid content 
[mg/ml] 
css in 
Transport 
Media 
[µM], 
37°C 
css in lipid 
phase [µM] 
37°C 
drug conc. 
[µM] 
Papp [cm/s] maximal flux 
J=P*Css 
[µmol/(cm2*s)] 
Progesterone solution 0 n.d - 63.60 2.9*10-4 1.85*10-2 
Progesterone liposomes 50 - n.d. 11193.44 8.5*10-6 9.54*10-2 
Progesterone emulsion 5 - 106800 534 4.3*10-5 2.32*10-2 
Progesterone microemulsion 5 - 53066 260 5.4*10-5 1.40*10-2 
Saquinavir solution 0 1.5 - 1.5 1.2*10-4 1.81*10-4 
Saquinavir emulsion 5 - 6490 32.4 1.2*10-5 3.78*10-4 
Saquinavir microemulsion 5 - 29056 145 1.2*10-5 1.70*10-3 
Propranolol solution 0 1243 - 1243 3.2*10-4 4.01*10-1 
Propranolol liposomes 10 - n.d. 794 6.6*10-5 5.25*10-2 
Propranolol emulsion 5 - n.d. 63.6 3.8*10-4 2.40*10-2 
Propranolol microemulsion 5 - 53700 269 3.3*10-4 8.79*10-2 
Triclabendazole solution 0 0.39 - 0.39 2.3*10-4 8.79*10-5 
Triclabendazole liposomes 10 - n.d. 794 1.6*10-6 1.30*10-3 
Triclabendazole emulsion 5 - 36757 183 3.8*10-6 7.02*10-4 
Triclabendazole microemulsion 5 - 158974 791 5.8*10-6 4.56*10-3 
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6.5 Determination of Inorganic and Organic Phosphate of the 
Acceptor Compartment after Equilibrium Dialysis of a 
Liposome Formulation 
If phosphatidylcholine is in contact with an aqueous environment, a degradation product, lyso-
phosphatidylcholine, may occur. This degradation product has surfactant like properties and may 
influence the solubility of a poor soluble drug in transport media. Because of its mass of approximately 
500 D it may pass the dialysis membrane and therefore alter drug partition between lipid- and water 
phase. Diffusion of lyso-phosphatidylcholine through the dialysis membrane can be determined by 
measuring the change of (anorganic and organic) phosphate content in acceptor compartment. 
6.5.1 Material and Methods 
Liposomes containing 50 mg/ml phospholipids were dialyzed as described and after 40 h of dialysis 
phosphate content of the acceptor compartment was determined and compared with transport media 
that contains a phosphate buffer. A method where phosphor in organic molecules is converted by 
sulfuric acid to anorganic phosphate was used to determine the organic and the anorganic phosphate 
(143). The phosphate forms a complex with ammonium molybdat and malachite green that can be 
detected by extinction measurement at 610 nm. Quantification was performed against a set of external 
standard solutions out of potassium hydrogenphosphat within the linear response concentration range 
(0-12 nM). Samples of 10 µl were pipetted into test tubes and amended with 990 µl distilled water. 
Three aliquots of the standard solutions (100 µl each) and of the diluted samples (50 µl each) were 
pipetted into test tubes and 700 µl of a reagent containing 5%(V/V) sulfuric acid and 7%(V/V) of 
perchloric acid solution (20%) in distilled water. The samples were incubated 1 h at 150°C and dried 
2 h at 230°C. After cooling down, 1000 µl distilled water was added to the tubes. Samples of 100 µl 
were transferred into 96-well plates (Nunc, Roskilde, Denmark) and mixed with 20 µl of a solution 
containing 1.25% (m/V) ammonium heptamolybdat in distilled water. After 20 min incubation at room 
temperature, 20 µl of a reagent, containing 0.35 g polyvinyl alcohol and 0.035 g malachite green in 
100 ml reagent, was added and after an incubation of 10 min the samples were measured with a plate 
reader (Versamax Tunable Multiplate Reader, No. SIN/B 02553, Molecular Devices Corporation, 
Sunnyville, USA). All reagents were of analytical grade and purchased from SIGMA-Aldrich (Fluka 
Chemie, Buchs, Switzerland).  
6.5.2 Results 
The result of the equilibrium dialysis of a liposome formulation is shown in Figure 55. Phosphate 
content of acceptor transport media after equilibrium dialysis of a liposome formulation containing 
50 mg/ml phospholipids did not change during dialysis compared to the initial phosphate concentration 
of transport media. This indicates that no phospholipids or degradation products cross the dialysis 
membrane during experimental duration. 
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Figure 55 Phosphate content of acceptor media after equilibrium dialysis of a liposome 
formulation containing 50 mg/ml phospholipids did not change during dialysis compared to 
the initial phosphate concentration of transport media. 
 
6.5.3 Conclusions 
No falsifying of the free fraction by phospholipids or degradation products of phospholipids is 
expected. Therefore, equilibrium dialysis under the chosen conditions is a valuable tool for the 
investigation of the liposomes used in this thesis.  
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6.6 Detailed Derivations of Used Models and Additional 
Calculations 
6.6.1 Detailed Derivation of Delineation of Apparent Permeability 
Coefficient Based on a Biophysical Model 
 
Figure 56 Schematic model of a substance flux over a Caco-2 cell monolayer. Donor and 
acceptor compartment contain lipid particles of the same formulation. 
 
Substance fluxes are defined as flux through cell membrane Jm (Equation 67) and flux through 
diffusion boundary layer JDBL (Equation 68): 
)c(c
h
DJ mm,
m
m
m 2,1 −=  
Equation 67 
 
where hm denotes thickness of cell membrane, Dm diffusion coefficient of drug in cell membrane, cm,1 
drug concentration at cell membrane surface inside of the membrane, cm,2 drug concentration at inner 
membrane surface inside of the membrane. 
( ) ( )L,mL
DBL
w,L
w,mw
DBL
w,d
DBL cch
D
cc
h
D
J −+−⋅=  
Equation 68 
 
The flux through diffusion boundary layer is composed of the flux of the free drug molecules and the 
flux of the lipid particles, where cw,m denotes drug concentration of the water phase at membrane 
surface, cL drug concentration associated with lipid phase referring to total volume, cL,m drug 
concentration associated with lipid phase referring to total volume at membrane surface, cw drug 
concentration in water phase, hDBL thickness of diffusion boundary layer, Dw,d the diffusion coefficient 
of drug in water phase, and Dw,L diffusion coefficient of lipid particle in water phase. 
The free fraction (z ) of a drug is defined as ratio of drug concentration in the water phase of the 
formulation to the drug concentration in formulation denoted by ctot: 
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z
c
c
tot
w
=  
Equation 69 
 
Substitutions that were used to replace unknown parameters were Equation 70 to Equation 75: 
w,L
w,d
D
D
q =  
Equation 70 
 
q is defined as ratio of diffusion coefficient of drug in water phase (Dw,d) to diffusion coefficient of lipid 
particle in water phase (Dw,L) 
tot
w
V
VVF =  
Equation 71 
 
The volume fraction VF is defined as ratio of the volume of the water phase (Vw) to the volume of the 
formulation Vtot. The volume of the water phase was assumed to be 
w
w
w
ρ
nV 18⋅=  
Equation 72 
 
where nw denotes the moles of water in the formulation, ρw the density of the water phase and the 
molecular weight of water was assumed to be 18 g/mol. The total volume of the formulation was 
assumed to be the sum of the volume of the water phase and the volume of the lipid phase 
tot
LLw
tot
ρ
MWnnV ⋅+⋅= 18  
Equation 73 
 
where nL denotes the moles of lipids in the formulation, MWL the molecular weight of lipids, and ρtot the 
density of the formulation. where nL denotes the moles of lipids in the formulation, MWL the molecular 
weight of lipids, and ρtot the density of the formulation. 
The mass of drug in lipid phase (mL) was assumed to be the total mass of drug (mtot) minus the mass 
of drug in water phase (mw). This was used to express cL with ctot and cw: 
Lwtot
tot
w
wtot
tot
wwtottot
tot
wtot
tot
L
L cVFccV
V
cc
V
VcVc
V
mm
V
m
c =−=−=
−
=
−
==  
Equation 74 
 
Equation 74 applies for bulk and with indices m (e.g. cw,m) at cell membrane surface. 
The unknown drug concentration at cell membrane surface inside of the membrane (cm,1) was 
substituted by the following equation: 
L
m
w
m KcKcc mLmwm ⋅+⋅= ,,1,  
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Equation 75 
 
where Km/w denotes the partition coefficient of the free drug between aqueous phase and cell 
membrane and Km/L denotes the partition coefficient of the drug between lipid associated drug 
concentration and cell membrane. 
The equation describing the fluxes through the membrane was transformed inserting Equation 75 into 
Equation 67 and rearranging yields:  
c
m
m
l,mm,Lw,mm,dm,
m
m
l,m
m
m
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m
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m
m
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m
m
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Equation 76 
 
In Equation 76 denotes Pm,d the permeability coefficient of the free drug through cell monolayer, Pm,L 
the permeability coefficient of the drug because of direct drug transfer from lipid particle to the cell 
membrane, cc cellular drug concentration and Km/c the partition coefficient between cellular drug 
concentration and cell membrane. 
Inserting Equation 69 and Equation 74 into Equation 76 and rearranging yields: 
c
c
m
m
m
m,L
m,L
m,dw,mm cKh
DVFP
z
P
PcJ ⋅−





⋅−+=  
Equation 77 
 
Inserting Equation 70 into Equation 68 and rearranging yields: 
( )L,mLw,mwdbl,dDBL ccqcqcq
P
J −+−⋅=  
Equation 78 
 
Where Pdbl,d denotes the permeability coefficient of the free drug through diffusion boundary layer.  
At steady state fluxes are set equal ( DBLm JJ = ), Equation 69 and Equation 74 were inserted and the 
resulting equation was solved for the unknown concentration cw,m. 
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Equation 79 
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Equation 84 was inserted into Equation 77. Transformation of this equation after insertion resulted in: 
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Equation 87 
 
Assuming for the sake of simplicity sink conditions on the receiver (cell) side and setting cc to zero and 
dividing Equation 87 by ctot, it follows 
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Conversion of this formula leads to the following equation: 
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Equation 89 
 
This equation looks similar to the model equation for the accumulation of permeability coefficients: 
mDBL PPP
111
+=
 
Equation 90 
 
The additional terms in Equation 89 can be regarded as model specific explements containing a term 
for the lipid/water partitioning of the drug and a term describing the contribution of the lipid particles on 
the drug transport. 
 
With Easyfit the following equation was used: 
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Equation 91 
 
The resulting Equation 91, was applied for the subdivision of the estimated apparent permeability 
coefficients Pa and Pb out of the transport studies (because there was no influence of the order of the 
layers see appendix (Subdivision of the Apparent Permeability Coefficient without Lipid Contribution 
Including Model Extension for Non-Sink Conditions ) for further explanation.) 
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6.6.2 Subdivision of the Apparent Permeability Coefficient Including 
Permeation through Diffusion Boundary Layer and through Cellular 
Membrane Including Model Extension for Non-Sink Conditions. 
In this section, a mathematical model is derived to determine the membrane permeability and the 
permeability through diffusion boundary layer out of permeability data of Caco-2 transport experiments 
and equilibrium dialysis experiments. This model is based on the following assumptions:  
1) Sink conditions on acceptor side 
2) Only unbound drug molecules may diffuse through the cell monolayer 
3) No drug transfer takes place if lipid particles collide into the cell membrane 
4) The free fraction (z) of a drug is dependent on lipid concentration and may be independent of drug 
concentration. 
 
 
Figure 57 Model for determination of the membrane permeability and the permeability through 
diffusion boundary layer out of permeability data of Caco-2 transport experiments and 
equilibrium dialysis experiments. 
 
 
Abbreviations: 
cw,m drug concentration of the water phase on membrane surface 
ctot, m total drug concentration of the formulation on membrane surface 
cL,m drug concentration of the lipid phase on membrane surface 
cm drug concentration in cell membrane 
cL drug concentration in lipid phase, referring to the total volume 
cw drug concentration in water phase, referring to the water phase 
ctot drug concentration in formulation 
hm thickness of cell membrane 
donor acceptor
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hDBL thickness of diffusion boundary layer 
Jm flux through membrane 
JDBL flux through diffusion boundary layer 
Dw,d diffusion coefficient of drug in water phase 
Dw,L diffusion coefficient of lipid particle in water phase 
Dm diffusion coefficient of drug in cell membrane 
VF Volume fraction 
Vw Volume of water phase 
Vtot Volume of the formulation 
nw moles of water in the formulation 
nL moles of Lipids in the formulation 
MWL molecular weight of lipids 
ρw density of water phase 
ρtot density of the formulation 
Km/w membrane/water partition coefficient  
mtot total mass of drug 
mw mass of drug in water phase 
mL mass of drug in lipid phase 
PDBL,d Permeation coefficient of the Drug through diffusion boundary layer 
Pm Permeation coefficient of the Drug through the cell monolayer 
 
The free fraction of a drug is defined as 
z=
tot
w
c
c
 
Equation 92 
 
Fluxes through cellular membrane and diffusion boundary layer are defined as: 
m
m
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Some substitutions: 
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where 
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Unknown parameters were replaced by the use of some substitutions. The resulting equation was 
solved for the unknown parameter cw,m. 
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The term for cw,m was inserted into the following equation: 
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If 
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c
JPcPJ =⇒⋅=  
Equation 113 
 
then 
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Conversion of this Equation 114 leads to the following equations: 
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Equation 118 
 
Equation 118 looks similar to the model equation for the accumulation of permeability coefficients: 
mDBL PPP
111
+=  
Equation 119 
 
 
The additional terms (in brackets) in Equation 118 can be regarded as model specific explements 
containing a term for the lipid/water partitioning of the drug. With Easyfit the following equation was 
used: 
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Equation 120 
 
6.6.2.1 Fitting the Biophysical Model for the Subdivision of Apparent 
Permeability Coefficient Including Permeation through Diffusion 
Boundary Layer and through Cellular Membrane to Apparent 
Permeability Coefficients out of Cell Permeation Experiments  
Equation 120 was fitted to the experimental free fractions and apparent permeability coefficients. The 
results of the best obtained estimation for Pm and PDBL are shown in Table 22. 
 
Table 22 Estimated parameters if the permeability coefficient of the free drug through the cell 
membrane and the permeability coefficient of the drug because of direct drug transfer from 
lipid particle to the cell membrane are merged to the permeability coefficient of the drug 
through the cell membrane, Pm. Except for triclabendazole, very poor description of the data by 
the model was obtained. 
Drug Type of Formulation 
Pm 
[cm*s-1] 
PDBL 
[cm*s-1] 
Triclabendazole A Emulsion 0.088 
 Microemulsion 0.041 
 Liposomes 0.00698 
1.94*10-4 
Progesterone Emulsion 133.67 
 Microemulsion 294.31 
 Liposomes 190.6 
3.49*10-4 
Propranolol Emulsion 276.93 
 Microemulsion 0.0034 
 Liposomes 0.0021 
3.98*10-4 
Saquinavir Emulsion 58.9 
 Microemulsion 30.46 
1.23*10-4 
A
 to improve fitting quality, a scaling of -1 instead of 1 was used 
 
6.6.2.2 Model Extension for Non-Sink Conditions of the Subdivision of the 
Apparent Permeability Coefficient Including Permeation through 
Diffusion Boundary Layer and through Cellular Membrane 
The model described in the last chapter was extended for non sink conditions on the acceptor side, 
which leads to the following equations (cm2≠0, see Figure 57): 
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Step donor compartment to cell lumen 
( )2,1, mm
m
m
m cch
DJ −=  
Equation 121 
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it is essential 
DBLm JJ =  
Equation 123 
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Equation 124 
 
In Equation 124 some unknown variables were substituted and the equation was solved for cw,m: 
( )mLLmwwdDBLcmmwm ccqcqcq
P
cKPcP
C
w ,,
,
,
−+−=−  
Equation 125 
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( ) 





+−−+−+=− VFc
z
c
qc
q
P
zVFccqzc
q
P
cKPcP mw
mw
mw
dDBL
tottottot
dDBL
cmmwm C
w ,
,
,
,,
,
 
Equation 127 
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Equation 128 
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Equation 129 
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Equation 130 was inserted into Equation 131: 
)(
, cmwm cKcPJ Cw−=  
Equation 131 
 
( )






−++






−+−−+−+
⋅=
VF
z
q
q
P
P
VF
z
q
q
P
cKcKPcKPzVFqzc
q
P
P
dDBL
m
dDBL
ccmcmtot
dDBL
m
C
w
C
w
C
w
1
11
,
,,
 
Equation 132 
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Equation 133 
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Equation 134 
 
Equation 134 is in fact the same equation as the equation including sink conditions, because 
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Step from cell lumen to acceptor compartment: 
( )21 mm
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(it is essential: DBLm JJ = ) 
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Equation 144 was inserted to Equation 145: 
 
)(
,mwcmDBLm ccKPJJ Cw −==  
Equation 145 
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Equation 146 
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Equation 147 
 
Since concentration gradient is directed to the opposite direction, Equation 147 is the same as 
Equation 133. This derivation leads to the same solution as the derivation with sink conditions. If sink 
conditions were not warranted, there is no influence on the calculated permeation coefficient. 
Furthermore the order of the layers does not influence the permeation. 
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